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General introduction and outline of the thesis 
Chapter 1 
INTRODUCTION 
Although our knowledge about etiology, pathophysiology and treatment of 
cardiovascular disease has increased enormously, it still remains the most frequent cause 
of death in western countries In 1992, 40% of all deaths (about 52 000 deaths) in the 
Netherlands was due to a form of cardiovascular disease The last 15 years numerous 
retrospective studies have provided accumulating evidence for the causal role of elevated 
plasma cholesterol in the origin of cardiovascular disease Only recently, also large scale 
prospective primary and secondary prevention trials indisputably showed a decrease in 
cardiovascular mortality and regression of angiographically defined atherosclerotic lesions 
by a reduction of plasma cholesterol levels (1-5) Furthermore, mounting evidence 
indicates that next to elevated plasma cholesterol, elevated concentrations of tnglycende-
rich lipoproteins determine the cardiovascular risk as well (6-9) 
Among the different lipid disorders, the most frequently occurring one, known as 
familial combined hyperhpidemia (FCH), has still kept lots ot its secrets about etiology, 
pathophysiology and mechanism of associated premature atherosclerosis As a 
consequence, a specific marker, based on supposed specific metabolic abnormalities in 
FCH, and necessary for individual diagnosis, is lacking (10) Patients suffering from FCH 
frequently show only marginal elevated lipid levels Therefore, the observed 
disproportional increase in cardiovascular risk of these subjects must come from certain 
abnormalities in their lipid profiles, which is determined by overproduction of very low 
density lipoproteins (VLDL) (11,12) Besides VLDL overproduction, also an impaired 
physiological clearance of triglycende-nch particles, both of exogenous and of endogenous 
origin (13), contributes to an increased pool ot triglycende-nch lipoproteins underlying 
the multiple lipid phenotype expression of FCH patients (11,14-16) Such a lipid profile is 
frequently associated with an unfavorable decrease in high density lipoprotein (HDL) 
concentration and a preponderance of atherogenic small dense low density lipoprotein 
(LDL) subfractions (17-21) 
To have a chance to obtain a specific marker for the disorder FCH, both the 
etiology of the increased pool of apolipoprotein В100 containing tnglycende-nch 
lipoproteins as well as that of the preponderance of small dense LDL particles in FCH 
patients have to be elucidated Consequently, factors involved in VLDL-apoBlOO 
overproduction and clearance ot these particles, as well as metabolic influences of elevated 
plasma triglyceride levels on LDL subtraction distribution and possible genetic control on 
LDL density in FCH are of great interest 
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METABOLISM OF APOB100 CONTAINING LIPOPROTEINS 
Once produced, VLDL is melabolically converted into LDL with persevation of 
apoBlOO. The increase in lipoprotein density during this conversion depends on constant 
triglyceride hydrolysis by lipoprotein lipase (LpL) and hepatic triglyceride lipase (22). 
Abnormal LpL activity is reported to be a major cause of impaired triglyceride-rich 
lipoproteins clearance in FCH (23-27). The metabolic role of HtgL is only partly 
understood. As has been reported, HtgL may determine LDL density (28-30). 
Due to lack of apoE-mediated receptor uptake of triglyceride-rich apoBlOO particles, 
patients suffering from familial dysbetalipoproteinemia exhibit an increased plasma 
cholesterol and triglyceride level. This is caused by a defective B/E receptor binding in 
case of homozygous apoE2/2. However, for complete phenotypic expression of this form 
of hyperlipidemia additional factors are needed. In general, apoE polymorphism 
determines a detectable fraction of the hypertriglyceridemia, in the presence of an apoE2 
allele, and of the hypercholesterolemia in the presence of an apoE4 allele, in some forms 
of hyperlipidemia (31-36). Consequently, apoE polymorphism may play a role in lipid 
phenotypic expression of FCH as well. 
The increased secretion rate of VLDL-apoBlOO in FCH depends at least in part on 
free fatty acids (FFA) availability to hepatic cells, which are either released from 
adipocytes, intrahepatically stores, or are de novo synthesized from dietary carbohydrates 
(22,37). Insulin resistance is frequently associated with elevated plasma FFA 
concentrations due to an impaired postprandial FFA uptake by adipocytes which stimulates 
VLDL synthesis (38). Furthermore, insulin resistance is associated with an impaired 
ability of insulin to stimulate LpL (39,40). By measuring plasma FFA and insulin 
concentrations, it was suggested that insulin resistance may underly FCH (41-43). 
FCH AND LDL HETEROGENEITY 
Since the first reports by Hammond and Fisher, it has been recognized that LDL 
particles are markedly heterogeneous in physical and chemical properties, which includes 
particle size, buoyant density, chemical composition, surface electrical charge and 
hemodynamic behaviour (44-50). Recently it was demonstrated that small dense LDL 
subspecies exhibit an enhanced susceptibility to oxidative modification compared with 
buoyant subfractions, and may therefore be more atherogenic than buoyant subspecies 
(51-53). The hypothesis of oxidative modification preceeding atherogenesis is supported 
by the demonstration of oxidized LDL in vivo and autoantibodies against oxidized LDL 
particles (54-56). Differences in oxidative susceptibility are explained by variability in 
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fatty acid and antioxidant contents (53), whereas specific different physiochemical and 
structural properties of the LDL subfractions in FCH may contribute (46). 
The origin of LDL heterogeneity and the cause of LDL subfraction profiles 
predominated by small dense LDL particles is only partly understood. Most likely, LDL 
heterogeneity results from a large variety of metabolic, genetic as well as environmental 
factors. Intravascular formation of LDL subfractions involves the conversion of VLDL 
precursors. Exchange of LDL cholesteryl ester for VLDL triglycerides, mediated by the 
cholesteryl ester transfer protein (CETP), would result in an enrichment of the LDL with 
triglycerides (57,58). The subsequent triglyceride hydrolysis by mainly hepatic triglyceride 
lipase would result in a decreased particle size (29,30,59,60). Although this theory 
explains the preponderance of small dense LDL particles in hypertriglyceridemia, it can 
not account for less frequently observed buoyant LDL particles in this condition, or the 
predominance of small dense LDL in the absence of hypertriglyceridemia. Therefore, also 
direct hepatic secretion of dense IDL or LDL, and small dense LDL selectively originate 
from certain VLDL precursors are hypothesized (61-63). 
Recently, genetic influence on individual LDL subfraction distribution investigated 
by segregation analysis has been reported (64-66). These studies suggested the presence of 
susceptibility genes determining the LDL subfraction profile, which may have connections 
to metabolic pathways involved in hyperlipidemia. Therefore, assessing genetic influence 
on the LDL subfraction profile of FCH patients may reveal metabolic defects underlying 
FCH. 
OUTLINE OF THE INVESTIGATIONS 
Since 1973, FCH has been recognized as autosomal inheritable primary lipid 
disorder. The recognition of individual patients with familial combined hyperlipidemia 
who are prone to develop premature cardiovascular disease is, however, complicated by 
the absence of one or more specific markers for the disorder. Therefore, putting a proper 
diagnosis still necessitates laborious and time consuming family investigation. 
Furthermore, the mechanism by which FCH patients are more prone to premature 
cardiovascular disease is only partly understood and may be related to the increased pool 
of triglyceride-rich lipoproteins and the predominance of small dense LDL particles 
characteristic for the disorder. The objective of the studies presented in this thesis is to 
establish in FCH patients the role of several metabolic factors involved in the production 
and clearance of apoBlOO containing lipoproteins in order to gain more insight into the 
etiology of FCH. Especially, the origin of LDL heterogeneity in FCH was investigated. 
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By performing family studies the impact of metabolic and genetic factors determining 
small dense LDL could be elucidated. Furthermore, a possible mechanism underlying the 
augmented prevalence of atherogenesis in FCH due to predominance of small dense LDL 
was studied. 
In detail, blood samples and required data of 687 family members from 40 well-
defined FCH families were collected. To investigate features of metabolic coherence in 
FCH, the effects of two different hypolipidemic drugs on apoBlOO containing lipoproteins 
were evaluated in 81 FCH patients. This allowed us to establish in a subgroup of this 
study the metabolic relations between different lipids or lipoprotein fractions and LDL 
heterogeneity. In addition, the susceptibility of LDL to in vitro oxidative modification, 
both before and after treatment was determined to evaluate possible consequences for the 
atherogenic potential of this lipid fraction in FCH. 
As outlined above LpL and ApoE are determinants of the catabolism of triglyceride-
rich particles. Hydrolysis of lipoproteins by LpL results in remnant particles and apoE 
faciliates a receptor-mediated uptake of lipoproteins. The role of apoE polymorphism on 
the lipid phenotypic expression and the distribution of LDL subfractions was investigated 
in all FCH families. Furthermore, the consequences of impaired LpL activity due to 
mutations in the LpL gene were investigated. In 3 large families of probands exhibiting 
the recently discovered LpL Asn291-»Ser mutation, the relationship between genotype and 
phenotype could be established. 
Insulin resistance is reported to be associated with typical features of FCH, like 
VLDL overproduction, an impaired postprandial clearance of triglyceride-rich 
lipoproteins, and a predominance of small dense LDL. Furthermore, hyperinsulinemia per 
se is also directly associated with cardiovascular disease. To investigate whether insulin 
resistance plays a role in the etiology of FCH, the insulin sensitivity of 11 non-obese FCH 
patients and 11 first-degree relatives was compared directly by the euglycemic 
hyperinsulinemic clamp test. In this study, differences in insulin induced vasodilation 
which may in part be responsible for diminished glucose uptake were measured as well. 
As recently postulated, enhanced susceptibility of small dense LDL particles to 
oxidative modification would explain the atherogenic potential of these particles. 
Resistance against in vitro oxidation may be related with the presence of lipophilic 
antioxidants. In the FCH families, possible disorder-related differences in susceptibility 
towards oxidative modification, expected by differences in the presenting LDL subfraction 
profile, were investigated. In 35 FCH family members with either a predominance of 
dense or a predominance of buoyant LDL particles, the oxidizability of total LDL was 
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determined and a relation to LDL density and the redox status of the antioxidant 
ubiquinol-10, reflecting the actual in vivo LDL oxidation status, was observed. 
To investigate whether genetic factors influence the LDL subfraction profile in FCH, 
a segregation analysis using a continuous variable К to describe individual LDL 
subfraction profiles was performed in the FCH families. The presence of small dense LDL 
shows strong correlation with plasma triglycerides and plasma apoB. Consequently, 
evidence for a major locus controlling the observed LDL heterogeneity in these families 
may be due to genetic factors directly responsible for hypertriglyceridemia or 
hyperapobetalipoproteinemia. Cholesterol concentrations in ApoBlOO containing 
lipoproteins were found to correlate well with plasma apoBlOO levels both in 
normolipidemic and hyperlipidemic relatives. Therefore, also a segregation analysis on 
plasma apoBlOO was performed to study inheritance of this lipid parameter in FCH 
families. In order to investigate whether observed genetic models for inheritance of LDL 
subfraction profiles and plasma apoBlOO represent different genetic mechanisms, a final 
analysis was performed. In this segregation analysis the LDL subfraction profiles were 
corrected for the predicted apoBlOO level genotype influence. 
All these studies revealed arguments for considering the presence of small dense 
LDL as a biochemical marker for the lipid disorder FCH. 
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INTRODUCTION 
The relationship between elevated plasma cholesterol and the risk of coronary artery 
disease is definitively established now (1-5). Accumulating evidence indicate that the total 
amount of triglyceride-rich lipoprotein particles, i.e. chylomicron remnants, very low 
density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) determine the 
risk to develop cardiovascular disease as well (6-8). This would explain the extending 
benifit of cholesterol-lowering therapy observed in the majority of patients with coronary 
disease who have only marginally elevated plasma cholesterol levels, but may exhibit 
other lipid abnormalities (4,9). 
In patients suffering from familial combined hyperlipidemia (FCH) elevated levels of 
triglyceride-rich lipoproteins mainly determine the presenting lipid phenotype. Because 
FCH appeared to be the most common form of hyperlipidemia in young survivors of 
myocardial infarction (10,11), causing an estimated 10% of all premature coronary heart 
disease (12,13), recent research has been focussed on the pathophysiological mechanism 
underlying premature atherogenesis in FCH. In this review, hypotheses about the 
metabolic and genetic basis of FCH and its related entities, as well as the origin of LDL 
heterogeneity associated with these lipid disorders will be discussed. 
PHENOTYPIC DIAGNOSIS OF FCH 
In 1973, FCH was first described by Goldstein et al. (10) and Rose et al. (12), 
shortly followed by others (11,14,15), as a new autosomal dominant inherited lipid 
disorder, characterized by elevated plasma cholesterol and triglyceride levels in first-
degree relatives, and strongly associated with premature cardiovascular disease. At that 
time, the recognition of FCH confounded the previously formulated Fredrickson 
classification of hyperlipoproteinemias by the presence of first-degree relatives exhibiting 
different lipid phenotypes within one single family. 
Because there is no specific marker for the disorder while the lipid phenotypic 
expression among affected individuals may show some variation in time, the diagnosis is 
necessarily based on family investigation to demonstrate a so called 'mixed 
hyperlipidemia' with either hypercholesterolemia, hypertriglyceridemia, or combined 
hyperlipidemia in first-degree relatives. Criteria supporting the FCH diagnosis are 
presented in Table 1. Nowadays it is common sense that all main inclusion criteria, in the 
abcense of all exclusion criteria, should be met for a true diagnosis, whereas the 
diagnositic value of the mentioned additional inclusion criteria is still under debate. 
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Table 1. Inclusion and exclusion entena supporting the diagnosis familial combined hyperlipidemia. 
Main inclusion criteria: 
Presence of a multiple type hyperlipidemia in first-degree relatives of a single family 
compnsing hypertriglyceridemia, hypercholesterolemia, and combined hyperlipidemia, as 
defined by fasting plasma cholesterol and/or plasma triglycende concentrations above the 90th 
percentile for age and gender 
Autosomal dominant inheritance of the hyperlipidemia 
Presence of premature atherosclerosis (before age of 60 years) in first-degree relatives 
Additional inclusion criteria: 
An elevated total plasma apohpoprotein-B concentration 
A LDL subtraction profile predominated by small dense LDL particles 
Manifestation of the hyperlipidemia in adolescence 
Exclusion criteria'. 
Presence of any form of xanthoma in first-degree relatives 
Presence of a secondary cause for the hyperlipidemia in affected relatives 
Presence of the Apo c2/e2 genotype in first-degree relatives 
Although FCH patients frequently exhibit elevated plasma apo В concentrations 
(13,16) when compared with their normolipidemic relatives, the interpretation of total 
plasma apolipoprotein-B (apo B) levels as diagnostic criterium is still open for discussion. 
A plasma apo B100 level above 130 mg/dl, standardized upon the radioimmunoassay 
method of the International Union of Immunological Societies, may contribute to define 
FCH patients (17,18). Considering that the lipid to protein ratio of VLDL and LDL 
particles is relatively constant even in FCH patients (13,19,20), total plasma apo В could 
be derived from the strong correlation that appeared to exist between VLDL plus LDL 
cholesterol and plasma apo В (16). Therefore, plasma apo В strongly correlates with the 
presented FCH lipid phenotype based on elevated VLDL and/or LDL concentrations (16). 
For unclear reasons, the manifestation of hyperlipidemia in childhood, as frequently 
observed in familial hypercholesterolemia, does rarely occur in FCH (21). However, 
hyperapobetalipoproteinemia, a feature associated with FCH, has been detected in children 
of parents with premature cardiovascular disease (22,23). 
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FCH AND ITS RELATED LIPID PHENOTYPES 
Initially FCH was thought to be inherited as a single gene disorder with a major 
effect on triglyceride levels (10). Recently, again evidence for a major gene effect on 
triglyceride levels was provided by complex segregation analysis in British FCH families 
(24). Whereas this supposed gene mutation has still not been located, other studies 
indicated that a variety of metabolic and biochemical defects predispose for the FCH 
phenotype, suggesting that the genetic basis of this trait is heterogeneous and may even 
involve several defects in one family. 
Atherogenic Lipoprotein Pattern 
Hyperapobetalipoprotelnemia 
1 \ i \y 
V 4 s / 
Familial Dyslipidemic Hypertension 
I 
Insulin Resistance 
FAMILIAL COMBINED HYPERLIPIDEMIA 
Figure 1: Overlapping characteristics of four entities with key features of the FCH phenotype, which may 
contribute to the complete picture of FCH. (freely adapted from Kwiterovich P.O.J , Curr. Opin Lipidol. 
(1993)4:133-143). 
According to these reports FCH may be considered more like a 'syndrome', showing 
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overlapping characteristics with other entities such as (i) hyperapobetalipoproteinemia 
(hyperapoB) defined by a normal LDL cholesterol level with an increased LDL protein 
(apo B) content (25); (ii) the 'atherogenic lipoprotein phenotype' (ALP) characterized by 
increased triglyceride and apo В levels, decreased HDL levels and a predominance of 
small dense LDL (26); (iii) familial dyslipidemic hypertension (FDH) a syndrome of 
mixed lipid abnormalities resembling the FCH phenotype, associated with mild 
hypertension (27); and (iv) the insulin resistance syndrome associated with increased 
VLDL production and impaired clearance of triglyceride-rich particles, also key features 
of FCH (28,29) (Figure 1). 
PATHOPHYSIOLOGY OF FCH 
In general, FCH is thought to be caused by hepatic VLDL overproduction with or 
without impaired clearance of triglyceride-rich lipoproteins (30,31). Since no single 
metabolic defect detected sofar could fully account for the FCH phenotype, it was 
hypothesized that a number of defects are involved. Considering these defects, it still has 
to be settled whether they are causal for the disorder or are a regulatory consequence of 
an underlying metabolic defect. In general, circulating triglyceride-rich lipoproteins are of 
exogenous or endogenous origin. For better comprehension, these pathways are described 
more specific below. 
The exogenous pathway 
This pathway involves the transport of dietary lipids from the intestine to the liver 
by apo B48 containing chylomicrons. Due to the action of the enzyme lipoprotein lipase 
(LpL), activated by cofactor apo СП, fatty acids are liberated from chylomicrons and pass 
to the adipose tissue or skeletal muscle cells to be oxidized or stored. Reduced LpL 
activity due to LpL gene mutations has been reported repeatedly in subsets of FCH 
populations (32,33) and may result in impaired clearance of chylomicrons. For storage in 
adipocytes, free fatty acids (FFA) are intracellularly reesterified to triglycerides, a process 
that is mediated by the action of a basic protein called acylation stimulatory protein (ASP) 
(34). Due to impaired ASP activity, as reported in hyperapoB, a reduced rate of FFA 
uptake into adipocytes may result in an increased flux of FFA to the liver and 
consequently in an increased hepatic VLDL synthesis (35). After the release of FFA, the 
remainder chylomicron remnant particles are taken up by the liver via a specific remnant 
receptor that only recognizes apo E as ligand (36). A delayed clearance of atherogenic 
chylomicron remnants, possibly due to competition between chylomicrons and endogenous 
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VLDL for available LpL activity and competition for remnant receptor capacity, has been 
reported to exist in FCH patients (37). In the hepatocytes, all components of the remnants 
are hydrolyzed in the lysosomal compartment and a part of this material is re-used to form 
nascent VLDL particles entering the endogenous pathway. Intracellular increase of 
cholesterol in hepatocytes may increase plasma LDL cholesterol concentration because of 
hepatic LDL receptor down-regulation. 
The endogenous pathway 
This pathway involves the assembly of formed endogenous cholesterol and 
triglycerides in the core of VLDL followed by excretion into the circulation. In vitro 
studies show that in HepG2 cells intracellular triglyceride biosynthesis, but not the rate of 
cholesterol or cholesteryl esters determines the secretion rate of VLDL-apo В (38). The 
triglyceride biosynthesis itself depends on the availability of required FFA which are 
either released from adipocytes, intrahepatically stored, or converted from dietary 
carbohydrates (39). The release of required FFA from visceral adipocytes is mediated by 
the action of the enzyme hormone sensitive lipase (HSL) (40,41). Postprandial 
hyperinsulinemia plays a regulatory role because it inhibits the lipolytic effect of HSL to 
allow FFA uptake by adipocytes (42). FCH is associated with increased insulin resistance 
which would allow for increase of VLDL production by net increase of serum FFA 
(43,44). Without merging with lipids to allow the formation of a VLDL particle, nascent 
apoprotein B100 is degraded. This process is catalyzed by the action of microsomal 
triglyceride transfer protein (MTP), referring to its site of action in the hepatic 
endoplasmatic reticulum (45,46). Recently, abetalipoproteinemia, the metabolic Opposite' 
of FCH, was found to be caused by MTP absence (47). Consequently, it has to be 
established whether MTP overexpression could also play a role in VLDL-apo В 
overproduction of FCH. 
The continuous hydrolysis of core triglycerides in FFA by LpL converts VLDL into 
smaller apoprotein B100 containing VLDL remnants, IDL and LDL (39,48,49). Recent 
reports suggest that a heterozygous state for one of the mutations found in the LpL gene 
affecting its activity, may result in a lipoprotein pattern classified as FCH (32,33,50). 
However, it remains unclear whether this phenomenon is only more pronounced in 
hyperlipidemic subjects compared to normolipidemic individuals without an underlying 
metabolic defect. Accurate data about the prevalence of these mutations in different 
populations may help to interpret the observed influences. Increased apo CIII levels are 
associated with impaired clearance of triglyceride-rich lipoprotein due to direct inhibition 
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of LpL by apo CIII (51) Interestingly, linkage between the FCH phenotype and the 
AI/CIII/AIV gene cluster has been reported (52). However, this finding could not be 
confirmed by others, although several polymorphisms in the gene cluster were recently 
found to amplify the phenotypic expression in FCH (53). 
A portion of small VLDL, ι e , IDL, is catabohzed after apoprotein E mediated 
binding to hepatic LDL or B/E receptors, which differ from the chylomicron remnant 
receptor The affinity for the B/E receptor depends on the apo E isoform (i.e., high for 
apo E3 and E4, but low for apo E2). A recent study on the effects of apo E 
polymorphism on presenting lipid phenotype in FCH suggested that differences m apo E 
ìsoform-related clearance may only contribute to the hyperlipidemia due to other defects 
(54) Further hydrolysis ot triglycerides predominantly by hepatic triglyceride lipoprotein 
lipase (HtgL) processes remaining IDL into LDL particles which then mainly consist of 
cholesteryl esters and apoprotein В100 (55) Exchange of LDL cholesteryl esters with 
VLDL triglycerides mediated by cholesteryl ester transfer protein (CETP) activity 
determines in part the observed heterogeneity of LDL particles (56), as will be discussed 
later 
FCH AND LDL HETEROGENEITY 
Introduction 
It has been recognized for a number ot years that LDL particles are markedly 
heterogeneous in physical and chemical properties (57-61). In FCH, these properties of 
LDL are reported to be different from normal (19,62,63) The LDL subspecies in FCH 
are heterogeneous with a propensity toward small dense particles (13,19,64) The 
predominance of small dense LDL subfractions in FCH family members may not be fully 
explained by metabolic processing alone Direct still unclanfied genetic influences on the 
distribution are proposed as well (16,65,66) It is only recently that also the relationship 
of qualitative features of LDL particles to cardiovascular disease has attracted considerable 
interest This interest was raised by reports that certain LDL subpopulations may be more 
atherogenic than others due to differences in susceptibility towards oxidative modification 
(58,67-70) However, major questions about origin, structural variation and biological 
function of LDL subspecies are still only partly understood 
Identification and characterization of LDL subfractions 
Since the first reports on measurements of LDL heterogeneity, two basically 
different techniques have been used to identify LDL subspecies (ι) Nondenaturating gel 
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electrophoresis (GGE) of whole plasma or of isolated LDL, which separates several LDL 
subspecies based on differences in size (57); (ii) Density gradient ultracentrifugation 
(DCUG) of whole plasma, based on differences in density within the LDL subclass 
population (71,72). Nowadays, both techniques are widely used in large-scale studies to 
identify LDL heterogeneity. 
Using GGE, most individuals are characterized by only two or three peaks or 
shoulders on the densitometric scan. Based on the location of these peaks on the gel, LDL 
subclass pattern can be classified dichotomously in a pattern A, predominantly 
characterized by large LDL particles, and a pattern B, predominated by small LDL 
particles (26,68). Recently, the LDL peak particle diameter, was defined by the estimated 
diameter or size of the major observed LDL subclass, to classify LDL subfraction pattern 
in a more continuous fashion (73). Single-spin DGUC procedures are designed for optimal 
resolution of prestained apo В containing lipoproteins (59,61,63,74,75). Depending on the 
used salt gradient and performed ultracentrifugation, up to 15 fractions can be isolated 
within the LDL density of 1.019 to 1.063 g/ml. A single-spin DGUC procedure using 
prestained whole plasma has been the basis of the research in our laboratory. This method 
reveals up to five different LDL subtractions. Quantification by densitometric scanning 
allows the calculation of a continuous variable К describing the relative contribution of 
each LDL peak height to the total LDL (76). In a comparison study, the number of LDL 
subfractions detected by GGE or DGUC was the same for more than 90% of the sera 
(77). However, different LDL subfractions were less well separated by GGE compared 
with DGUC. Furthermore, an advantage of the DGUC is that isolated subfraction samples 
are available for further biochemical analysis. In the near future, a capillary 
electrophoretic technique may combine rate, small amount of required plasma and 
distinguisability between different LDL subtraction (78). 
Metabolic aspects of LDL subfractions 
The intravascular formation of LDL subfractions involves the conversion of VLDL 
precursors (79,80), and possibly also a direct hepatic secretion of different IDL (81), or 
LDL subspecies (30,82). Previously, it was postulated that exchange of LDL cholesteryl 
ester for VLDL triglyceride, mediated by the cholesteryl ester transfer protein (CETP), 
results in a net transfer and a significant enrichment of the LDL with triglyceride (83-85). 
The subsequent action of lipoprotein lipase (LpL) or hepatic lipase (HtgL) results in 
hydrolysis of a significant amount of the LDL triglycerides and thereby a decrease in 
particle size (86-89). The rate and magnitude of exchange may depend upon the relative 
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pool size of triglyceride-rich lipoproteins versus the cholesteryl ester-rich lipoproteins. In 
general, this hypothesis of exaggerated triglyceride transfer and lipolysis can explain the 
predominance of small dense LDL in any form of hypertriglyceridemia. However, in 
FCH, the pool of triglyceride-rich lipoproteins is primairily enlarged and consists of 
chylomicron remnants as well (37). Furthermore, also VLDL heterogeneity may underly 
LDL heterogeneity. Large triglyceride-rich VLDL, resembling chylomicrons in patients 
with LpL deficiency, were found to be rapidly removed from the circulation (49). Several 
studies demonstrated that predominantly small VLDL particles secreted into the circulation 
are converted in LDL (48,90). Using stable isotopes, it was recently demonstrated that in 
subjects with predominantly dense LDL, both an increased production and reduced 
clearance of large VLDL occurred, which then undergo intravascular catabolism to 
successively smaller remnant particles, a pathway not apparent in subjects with larger 
more buoyant LDL (91). This and numerous other studies demonstrate the complexities of 
apo В particle metabolism. However, all these studies have in common that the metabolic 
actions of lipid transfer proteins and lipases, eventually combined with substrate specificity 
as well as heterogeneity among apo В precursor particles, could account for the multiple 
different LDL subfractions observed in normal and hyperlipidemic subjects. 
Genetic aspects of LDL heterogeneity 
Accumulating data suggest that the formation of LDL subfraction profiles is 
influenced genetically (92). Especially the finding of inherited LDL subfraction profiles in 
normolipidemic families (76,93) strongly suggests a genetic background. Initially, Fisher 
et al. reported a single genetic locus without dominance thought to be responsible for 
inheritance of LDL molecular weight quality in five families (94). Complex segregation 
analysis in healthy families (93) and in families of probands with familial combined 
hyperlipidemia (65) have indicated that LDL subclass pattern B, as assessed by gradient 
gel electrophoresis, is under the influence of a major gene or genes with a dominant or 
additive mode of inheritance. Two recent studies, a study in normolipidemic families (76) 
and a study in FCH families (66) from our laboratory, in which LDL subfractions were 
detected by DCUG confirmed a major gene effect. However, in contrast with the previous 
studies of Austin et al. (65,93), we observed a recessive mode of inheritance and gene 
frequencies significantly different between the normolipidemic and FCH population 
(66,76). However, all these studies including a recently performed heritability analysis of 
a continuous LDL peak particle diameter performed in twins (95), have indicated that 
genetic factors could account for at least 40% of the variation in LDL particle size and 
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density both in normolipidemic and hyperlipidemic subjects, with the remainder 60% due 
to nongenetic or environmental influences. Among these environmental factors are age, 
gender, body mass index, smoking habits, hormonal status in women (combined estimated 
effect of 20%), and lipid and lipoprotein levels (estimated effect of 40%) (66,76). 
Additional genetic studies have linked candidate genes to the small dense LDL 
phenotype. Although only once reported, remarkably strong linkage (LOD score of 4.43) 
of pattern В to a gene locus near the LDL receptor on chromosome 19p was found in 51 
family members of 9 probands with an 'atherogenic lipoprotein phenotype' (ALP), 
whereas weaker linkage was observed with the insulin receptor locus on same 
chromosome 19p (96). In another study, the apo B100 EcoRI polymorphism, previously 
associated with variation in plasma lipids, reportedly plays a role in the susceptibility to 
develop dense LDL in presence of visceral obese hyperinsulinemic men (97). Evidence for 
linkage of pattern В to three markers on the LDL receptor itself, the apo CHI gene on 
chromosome 11, the CETP gene on chromosome 16p and the manganese superoxide 
dismutase (MnSOD) gene on chromosome 6q has also been reported. However, no linkage 
was observed for other candidate loci tested: apo B, apo Al, apo (a), apo E/CI/CIII, LpL, 
and HDL binding protein (98,99). Although the investigated genetic loci have been 
identified by polymorphic DNA markers, which do not necessarily indicate the presence 
of causative mutations, it is remarkable that the protein products of genes with observed 
linkage have connections with metabolic pathways possibly involved in the generation or 
an impaired clearance of small dense LDL: (i) because small dense LDL particles have 
been shown to have reduced affinity for the LDL receptor (100-102), altered LDL 
receptor function or regulation could result in further impairment of plasma clearance of 
these LDL or their metabolic products, (ii) Apo OH gene haplotypes are associated with 
variation in plasma triglyceride levels (51), which in turn could affect levels of small 
dense LDL. (iii) CETP may facilitate lipolytic conversion of larger to smaller LDL 
particles by promoting triglyceride transfer into the LDL core (103). (iv) A possible 
mechanism associated with MnSOD activity is unclear, but it is conceivable that defective 
function of MnSOD results in increased lipid hydroperoxides in plasma lipoproteins, with 
concomitant increase in oxidative susceptibility, or otherwise alter lipoproteins in a 
manner leading to formation of small dense more oxidizable LDL (70,99,104). 
Although genetically influenced factors resulting in retardation of catabolism of 
triglyceride-rich lipoproteins or their remnants may have an etiological or contributory 
role to formation of small dense LDL, it is striking that mutations in the gene coding for 
LpL were not linked to the pattern В (99), even so, because the LpL Asn291-»Ser was 
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recently found to be significantly linked to the presenting lipid phenotype in FCH families 
(50). 
Altogether, LDL heterogeneity results from a variety of environmental influences 
and probably also from direct genetic factors. In a family one or more defects may be 
responsible for the major gene and additive effects identified by segregation analysis. 
FCH AND PREMATURE ATHEROGENESIS 
In spite of often mildly elevated lipid levels compared to other lipid disorders, a 
high prevalence of cardiovascular diseases occurs in FCH families. The explanation for 
premature cardiovascular disease in FCH may be attributed to the increased prevalence of 
small dense LDL (26,105). 
One of the earliest events in the formation of atherosclerotic plaques is the massive 
accumulation of cholesterol in so called scavenger cells to convert into foam cells in the 
artery wall (106,107). Since normal receptor-mediated endocytosis of cholesterol via the 
LDL receptor initiates intracellular processes that prevent from further LDL uptake, 
alternative mechanisms are necessary to explain the foregoing intracellular cholesterol 
accumulation (108). Many lines of evidence support the hypothesis that oxidative 
modification of LDL plays a pivotal role in atherogenesis (109-112). However, this theory 
cannot be considered proven for the human disease (113). The oxidative modification 
hypothesis proposes that oxidative damage to LDL generates a series of modified forms of 
LDL (oxLDL) that are in a number of ways more atherogenic than native LDL. In 
contrast to native LDL, oxidized LDL is recognized and rapidly internalized by 
macrophage scavenger receptors (109), oxidized LDL (oxLDL) exhibits marked effects on 
the viability of endothelial cells and smooth muscle cells, and it alters the chemotactic 
activity of monocytes and monocyte-derived macrophages, all features of which have been 
implicated in atherogenesis (109). Special oxLDL receptors on the macrophages may not 
be down-regulated by the endocytosis of several forms of modified LDL and facilitate 
intracellular accumulation of oxLDL (114-117). Small dense LDL being more susceptible 
to oxidative modification (63,70,118) may increase the supply of oxLDL to these 
receptors. Recently, in subjects with FCH total LDL was found to be more prone to in 
vitro oxidation, due to the predominance of dense LDL particles. In addition, it was 
suggested that the decreased redox status of coenzyme Q10 in LDL from subjects with a 
dense LDL subfraction profile reflected the presence of already in vivo modified LDL due 
to lipid peroxidation in the circulation (119,120). 
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THERAPEUTIC OPTIONS IN ГСН 
Because of the up to 10-fold increased incidence of cardiovascular diseases in FCH 
patients (10,13), family screening and lipid-lowering treatment should be initiated. Both 
lowering of the total amount of atherogenic lipoproteins, i.e., LDL cholesterol and 
triglyceride-rich lipoproteins, as well as a reduction of the atherogeneity of LDL, i.e., 
reduction of total amount of small dense LDL particles should be aimed at. For this 
purpose, diet and lifestyle changes have usually insufficient effect, and consequently drug 
therapy is frequently indicated. Last decade, a spectrum of effective lipid-lowering drugs 
became available. The HMG-CoA reductase inhibitors are highly effective in patients with 
primary hypercholesterolemia to reduce LDL cholesterol (121). Although these drugs 
show some triglyceride reduction as well, less effect is observed in reduction of the 
amount of small dense LDL particles (18,122,123). Fibrates show a primary triglyceride-
lowering effect (124). Convincingly related to this effect on triglyceride levels, a reduction 
of the amount of small dense LDL subfraction is observed, whereas the total amount of 
LDL cholesterol is unaffected or may even increase (18,125,126). Due to several side 
effects, nicotinic acid which reduces especially triglyceride levels (127) is less prescribed 
in Europe. Bile acid-binding resins are frequently contra-indicated in FCH because of an 
increase of VLDL concentration (128,129). The effectivity of antioxidants, i.e., vitamin 
E, C, /3-carotene and flavonoids, to prevent LDL particles from oxidative modification is 
still under investigation. Although a reduction of in vitro LDL oxidizability has been 
observed (130-133) and a reduced risk of coronary heart disease was found (134-139), the 
results of these studies are not totally consistent. 
A direct comparison of the HMG-CoA reductase inhibitor simvastatin and the fibrate 
gemfibrozil in the treatment of FCH subjects with a combined hyperlipidemic phenotype 
demonstrated the specific effect of both drugs. However, none of these agents alone 
completely normalized the lipid and lipoprotein profiles. Interestingly, an overal dense 
LDL subfraction profile, although less pronounced, remained despite a substantial 
triglyceride-lowering (18). This finding further supports the hypothesis of small dense 
LDL being present in FCH subjects irrespective of metabolic influences. 
So far, the use of drugs should be based on which lipoprotein fraction is elevated the 
most, and probably a combination of a statin and a fibrate may be the therapy of choice in 
selected FCH patients with a high risk of cardiovascular disease. In the future, possibly 
more potent HMG-CoA reductase inhibitors, such as atorvastatin, which have also a 
strong triglyceride-lowering effect, may become the drug of choice (140,141). 
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CONCLUSION 
Because of its large impact on total cardiovascular mortality, knowledge of the 
pathogenesis of the heterogenous FCH syndrome as well as the cause of the associated 
premature atherogenesis is essential. A major difficulty arises in identifying affected 
subjects, because a specific marker for the disorder is still lacking. Therefore, family 
investigation should be performed to verify the diagnosis in a patient with combined 
hyperlipidemia and/or premature cardiovascular disease. 
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Chapter За 
ABSTRACT 
Background: Familial combined hyperlipidemia (FCH), characterized by elevated very low 
density lipoprotein (VLDL) and/or low density lipoprotein (LDL), is associated with an 
increased prevalence of premature cardiovascular disease. Therefore, lipid-lowering is 
frequently indicated. Material and methods: We evaluated in a double-blind, randomized 
fashion, parallel the effect of gemfibrozil (1200 mg/day) (n=40) or simvastatin (20 
mg/day) (n=41) on lipids, apolipoprotein-B (apo-B) containing lipoproteins, apo-CIII and 
lipoprotein(a) (Lp(a)), in 81 well defined FCH patients. Results: While both drugs 
lowered plasma cholesterol- and triglyceride levels, gemfibrozil lowered plasma 
triglycerides more effectively by reduction of triglycerides in VLDL and LDL, whereas 
simvastatin was more effective in its reduction of total plasma cholesterol by exclusively 
decreasing LDL cholesterol. High density lipoprotein (HDL) increased to an equal extent 
on both therapies. Total serum apo-B levels were reduced with both drugs; however, 
gemfibrozil decreased apo-B only in VLDL+1DL, whereas simvastatin decreased apo-B in 
both VLDL+IDL and LDL. In keeping with a more effective reduction of VLDL 
particles, also a more pronounced reduction of apo-CIII was observed after gemfibrozil, 
which correlated with the reduction in plasma triglycerides. Baseline concentrations of 
Lp(a) showed a wide range in both treatment groups. Median Lp(a) levels increased after 
simvastatin, but were not affected with gemfibrozil. Conclusion: Both therapies exhibited 
their specific effects, although none of the drugs alone completely normalized the lipid 
profiles of these patients with FCH. Therefore, the choice of treatment should be based on 
the most elevated lipoprotein fraction, and in some cases, a combination of the two drugs 
may be indicated. 
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INTRODUCTION 
Familial combined hyperlipidemia (FCH) is the most common of hereditary lipid 
disorders, with an estimated prevalence of 0.5-1.0% in the general population and 
charactarized by a strong predisposition for premature cardiovascular diseases in patients 
and first-degree relatives (1). Affected individuals have elevated very low density 
lipoprotein (VLDL) concentrations, low density lipoprotein (LDL) concentrations, or both. 
Furthermore, a low high density lipoprotein (HDL) cholesterol concentration, an elevated 
apolipoprotein-B (apo-B) concentration (2), and an increased prevalence of atherogenic 
small dense LDL subfractions is observed (3-5). Because of the absence of a specific 
clinical or metabolic marker for the disorder, and because of characteristic variability in 
the presenting lipid phenotype, family investigation is pivotal to establish the diagnosis 
FCH in a single patient (2). FCH seems to be a metabolically and genetically 
heterogenous lipid disorder (6), which, in general, is explained by an overproduction of 
VLDL particles (7,8). Furthermore, an impaired hydrolytic capacity of lipoprotein lipase 
(LpL) itself (9), or elevated plasma levels of a LpL inhibitor apo-CIII, possibly linked to 
genetic polymorphisms in the AI-CI11-AIV gencluster on chromosome 11 (10,11), may be 
related to the FCH phenotypes. 
In general, elevated concentrations of lipoprotein(a) (Lp(a)) are related to an 
increased risk for cardiovascular disease, which is independent of the cardiovascular risk 
associated with elevated lipid levels (12). Although FCH is not associated with elevated 
Lp(a) levels (13), Lp(a) concentrations correlate positively with LpL mediated metabolism 
of triglyceride-rich lipoproteins (14). Reduction of the elevated pool of triglyceride-rich 
lipoproteins, as seen in FCH, may influence plasma Lp(a) levels (15). 
Because of the high incidence of cardiovascular diseases in these patients, lipid-
lowering treatment should be initiated. If diet and lifestyle changes have insufficient 
effect, drug therapy may be indicated. For this purpose, the HMG-CoA reductase 
inhibitor simvastatin, highly effective in patients with primary hypercholesterolemia (16), 
and fibrates like gemfibrozil with a primary triglyceride-lowering effect (17) are useful. 
Until now few comparative data are available about the different effects of these 
agents in FCH. In the present study we describe the baseline levels of lipids, apo-B 
containing lipoproteins, apo-CIII and Lp(a) in well defined patients with FCH, and 




MATERIAL AND METHODS 
Subjects 
In total, 81 FCH probands trom 3 centers participated in this study. A subgroup of 
this population has been studied regarding LDL subfraction profiles and LDL oxidizability 
(5). In the present study the effects of treatment with either gemfibrozil or simvastatin on 
serum lipids, lipoproteins, apolipoprotein СШ and Lp(a) in all 81 FCH probands are 
presented. 
At the end of the screening period, all FCH patients met the following criteria: (i) a 
total serum cholesterol >6.5 mmol/1 and triglyceride level between 2.3 and 5 6 mmol/1, 
without hypolipidemic drugs and on a standard-lipid lowering diet (30 energy % fat, P/S 
ratio of 2:1, and a cholesterol intake <300 mg/day), (и) at least 1 first-degree relative 
with significant hypercholesterolemia, hypertriglyceridemia or both, (m) a positive family 
history of premature coronary heart disease, (îv) total apo-B levels above 1200 mg/1. 
Furthermore, all patients were >30 years old and patients with secondary causes for 
dyslipidemia or with apolipoprotein phenotype E 2/2 were excluded The study protocol 
was approved by the local medical ethical committees, and all patients participated after 
informed consent was obtained 
Experimental design 
This study was a double-blind trial with a double dummy design, divided into a 
screening period (weeks -8 to -5), a baseline placebo period (weeks -4 to day 0) and an 
active treatment period (day 0 to week 12) In the screening period, patients were taken 
off all hypolipidemic drugs, receiving a standard lipid-lowenng diet When total plasma 
cholesterol concentration exceeded 6 5 mmol/1, and plasma triglyceride concentration 
remained between 2 3 and 5 6 mmol/1, the patients entered the baseline placebo period of 
the study. During this period, each patient received 2 bottles, one containing placebo 
matching gemfibrozil and one containing placebo matching simvastatin During the active 
treatment period, patients were randomly assigned to receive either simvastatin 20 mg/day 
together with a placebo matching gemfibrozil (n=41) or gemfibrozil 1200 mg/day 
together with a placebo matching simvastatin (n=40) In the present study we compared 
concentrations of total plasma cholesterol and plasma triglycerides obtained at the end of 
the entering period, at the end ot the placebo period and at two time points (6 and 12 
weeks) during the period of active treatment. Furthermore, analyses of lipoproteins, 
apoproteins and Lp(a) at the end ot the placebo-controlled period were compared with the 
same data at the end of the active treatment period 
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Plasma 
Blood samples were obtained after an overnight fast and collected into 
ethylenediaminetetraacetic acid (EDTA) (lmg/ml)-containing vacutainers. Plasma was 
isolated immediately and a saccharose solution (600 mg/ml H20) was added to prevent 
denaturation of VLDL and LDL during freezing; samples were stored at -80 °C for 4 to 
15 weeks. The analysis of apo-CIII and Lp(a) was performed in the lipid research 
laboratory, university hospital of Utrecht, Apo-B was determined in the lipid research 
laboratory, university hospital of Amsterdam, all other lipid determinations were 
performed in the lipid research laboratory, university hospital of Nijmegen. 
Analytic methods 
Very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) 
were isolated together by ultracentrifugation at density < 1.019 g/ml for 16 hours at 
40,000 rpm in a fixed angle rotor (TFT 45.6 rotor, Kontron, Zürich), in a Beekman L7-
55 ultracentrifuge (Beekman, Palo Alto, USA) (18). After removal of VLDL+IDL, we 
measured cholesterol and triglycerides in the remaining plasma and in total plasma. HDL 
was determined from whole plasma by the polyethylene glycol method (19). All 
cholesterol and triglyceride measurements were determined by enzymatic methods 
(BoerhringerMannheim, Mannheim, Germany, cat. no. 237574 and Sera Pak, Tournai, 
Belgium cat. no. 6669, respectively) with a centrifugal analyzer (Multistat III; 
Instrumentation Laboratory, Lexington, MA). VLDL+IDL cholesterol and triglyceride 
were calculated by subtraction. Apo-B and apo-AI concentrations in total plasma and apo-
B concentrations in the fraction that remained after VLDL+IDL removal, were 
determined by nephelometry (20). VLDL+IDL-apo-B was calculated by subtraction. Apo-
CIII was determined quantitatively by radial immunodiffusion using plates and apo-CIII 
standards, according to manufacturer's instructions (Daiichi Pure Chemicals, Ltd, Japan). 
The diameter of the precipitation ring was measured by an investigator unaware of the 
specimen's identity. Serial samples from each subject were measured in the same assay. 
Lp(a) concentrations were determined by measuring the apoprotein(a) moiety in a 
commercially available solid phase two-site immunoradiometric assay (IRMA) using 2 
different specific anti-apoprotein(a) monoclonal antibodies (Pharmacia, Uppsala, Sweden). 
Statistics 
Results are expressed as mean + SD and as median for Lp(a). Statistical analysis of 
alterations within one group of treatment was performed with Wilcoxons' Signed Rank 
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test Differences in terms of percentage between the two groups of treatment were 
analyzed with the Mann-Whitney test. A two-tailed probability value of less than 0 05 was 
considered to be significant. The statistical analysis were performed with procedures 
available in the SPSS PC+ (Statistical Package for the Social Sciences) software package 
Version 4.0 (SPSS Inc. Chicago, II, USA). 
RESULTS: 
Participants 
After the screening period (4 weeks), participants who exhibited a lib phenotype 
(total plasma cholesterol concentration >6.5 mmol/1 and plasma triglyceride concentration 
>2.3 mmol/1) were allowed to enter the placebo period. Due to variability in presenting 
lipid phenotype during the placebo period (4 weeks), 55 patients exhibited a phenotype 
lib, 12 patients exhibited a phenotype Ha (total plasma cholesterol concentration >6.5 and 
plasma triglyceride concentrations <2 3 mmol/1), and 14 patients exhibited a phenotype 
IV (total plasma cholesterol concentration < 6 5 mmol/1 and plasma triglyceride 
concentration >2 3 mmol/1, respectively) at the end of the baseline placebo period. 
Description of the two treatment groups, the body mass index (BMI), and the blood 
pressure are presented in Table 1. 
Table 1: Age, gender.bloodpressure and body mass index of 81 patients with 
Familial Combined Hyperhpidemia 
gemfibrozil 
η 40 
53 4 ± 9 4 
26/14 
131 ± 18 
84 ± 9 
27 2 ± 3 0 
Age (years) 
Gender M/F 
Systolic bloodpressure (mmHg) 
Diastolic bloodpressure (mmHg) 
Body mass index (kg/nr) 
simvastatin 
41 










Values are presented as mean + SD 
Effect of treatment on lipid and lipoprotein concentrations 
In Figure 1 the changes of the mean total plasma cholesterol and plasma triglyceride 
concentrations during the placebo period and the period of treatment are presented. 
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Figure 1: Change in plasma concentration!, (mmol/l) of total cholesterol (TC) and triglycerides (TG) during 
the placebo period (week -4 to day 0), and on two time points (week 6 and week 12) during the period of 
active treatment with eihter gemfibrozil (D), (n = 40) or simvastatin (Ш), (n = 41) ot patients with familial 
combined hyperlipidemia; *p<0.001, ** p<0.0001, compared with the baseline level (week 0). 
At entry and at the end of the placebo period there were no significant differences in mean 
lipid and lipoprotein concentrations between the two groups, and as shown in Figure 1, 
mean lipid levels were unaffected during the placebo period. Lipoprotein levels at the end 
of the baseline period and after therapy are summarized in Table 2. During the treatment 
period, the BMI appeared to be constant in both groups. Gemfibrozil affected total 
triglyceride levels in plasma as well as in the VLDL+IDL and LDL fraction significantly 
more than simvastatin, whereas simvastatin induced the largest reduction in total plasma 
cholesterol with an exclusive reduction of LDL-cholesterol. Gemfibrozil tended to increase 
LDL-cholesterol (+8.3%, not significant). In both groups, the reduction of cholesterol 
and triglycerides in the VLDL+IDL fraction was responsible for the major decrease of 
total plasma cholesterol and triglycerides. With both drugs, HDL-cholesterol 
concentrations increased significantly to an equal extent. 
Effect of treatment on apo-B containing lipoproteins 
Alterations in the apo-B concentrations in total plasma, the VLDL+IDL fraction and 
the LDL fraction are presented in Figure 2. Simvastatin and gemfibrozil reduced total 
plasma apo-B (-25.6% and -13.7%, respectively, but simvastatin was more effectively if 
measured in percentage of change, p=0.02). Simvastatin reduced apo-B in both the 
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VLDL+IDL and the LDL fraction (-35.4% and 16.7%, respectively). 
Table 2: Lipid and lipoprotein concentrations at the end of the placebo period ( = before) and after treatment 
(=afler) with eihler gemfibrozil (n=40) or simvastatin (n=41) of patients with Familial Combined 
Hyperlipidemia 
Drug Before After Delta (%) ρ 
TC G 7.50 ± 0.98 6.73 ± 0.91 
S 7.30 ± 0.96 5.67 ± 1.00 
TG G 3.22 ± 1.22 1.64 ± 0.59 
S 3.20 ± 1.20 2.63 ± 0.88 
HDL-C G 0.91 ± 0.20 1.07 + 0.26 
S 0.84 + 0.19 0.95 ± 0.21 
VLDL + IDL-C G 2.43 ± 0.84 1.15 ± 0 . 8 4 
S 2.60 ± 1.02 1.56 ± 0.62 
VLDL+IDL-TG G 2.61 ± 1.18 1.43 ± 1.15 
S 2.59 + 1.04 2.08 + 0.79 
LDL-C G 4.08 ± 0.99 4.29 ± 1.26 
S 3.87 ± 0.98 3.16 + 0 87 
LDL-TG G 0 . 6 7 + 0 . 2 0 0.49 ± 0 . 1 3 
S 0.60 ± 0.12 0.53 ± 0 . 1 2 
Values are presented in mmol/1 as mean + SD; TC, total plasma cholesterol; TG, plasma triglycerides; 
VLDL, very low density lipoproteins; 1DL, intermediate density lipoproteins; HDL, high density 
lipoproteins; LDL, low density lipoproteins; G gemfibrozil, S simvastatin; NS, not significant; * p<0.001, 
** p<0.0001, S versus G. 
-9.5 ± 13.2 
-22.4 ± 9.2** 
-45.5 ± 19.7 
-14.6 + 27.8** 
17.4 ± 17.6 
13 9 ± 13 1 
-50.6 ± 20.6 
-37.6 ± 20.1** 
-44.7 ± 28.0 
-14.1 ± 32 6** 
8.3 ± 4 1 9 
-16.3 ± 21.0** 
-22.9 ± 19.9 
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Gemfibrozil, on the contrary, reduced apo-B only in the VLDL+IDL fraction (-42.4%; 
difference simvastatin vs. gemfibrozil in terms of percentage change, ρ < 0.0001), without 
affecting the LDL fraction (+5.5%, not significant; difference simvastatin vs. gemfibrozil 
in terms of percentage ρ < 0.0001). 
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Figure 2: Effect of treatment with eihter gemfibrozil (n = 40) or simvastatin (n=4l) on apolipoprotem-B 
containing lipoproteins in total plasma, the LDL traction and the VLDL + IDL traction ot patients with 
familial combined hyperlipidemia, black before and hatched after treatment; + p=0.000l, ** p<0.000l. 
Effect of treatment on apo-AI and -CHI 
Changes in apoprotein-ΑΙ and -OH are summarized in Table 3. The increase in 
HDL-cholesterol on both treatments was not accompanied by an increase of apo-AI in 
both groups. Apo-CIII decreased significantly with both therapies, but more pronounced 
after gemfibrozil. In general, the absolute decrease in Apo-CIII concentrations coincided 
with the decrease of VLDL+IDL particles, as measured by apo-B concentrations in this 
fraction. There was a significant correlation between the changes in apo-CIII and the 
change in plasma triglycerides after gemfibrozil and simvastatin (r=0.69 and r=0.67; 
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10.2 ± 38.9 
14.9 + 31.1 
2.9 ± 12.2 
-0.1 ± 18.1 
-26.0 ± 17.2 








Table 3: Lipoprotein (a), apolipoprotem-Al and apolipoprotein-CIII at the end of the placebo period 
(=before) and after treatment (=after) with either gemfibrozil (n=40) or simvastatin (n=41) of patients 
with Familial Combined Hyperlipidemia 
Drug Before After Delta (%) Ρ 
Lp(a) G 18.0 20.7 
S 19.6 26.1 
Apo-A I G 131.5 ± 24.7 134.4 + 24.1 
S 136.7 + 25.4 133.7 ± 22.2 
Apo-CIII G 14.8 ± 3.4 10.6 ± 2.3 
S 14.7 ± 4.7 13.6 ± 3.6 
Values are presented in mg/dl as median tor Lp(a) [lipoprolein(aj) and as mean ± SD for apo-AI 
(apolipoprotein-AI) and apo-CIII (apolipoprotein-CIII); S, simvastatin; G, gemfibrozil; NS, not significant; 
*p<0.0001, S versus G. 
Effect of treatment on Lp(a) 
Before and after therapy Lp(a) values showed a wide distribution. Effects on median 
levels are summarized in Table 3. The effect of gemfibrozil was not significant, 18 out of 
40 patients showed a decrease, but conversely, 27 out of 41 patients showed an increase 
of Lp(a) levels on simvastatin. 
DISCUSSION 
In spite of often mildly elevated lipid levels compared to other lipid disorders, there 
is a high prevalence of cardiovascular diseases in FCH families. Consequently, family 
screening and pharmacological intervention in affected individuals may be indicated (21). 
The increased tendency to premature cardiovascular disease in these patients must be 
related to the increased pool of triglyceride-rich apo-B containing lipoproteins in 
conjunction with elevated LDL cholesterol levels (22,23). In addition, 
hypertriglyceridemia, as found in FCH with type lib and IV phenotypes, is associated 
40 
Effect of gemfibrozil or simvastatin in FCH 
with augmented exchange of lipids between VLDL, HDL and LDL, mediated by 
cholesteryl transfer protein (CETP), which may result in more small dense atherogenic 
LDL particles in total LDL (24,25). Elevated apo-CIII concentrations may be associated 
with hypertriglyceridemia, because of a possible inhibition of the LpL activity by apo-CIII 
(26). Furthermore, decreased HDL cholesterol, apo-AI concentrations and elevated 
concentrations of Lp(a), may also be involved in the atherogenesis in FCH (13,27). 
Recently, large prevention trials and studies with solid cardiovascular end-points 
have established now that cholesterol lowering results in a decrease in mortality from 
cardiovascular disease, and regression of atherosclerotic lesions (28-31). Although the 
study populations did not met the FCH diagnostic criteria, it can be deduced from these 
results that lipid lowering may affect mortality and morbidity from cardiovascular events 
in FCH patients as well, because lipid parameters associated with an increase in 
cardiovascular risk are also influenced in the present study. 
The observed reduction of total plasma cholesterol and plasma triglyceride 
concentrations with simvastatin (-22.4 % and -9.5 %, respectively) and gemfibrozil (-14.6 
% and -45.5 %, respectively) after 12 weeks of treatment in our study are in accordance 
with previous reports (32,33). To investigate the effect of both therapies on triglyceride-
rich apo-B containing lipoproteins, VLDL and IDL particles were isolated together. This 
explains the relatively large contribution of VLDL+1DL cholesterol and the relatively 
small contribution of LDL cholesterol to total plasma cholesterol, both before and after 
treatment. The increase of HDL cholesterol with gemfibrozil therapy agrees with previous 
studies as well (32,34), but the increase of HDL on simvastatin, despite a less pronounced 
reduction of triglycerides, is larger than previously reported (32). The mean apo-AI 
concentration was unaffected, despite an increase in HDL cholesterol and may reflect 
HDL cholesterol particles containing less protein (35). The effects on LDL cholesterol are 
comparable with other reports (32,33). The depletion of triglycerides in the VLDL+IDL 
fraction, leading to more small dense particles, which are more likely to be converted into 
LDL particles is suggested to be a cause of the observed increase of LDL cholesterol after 
gemfibrozil (36). On the other hand, a triglyceride reduction in the LDL particle, more 
pronounced after gemfibrozil, yields more buoyant LDL subfractions, as we have 
demonstrated before (5,37). These buoyant LDL subfractions may be less atherogenic, 
because an increased resistance against oxidative modification has been described (18). 
We observed that simvastatin most effectively reduced the total LDL cholesterol 
concentration, but did not affect the LDL subfraction profile of FCH patients (5), which 
was recently demonstrated for pravastatin as well (38). 
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All patients had moderate to severe elevations of apolipoprotein-B levels. Both 
therapies reduced total apo-B, but in accordance with the reduction of total apo-B 
containing particles, simvastatin reduced apo-B in both the VLDL+IDL and LDL 
fraction more effectively than gemfibrozil, which only reduced VLDL+IDL-apo-B. Since 
VLDL+IDL and LDL particles contain only one molecule of apo-B per particle, a 
reduction of apo-B observed in these fractions reflects a reduction of the number of 
potential atherogenic particles per isolated fraction. 
It has been suggested that an elevated apo-CIII concentration may be a metabolic 
marker for FCH. The decrease of the apo-CIII concentrations in this study, however, 
significantly correlated with the decrease in triglyceride-rich lipoproteins and parallelled 
the reduction of the particle numbers in the VLDL+IDL fraction. Recently, Patsch et al, 
found a lower apo-CII/apo-CIII ratio, due to an elevated apo-CIII concentration, in VLDL 
particles of patients with type IIb hyperlipidemia, which was related to sequence variations 
in the minor allei of the AI/CIII/AIV gene cluster on chromosome 11 (39). From our 
results, it remains to be seen whether increased apo-CIII concentrations have some role in 
the pathophysiology of FCH and can serve as a metabolic marker. 
Sofar, the effects of hypolipidemic drugs on Lp(a) levels have not been very 
succesful. Studies with simvastatin demonstrated either no effect (40), or an increase of 
Lp(a) concentrations (15). Although it has been shown that Lp(a) may be bound to 
triglyceride-rich lipoproteins (41) and that LpL mediated clearance of triglyceride-rich 
lipoproteins influence Lp(a) concentrations (14), the mechanism behind this association 
remains unclear. Synthesis of Lp(a) in the liver may share some characteristics with 
VLDL synthesis, which is dependent on the amount of free fatty acids to the liver cell 
(42). It is still unclear which causes underly this possible increased supply of free fatty 
acids to the liver cell in FCH. Gemfibrozil, however, which may have some effect on the 
release of fatty acids from the adipose tissue, had no significant effect on Lp(a) 
concentrations. 
In conclusion, we directly compared the effects of two drugs with different working 
mechanisms in a well-defined large group of FCH patients, in order to support the choice 
of treatment for this heterogeneous lipid disorder. None of these agents completely 
normalized the lipid and lipoprotein profiles. However, each agent has its specific effect 
in the treatment of subjects with both elevated total plasma cholesterol and triglyceride 
concentrations. The use of drugs should be based on which lipoprotein fraction is elevated 
the most during several visits to the out-patient clinic, and probably a combination of 
gemfibrozil and simvastatin may be the therapy of choice in selected FCH patients with a 
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high risk of cardiovascular disease. 
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Chapter 3b 
ABSTRACT 
We evaluated in a double-blind, placebo-controlled randomized trial of 45 well 
defined patients with familial combined hyperlipidemia, the effect of gemfibrozil (1,200 
mg/day) or simvastatin (20 mg/day) on apolipoprotein-B (apo-B) containing lipoproteins, 
low-density lipoprotein (LDL) subfraction profile and LDL-oxidizability. Although both 
therapies lowered plasma cholesterol and triglycerides concentrations, gemfibrozil reduced 
plasma triglycerides more effectively and simvastatin reduced plasma cholesterol more 
effectively. LDL cholesterol was reduced by simvastatin. With both drugs, total serum 
apo-B concentration decreased. With gemfibrozil, this was due to an exclusive reduction 
(-46%) of very low/intermediate-density lipoprotein (VLDL+IDL) apo-B, whereas simva-
statin decreased apo-B in both VLDL+IDL and LDL (34% and 15%, respectively). 
Initially, a dense LDL subfraction profile was present in all patients. The decrease of 
LDL cholesterol with simvastatin was due to a decrease in all isolated LDL subfractions 
except LDL2; gemfibrozil increased LDL1 cholesterol and LDL2 cholesterol (p=0.001) 
and reduced LDL4 cholesterol, resulting in a more buoyant LDL sub fraction profile 
compared with simvastatin. In both groups, a predominance of small dense LDL remained 
despite therapy. LDL fatty acid composition showed a shift from oleic acid to linoleic acid 
after gemfibrozil; arachidonic acid increased after simvastatin. Vitamin E was lower after 
gemfibrozil. In the measurements of LDL oxidation, only the oxidation rate was 
significantly reduced with simvastatin. Thus, quantitative and qualitative changes of LDL 
cholesterol had only a small effect on total in vitro LDL oxidizability in this population 
suffering from familial combined hyperlipidemia. 
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INTRODUCTION 
Familial combined hyperlipidemia is a metabolically and genetically heterogeneous 
lipid disorder (1-3) with affected individuals exhibiting elevations of total cholesterol, 
triglyceride, or both, at least in partially caused by very-low-density lipoprotein (VLDL)-
apo-B (apo-B) overproduction (4). Its prevalence is estimated to be 0.5% to 1.0% (2) and 
the trait predisposes to premature cardiovascular complications (1,5). Because of the 
absence of a specific metabolic parameter characteristic of familial combined 
hyperlipidemia, family studies are pivotal for diagnosis. The current diagnosis is based on 
the following criteria (1,6): prevalence of multiple lipoprotein phenotypes in first-degree 
relatives, premature atherosclerosis, decreased high density lipoprotein (HDL) cholesterol 
levels, elevated plasma levels of apo-B (7), impaired clearance of VLDL-remnants (8) and 
an increased prevalence of small dense low-density lipoprotein (LDL) (7). A 
predominance of small LDL and its enhanced susceptibility to copper mediated oxidative 
modification (9) is associated with atherogenesis (10,11). Because of the reported 
increased risk for premature atherosclerosis, treatment with lipid-lowering drugs is 
frequently indicated (12,13). In this report we described the baseline lipoprotein concen­
trations, LDL subfraction profiles and LDL oxidizability of well-defined patients with 
familial combined hyperlipidemia and compared the effectiveness of treatment with either 




In all, 81 out-patients suffering from familial combined hyperlipidemia were selected 
by 3 participating centers, to evaluate the effect of treatment with either gemfibrozil or 
simvastatin on serum lipids. Fourty-five patients of the 3 centers were randomly assigned 
for more extensive biochemical studies. They participated after informed consent was 
obtained. At entry into the placebo baseline period, patients met the following inclusion 
criteria: total serum cholesterol >6.5 mmol/1 and triglyceride level between 2.3 and 5.6 
mmol/1; at least 1 first-degree relative with significant hypercholesterolemia, hypertri­
glyceridemia or both; a positive family history of premature coronary heart disease; total 
apo-B 100 levels > 1,200 mg/dl, and age >30 years. Patients with secondary causes for 




This study was a double-blind trial with a double dummy design, divided into three 
consecutive periods over 20 weeks. During the first period (weeks -8 to -5) selected 
patients who had taken no lipid-lowering drugs for > 4 weeks received a standard lipid-
lowering diet. The second period (week -4 to day 0) was a baseline placebo period. Each 
patient received 2 bottles, 1 containing placebo matching gemfibrozil and 1 containing 
placebo matching simvastatin. During the third period of active treatment (day 0 to week 
12) patients were randomly assigned to receive either simvastatin 20 mg/day together with 
placebo matching gemfibrozil (n=23) or gemfibrozil 1,200 mg/day together with placebo 
matching simvastatin (n=22). In the present study data obtained at the end of the placebo 
period (day 0) were compared with results obtained at the end of the period of active 
treatment (day 84). 
Plasma 
Blood samples were obtained after an overnight fast and collected into vacutainers 
containing 1 mg/ml of ethylenediaminetetraacetic acid. Plasma was isolated immediately 
and a saccharose solution (600 mg/ml Η,Ο) was added to prevent denaturation of LDL 
during freezing; samples were stored at -80 °C for 4 to 15 weeks. All determinations were 
performed in the lipid research laboratory of the university hospital Nijmegen. 
Analytic methods 
VLDL+intermediate-density (IDL) (density [d]< 1.019 g/ml) were isolated by 
ultracentrifugation for 16 hours at 40,000 rpm in a fixed angle rotor (TFT 45.6 rotor, 
Kontron, Zürich), in a Beekman L7-55 ultracentrifuge (Beekman, Palo Alto, California) 
(14). After removal of VLDL+IDL, cholesterol and triglycerides were measured in the 
remaining plasma and in total plasma. HDL was isolated from whole plasma by the 
polyethylene glycol method (15). All cholesterol and triglyceride measurements were 
determined by enzymatic methods (Boerhringer-Mannheim, Mannheim, Germany, 
[catalog, no. 237574] and Sera Pak, Miles, Tournay, Belgium [catalog, no. 6669], 
respectively) with a centrifugal analyzer (Multistat III, Instrumentation Laboratory, 
Lexington, Massachusetts). VLDL+IDL cholesterol and triglyceride were calculated by 
subtraction. Apo-B concentrations in total plasma and in fractions that remained after 
VLDL+IDL removal, were determined by nephelometry (16). For improving the 
accuracy of the results, the values obtained in our laboratory were recalculated on the 
basis of values determined by an radioimmunoassay, standardized by the International 
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Union of Immunological Societies, in 40 specially selected fresh frozen control sera 
provided by Dr. S. Marcovina (Northwest Lipid Research Laboratory, Seattle 
Washington). VLDL+IDL Apo-B was calculated by subtraction. 
Low density lipoprotein subfractionation 
LDL subfraction analysis before and after treatment was performed by density 
gradient ultracentrifugation (14). For each patient at both occasions, this analysis was 
carried out in the same run. After ultracentrifugation the LDL subfractions were visible as 
distinct bands in the middle of the tube. Up to 5 LDL subfractions could be distinguished 
concentrated in the following density ranges: LDL1 (1.030-1.033g/ml), LDL2 (1.033-
1.040 g/ml), LDL3 (1.040-1.045 g/ml), LDL4 (1.045-1.049 g/ml), and LDL5 (1.049-
1.054 g/ml). The ultracentrifugation tubes, containing the LDL subfractions stained with 
Coomassie Brilliant Blue R, were placed in a specially designed rack and photographed. 
Accurate documentation of the different LDL subfraction patterns was obtained by 
scanning the obtained slides in triplicate on a LKB 2202 ultrascan laser densitometer 
(Pharmacia LKB, Uppsala, Sweden). The mean relative peak heights (hi to h5) of the 
LDL subfractions (LDLl to LDL5) on the 3 scans were used to calculate parameter К as 
a continuous variable, to describe each individual LDL subfraction pattern (17). When 
LDL4 and/or LDL5 were detected their relative peak heights were included in the formula 
LDL[100%] = LDLl[%hl] + LDL2[%h2] + LDL3[%h3] by converting %h3 into %h3' 
in which %h3'= (%h3 + %h4 + %h5). Variable К was calculated by: К = (%hl-
%h3')/(%h2-%hl-H) (17). A negative value (-1<K<0) reflects a dense subfraction 
profile, an intemediate subfraction profile is described by K=0, and a complete buoyant 
profile delivers a positive К value (0<K<1). After photography, the LDL subfractions 
were accurately isolated by aspiration with a rubber bulb pipet and total cholesterol 
content of each subfraction was determined. 
Determination of fatty acids and vitamin E in low-density lipoprotein 
Analysis of fatty acids, extracted from LDL by vortex mixing with 3 ml n-hexane, 
was performed by gas chromatography (Varían 3400 GC, Houten, The Netherlands) (18). 
Vitamin E concentrations were determined by high-performance liquid chromatography 
(HPLC Spectra Physics Model 8800), with fluorescence detection (14). For extraction of 
vitamin E, 0.2 ml LDL was vortex mixed with 2 ml acetone and 2 ml petroleum ether. 
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Oxidation of low-density lipoproteins 
The oxidation experiments were performed as described by Esterbauer et al (19), 
with modifications by Klein veld et al (20). 
Statistics 
Results are expressed as mean ± SD. Statistical analysis of alterations within one 
group of treatment was performed with Wilcoxon's Signed Rank test. Differences in per-
centage between the 2 groups of treatment were analyzed with Wilcoxon's Rank Sum test. 
A 2-tailed probability value <0.05 was considered significant. The statistical analysis 
were performed with procedures available in the SPSS PC+ (Statistical Package for the 
Social Sciences) software package version 3.1. 
RESULTS 
Population 
At the entry to the placebo period, all 45 patients described in this study met the 
inclusion criteria. Therefore, all patients had hyperlipidemia phenotype IIB. The 
gemfibrozil group (5 women and 17 men) and the simvastatin group (5 women and 18 
men) were similar in mean age and body mass index (mean age 53.9 + 9.8 vs. 53.1 ± 
10.3 years, respectively; body mass index 27.4 ± 3.1 vs. 26.6 ± 2.9 kg/m2, 
respectively). The lipid and lipoprotein levels, body mass index and age of the 45 patients 
were equal compared with the initial population. 
The effect of treatment on plasma lipid and lipoprotein levels 
The lipid and lipoprotein levels of the patients with Familial Combined 
Hyperlipidemia before and after treatment with gemfibrozil (n=22) or simvastatin (n=23) 
are summarized in Table 1. There were no significant differences of lipid concentrations 
between the two groups at baseline. Gemfibrozil significantly affected total triglyceride 
levels in plasma as well as in the VLDL+IDL fraction, whereas simvastatin induced the 
largest reduction in total plasma cholesterol. On the other hand, VLDL+IDL cholesterol 
was reduced with both therapies to the same extent. The largest contribution to the 
reduction in total cholesterol and triglycerides was generated by a decrease in the 
VLDL+IDL fraction. LDL cholesterol was only reduced by simvastatin and even tended 
to increase after gemfibrozil therapy. HDL cholesterol levels increased with both drugs. 
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Table 1: Changes in Lipids and Lipoproteins in Subjects With Familial Combined Hyperlipidemia After 



























7.54 ± 1.13 
7.15 ± 0.87 
2.90 ± 0.91 
3.27 ± 1 . 1 9 
2.24 ± 0.77 
2.58 ± 1.02 
2.26 ± 0.76 
2.62 ± 0.90 
4.36 ± 0.86 
3 68 ± 1.01 
0.92 ± 0 . 1 8 
0.82 ± 0.21 
213 6 ± 41.0 
202.9 ± 41.3 
After 
6.51 ± 0.91 
5.58 ± 1.12 
1.42 ± 0.41 
2.61 ± 0.86 
0.96 ± 0.38 
2.04 ± 0.74 
0.99 ± 0.47 
1.50 ± 0.51 
4.59 + 0.92 
3.12 + 0.98 
1.06 ± 0.26 
0.94 ± 0.21 
164.4 ± 38.8 
152.2 ± 40 6 
Change {%) 
-12.9 ± 11.7 
-22.2 ± 9.4" 
-48.1 ± 18.0 
-15.9 ± 25.8 f 
-54.5 + 20.0 
-15.1 ± 24.2f 
-55.3 ± 30.3 
-40.9 ± 18.1" 
+9.3 ± 36.6 
-13.3 + 21.6" 
+ 15.3 ± 20.9 
+ 16.3 ± 13.1 
-21.1 ± 20.7 
















Values are presented m mmol/l as mean ± SD, except apolipoprotein-B (apo-B) which іь presented in 
mg/dl; G indicates gemfibrozil (n=22); S, simvastatin (n=23); " P<0.01, f P<0.00l, G versus S. VLDL 
indicates very low density lipoprotein; IDL. intermediate density lipoprotein; HDL, high density lipoprotein; 
LDL, low density lipoprotein. 
Effect of treatment on apolipoprotein-B lipoproteins 
A significant correlation was found between apo-B and total apo-B related 
cholesterol (total cholesterol minus HDL cholesterol) (Pearsons' correlation coefficient 
0.91; p=0.001) (Figure 1). The concentrations of VLDL+IDL cholesterol and LDL 
cholesterol also correlated with their related apo-B content (correlation coefficient 0.70; 
p=0.001; 0.63; p=0.001, respectively). Both therapies reduced total apo-B to a similar 
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extent. Gemfibrozil reduced apo-B only in the VLDL+IDL fraction, while simvastatin 
reduced apo-B in the VLDL+IDL and in the LDL fraction (Figure 2). 
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Figure 1: Correlation between total apo-B related cholesterol (total plasma cholesterol minus HDL 
cholesterol) in mmol/l and total plasma apo-B (•), VLDL + IDL apo-B ( + ) and LDL apo-B (D) (in mg/1) 
in 45 patients with FCH. 
Effect of therapy on LDL subfraction profile and К value 
Initially in all patients, LDL tended to be monodisperse, consisting of a limited 
number of LDL subfractions, with a predominance of intermediate dense (LDL2) and 
small dense (LDL3 and LDL4) subfractions. In 3 of 45 LDL subfraction profiles a clear 
very dense LDL5 band could be distinguished, which in all cases completely disappeared 
after treatment (1 after gemfibrozil and 2 after simvastatin). This sporadic LDL5 appeared 
in 3 patients with lipoprotein levels comparable to the other subjects, was excluded from 
further statistical analysis. Gemfibrozil treatment induced a less dense LDL subfraction 
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predominance of LDL1 to LDL3 as the main LDL subfractions (Figure 3). The ratio 
cholestérol/triglycéride within the LDL particle increased, whereas that of 
triglyceride/apo-B decreased, probably due to a reduction of triglyceride per LDL particle. 
The ratio cholesterol/apo-B did not change (Table 2). Simvastatin treatment reduced total 
LDL, but did not induce a major shift to a less dense LDL subfraction profile as seen 
with gemfibrozil. The amount of cholesterol in all LDL subfractions, except LDL2, was 
significantly reduced (Figure 3). Neither the ratio cholestérol/triglycéride, nor that of the 
ratio cholesterol/apo-B, or triglyceride/apo-B changed significantly (Table 2). The value of 
parameter К increased more after gemfibrozil (-0.55 ± 0.18 to -0.32 ± 0.21; p<0.001), 
than after simvastatin (-0.55 ± 0.16 to -0.47 + 0.22; p=0.04; gemfibrozil versus 
simvastatin ρ<0.05). In 5 of 45 patients treated with gemfibrozil, the dense subfraction 
profile was altered into an intermediate subfraction profile, with an equal amount of 
buoyant and dense LDL particles. The other patients retained a dense subfraction profile, 
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Figure 2: Effect of treatment with either Gemfibrozil (n = 21) or Simvastatin (n = 23) on apolipoprotein-B 
containing lipoproteins in total plasma, the VLDL + IDL fraction and the LDL traction of patients with FCH; 
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Figure 3: Effect of treatment with either Gemfibrozil (n = 20) or Simvastatin (n = 21) on the cholesterol 
content in mmol/l of four LDL subfractions (LDL1-LDL4) of patients with FCH; * p<0.05; ** p=0.001; 
*** p<0.001. 
Table 2: Changes in the Ratios Cholestérol/Triglycéride, Cholesterol/Apo-B and Tnglyceride/Apo-B of the 














7.73 ± 2 27 
6.14 ± 1 75 
1.48 ± 0.17 
1.34 ± 0.16 
0.47 ±0 .11 
0.51 ±0 .13 
After 
10 26 ± 2.62 
6.18 ± 1.87 
1.54 + 0.21 
1.36 ± 0.16 
0 36 ± 0.08 
0 55 ± 0.17 
Change (%) 
53.7 ± 67.0 
1.6 ± 20.9' 
5.8 ± 22.0 
0.5 ± 12.9 
-17.5 ± 19.3 




Values are presented as mean ± SD; G indicates gemfibrozil; S, simvastatin; Apo-B, apolipoprotein-B; 
"p<0.01, +ρ<0.001; G versus S. 
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Fatty acid composition and vitamin E content of Low-density lipoprotein 
The fatty acid composition of each isolated LDL was determined (Table 3). For 
technical reasons, only the results of 14 patients treated with gemfibrozil and IS patients 
with simvastatin could be analyzed. 
Table 3: Change in fatty acid composition and vitamin E content of total LDL after treatment with 
gemfibrozil or simvastatin in FCH patients 



























22.3 ± 1.9 
23.4 ± 2.2 
6.6 ± 0.8 
6.6 ± 0.6 
18.7 ± 1.9 
18.8 ± 1.8 
44.1 ± 3.7 
43.4 ± 3.6 
8.2 ± 1.7 
7.8 ± 1.4 
4.06 ± 1.65 
3.65 ± 1.76 
846 ± 596 
801 ± 538 
21.7 ± 1.6 
23.5 ± 2.4 
6.3 ± 0.7 
6.8 ± 0.7 
17.8 ± 1.6 
19.0 ± 2.2 
45.8 ± 3.2 
41.6 ± 4.1 
8.4 ± 1.6 
9.1 ± 1.4 
3.42 ± 1.66 
3.82 + 1.68 
1102 ± 673 
727 ± 339 
-2.8 ± 6.2 
+ 0.2 ± 5.7 
-3.1 ± 5.9 
+ 2.8 ± 6.3" 
-4.8 ± 5.7 
+ 0.9 ± 8.6" 
+4.1 ± 4.3 
-4.0 ± 6.0* 
+ 3.0 ± 14.5 
+ 20.1 ± 21.0* 
-16.5 ± 18.2 
+ 14.0 + 45.9" 
+42 ± 83 







Values of fatty acids are presented in percentage of total tatty acids as mean ± SD; G indicates gemfibrozil 
(n=14); S, simvastatin (n=15); "vitamin E in mg/g LDL protein; 'ratio ot poly unsaturated fatty 
acids/vitamin E in μιηοΙ/mg; "p<0.05, 'p<0.0 l , *p<0.001, G versus S. 
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This reduction had no effect on lipid levels, apo-B levels, or the value of parameter К 
before and after therapy in this subset, if compared with the initial 45 individuals. In the 
gemfibrozil group the relative amount of stearic acid (18:0) and oleic acid (18:1) 
decreased, whereas that of linoleic acid (18:2) increased. In the simvastatin group the 
relative contribution of linoleic acid (18:2) decreased, with an increase of arachidonic acid 
(20:4). Vitamin E in LDL decreased significantly with gemfibrozil and was unaffected 
with simvastatin. The ratio polyunsaturated fatty acids/vitamin E tended to increase after 
gemfibrozil, whereas simvastatin did not affect this ratio. 
Total LDL oxidizability 
Because of technical reasons the results of only 17 patients treated with gemfibrozil 
versus 18 patients with simvastatin could be analyzed. This reduction had no effect on 
lipid and apo-B levels, or the value of parameter К before and after therapy in this subset, 
if compared with the initial 45 individuals. Although the lag time as preoxidative phase 
tended to increase, the differences were not significant in any of treatment groups. 
Oxidation rate decreased after simvastatin (p=0.01), in contrast to gemfibrozil. Total 
amounts of produced dienes per milligram of LDL protein were similar before and after 
treatment in both groups. 
DISCUSSION 
The underlying cause of the increased tendency toward cardiovascular diseases in 
patients with familial combined hyperlipidemia is probably related to increased levels of 
small dense LDL and other atherogenic lipoprotein remnant particles (8,14,21). A 
predominance of small dense LDL is observed either as a physiologic response to lipid 
abnormalities (22), or as a distinct characteristic of the disease with a possible genetic 
basis (17,23). These small dense subfractions are associated with atherosclerosis because 
of enhanced susceptibility to copper-induced oxidative modification (14). In the present 
study we therefore investigated the apo-B containing lipoprotein concentrations, LDL 
subfraction profiles and LDL oxidizability of 45 affected patients, and evaluated the 
effects of pharmacologic intervention on these parameters. 
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The observed reduction of total plasma cholesterol and plasma tñglyceride 
concentrations with simvastatin (-22.2% and -15.9%, respectively) and gemfibrozil 
(12.9% and -48.1%, respectively) after 12 weeks of treatment are in accordance with 
previous reports (24,25). Isolation of VLDL and IDL particles together (d< 1.019 g/ml) 
instead of isolating IDL together with LDL (d> 1.006 g/ml), explains the relatively large 
contribution of VLDL+IDL cholesterol and the relatively small contribution of LDL 
cholesterol to total plasma cholesterol and also the large impact of the 2 therapies on this 
VLDL+IDL fraction. The increase of HDL cholesterol with simvastatin similar to 
gemfibrozil, despite a less pronounced reduction of triglyceride concentration after 
simvastatin, is larger than previously reported (25,26). The decrease and increase in LDL 
cholesterol with simvastatin and with gemfibrozil, respectively, are also in line with other 
reports (12,13,26). A depletion of triglycerides in the VLDL fraction by gemfibrozil, 
leading to small, more dense VLDL+IDL particles that are more likely to be converted 
into LDL particles, is suggested to be a cause of the observed increase in LDL cholesterol 
after gemfibrozil (26,27). 
All patients had moderate to severe elevations of apo-B levels in accordance with 
their elevation of lipid levels. In normolipidemic subjects total apo-B related cholesterol 
concentration correlates highly with serum apo-B. In hypertriglyceridemic states this 
correlation is less pronounced because of possible underestimation of apo-B (28), although 
the correlation between total cholesterol minus HDL cholesterol and apo-B in these 
patients was still significant. Both therapies reduced total apo-B to a similar extent, but 
just like the reduction of VLDL+IDL cholestérol/triglycéride and LDL cholesterol, 
gemfibrozil reduced only VLDL+IDL apo-B containing particles and simvastatin reduced 
both VLDL+IDL and LDL apo-B containing particles. 
Initially all patients had a dense LDL subfraction profile, both determined by 
cholesterol content in isolated LDL subtractions and described by a continuous variable, 
parameter K. This method of approach provides the opportunity to obtain more detailed 
information about small alterations in the LDL subfraction profile than the often used 
dichotomous classification in pattern A (light) and pattern В (heavy) (17). The increase of 
cholesterol in the buoyant LDL1 and LDL2 subfractions after gemfibrozil, could be 
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explained by the observed decrease of the ratio triglyceride/protein of the LDL particle, 
only after gemfibrozil, reflecting an overall reduction of triglyceride in the LDL particles. 
This triglyceride reduction, not observed after simvastatin, is associated with more 
buoyant LDL subfractions (14). It is remarkable that despite the substantial reduction of 
plasma triglyceride concentrations, none of the patients with a dense LDL subfraction 
profile had complete conversion to a buoyant LDL subfraction profile. Only 5 patients had 
conversion to an intermediate profile. These results are supported by a recent study by 
Hokanson et al (29) in which they proposed that in familial combined hyperlipidemia 
small dense LDL and hypertriglyceridemia appear as interrelated but separate 
characteristics and regulated as separate processes. 
In general, the observed LDL fatty acid composition in this FCH population was 
similar to that found in normal subjects (18). After both therapies only small alterations in 
this composition were seen. The total amount of polyunsaturated fatty acids (linoleic acid 
and arachidonic acid), most susceptible for oxidative modification (18), did not change. 
On the contrary, vitamin E as the major antioxidant in LDL was reduced only by 
gemfibrozil. This might have implications for total LDL oxidizability. 
Our data show only little effect on LDL oxidizability after treatment, less than 
suspected on the basis of a more buoyant LDL subfraction profile (14). However some ex-
planations for this lack of change in LDL oxidizability are possible: We determined LDL 
oxidizability in total LDL, which is the addition of maximal 5 LDL subfractions, so small 
changes might be undetected. Despite treatment these patient still had a predominance of 
small dense LDL particles. The ratio cholesterol/protein of LDL particles correlating with 
LDL oxidizability (30) was unaffected after both therapies. Finally, the ratio 
polyunsaturated fatty acids/vitamin E increased only with gemfibrozil. This implies that 
the expected diminished susceptibility to copper-induced oxidation because of a more 
buoyant LDL subfraction profile (14) could be offset by a reduced protection of 
polyunsaturated fatty acids from oxidation by vitamin E. 
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Chapter 4 
ABSTRACT 
Familial combined hyperlipidemia (FCH) is a heterogeneous lipid disorder, caused 
by overproduction of very low density lipoproteins and characterized by the occurrence of 
small dense low density protein (LDL) particles, all features that are also associated with 
insulin resistance. Therefore, insulin sensitivity was examined directly by means of the 
euglycemic hyperinsulinemic clamp technique in male non-obese, normotensive FCH 
patients and compared with that of their non-affected relatives, matched for age and body 
mass index (BMI). In addition, an oral 75 gram glucose tolerance test (OGTT) was 
performed and lipid values, including the LDL subfraction profile, were determined. 
During the clamp, forearm blood flow (FBF) was measured by venous occlusion 
plethysmography. All participants had a normal glucose response after the glucose load, 
whereas FCH patients showed hyperinsulinemia after OGTT and higher fasting C-peptide 
levels. During the clamp insulin concentrations increased equally in both groups. Mean 
whole body glucose uptake (M) (120-180 minutes) was lower in FCH patients compared 
with the non-affected relatives (6.89+0.31 vs. 8.94+0.76 mg/kg.min; p=0.01). Also the 
glucose uptake per unit insulin (I) was lower in FCH patients (M/I 7.46+0.50 vs. 
9.51+0.53; p=0.009). Whole body glucose uptake significantly correlated with BMI, 
plasma cholesterol and triglyceride concentrations and the individual LDL density. The 
FBF correlated with insulin sensitivity and increased significantly in non-affected relatives 
(1.9±0.12 to 2.5±0.4 ml/min.dl; p=0.025), but not in patients. Thus, FCH patients 
characterized by a predominance of small dense LDL are insulin resistant as compared 
with their non-affected relatives. This insulin resistance may partly be explained by a 
decreased insulin-induced vasodilation in skeletal muscle. 
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INTRODUCTION 
Familial combined hyperlipidemia (FCH) is a common heritable and heterogeneous 
lipid disorder, characterized by the presence of a multiple type hyperlipidemia with 
elevated plasma cholesterol and/or plasma triglyceride levels, and the frequent occurrence 
of premature cardiovascular disease in first-degree relatives (1-3). Originally, FCH was 
supposed to be caused by the variable expression of a single autosomal dominant gene 
primarily regulating plasma triglyceride levels and secondarily affecting cholesterol levels 
(1). However, several metabolic and biochemical defects that have recently been related to 
the trait suggest that the genetic basis of FCH is more heterogeneous. As a consequence, 
the spectrum of FCH also comprises other related phenotypes such as 
hyperapobetalipoproteinemia (4), the low density lipoprotein (LDL) subclass pattern В 
phenotype (5), familial dyslipidemic hypertension (6) and some features of the insulin 
resistance syndrome (7-9). 
Insulin resistance, defined as a decreased ability of insulin to stimulate glucose 
uptake, is increasingly recognized as a common factor underlying various conditions, all 
of which predispose to coronary heart disease (10). Resistance to normal action of insulin 
is related to alterations in lipid metabolism such as an excessive postprandial release of 
non esterified fatty acids (NEFA), due to impaired suppression of hormone sensitive lipase 
activity (11). An increased supply of fatty acids to liver cells is associated with very low 
density lipoproteins (VLDL) overproduction (12,13), whereas an impaired activation of 
lipoprotein lipase adds to reduced clearance of triglyceride-rich lipoproteins (14). In 
addition, insulin resistance may coincide with a predominance of small dense LDL 
particles (6,15,16), although countered by others (17). Since these features (i.e., VLDL 
overproduction, impaired lipoprotein lipase activity and a predominance of small dense 
LDL), are also characteristics of FCH, the existence of insulin resistance may be an 
important factor modulating FCH phenotypes. The interpretation of data concerning the 
association between insulin sensitivity and lipid disturbances is, however, hampered by the 
fact that several features related to lipid disorders, as visceral obesity, age, gender, 
hypertension and existence of cardiovascular disease themselves also are associated with 
insulin resistance. Furthermore, hyperinsulinemia, as a consequence of insulin resistance, 
has been directly associated with cardiovascular disease (18). 
Recent reports hypothesized that diminished glucose uptake may partly be explained 
by a decreased insulin-induced vasodilation in skeletal muscle (19,20). Furthermore, 
insulin's effect on vascular tone has been reported to be nitric oxide dependent (21). 
Interestingly, in dyslipidemic patients, endothelium-dependent vasodilation has been shown 
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to be diminished (22,23). 
Several earlier reports have suggested the presence of insulin resistance in various 
forms of hyperlipidemia. However, these findings were either based on rather indirect 
measurements such as determination of plasma concentrations of glucose, insulin and 
NEFA (8), possible confounded by obesity of the study group (9), or obtained by steady-
state plasma glucose (SSPG) and insulin (SSPI) concentration determinations after 
somatostatin administration (7). Somatostatin in itself may exhibit vascular effects. 
Therefore, in this study we have determined the sensitivity to the metabolic and 
hemodynamic effects of insulin directly by means of the euglycemic hyperinsulinemic 
clamp technique in combination with skeletal blood flow measurements. The studies were 
performed in a careful selected sample of well defined non-obese normotensive male FCH 
patients, which were compared with each of their matched non-affected relative. 
SUBJECTS AND METHODS 
Subjects 
For this study, initially 12 unrelated non-obese normotensive male FCH patients, 
selected from an available sample of well defined Dutch FCH families, were compared 
with one of their non-affected male relatives. To anticipate environmental influences we 
carefully matched related individuals (i.e., affected and unaffected) for age, body mass 
index and waist to hip ratio. In addition, all subjects were apparently healthy and met the 
following inclusion criteria: a body mass index below 27 kg/m2, blood pressure below 
165/90 mmHg (measured in the supine position after 5 minutes rest), absence of diabetes 
mellitus, a medical history of vascular disease, and use of any medication, except lipid-
lowering drugs, which were discontinued at least 1 month before participation. Two FCH 
patients and 2 relatives were habitual smokers. 
The FCH diagnosis was based on the following criteria: (i) the presence of a 
multiple type hyperlipidemia in first-degree relatives, with at least two first-degree 
relatives with a different hyperlipidemia (i.e., hypertriglyceridemia, hypercholesterolemia 
or a combined hyperlipidemia). The assessment of hyperlipidemia was based on the 
presence of constant elevated cholesterol and/or triglyceride levels above the 90th 
percentile, in spite of dietary advice (24); (ii) a positive family history of premature 
cardiovascular disease before the age of 60 years. 
Participating FCH patients had both total plasma cholesterol and triglyceride 
concentration above the 90th percentile for age and gender, following dietary advice and 
after withdrawal of lipid-lowering drugs for at least 4 weeks. In contrast, unaffected 
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relatives (9 were brothers, 2 were cousins) had both total plasma cholesterol and 
triglyceride concentration below the 75th percentile for age and gender. None of the 
subjects was homozygous for the apo E2 allele. 
Protocol and Procedures 
All participants were asked to visit the department twice after an overnight fast. 
During a first visit, a questionnaire was filled out in order to collect information on their 
medical status, and supine blood pressure, body mass index as well as the waist-hip ratio 
were measured. Further, blood was sampled for determination of baseline values for 
lipids, lipoproteins, HbA,
c
 and C-peptide and for determination of the individual 
distribution of LDL subfractions in the LDL subfraction profile. Moreover, a 75 gram 
oral glucose tolerance test (OGTT) was performed to exclude impaired glucose tolerance 
or overt diabetes mellitus. In these tests glucose and insulin concentrations were 
determined at baseline and 30, 60, 90 and 120 minutes after the glucose load. Only when 
participants showed 2-hour post-load glucose levels below 7.8 mmol/1, a hyperinsulinemic 
euglycemic clamp was performed, combined with hemodynamic measurement of blood 
pressure, heart rate and forearm blood flow, during a second visit, one to two weeks 
later. After OGTT, one FCH patient and his related control were excluded from further 
analyses due to impaired glucose tolerance of this FCH patient (2-hour glucose level of 
10.2 mmol/1). The experimental protocol was approved by the ethical committee of our 
Hospital, and all participants gave their written informed consent. 
Euglycemic Hyperinsulinemic Clamp 
Experiments were performed with the participants in the supine position in a quiet, 
temperature-controlled room (24-25°C). Under local anaesthesia (0.3-0.4 ml lidocaine 
HCL 20 mg/ml), a 20-gauge catheter (Angiocath®, Deseret Medical Inc., Becton 
Dickinson and Сотр., Sandy, Utah, USA) was inserted into the left brachial artery and 
connected with an arterial pressure monitoring line (Viggo Spectramed, No 
992399A/14368, Bilthoven, The Netherlands) to a Hewlett Packard monitor (type 78353B, 
Hewlett Packard GmbH, Böblingen, Germany). Mean arterial blood pressure (MAP) was 
determined by electronically integrated area under the brachial arterial pulse-wave form. 
The arterial line was kept patent with saline infusion (with 2 U heparin/ml added). On the 
contralateral side an identical venous catheter was inserted into a large forearm vein for 
infusion of insulin and glucose. Insulin (Actrapid®, Novo-Nordisk, Denmark) was infused 
in a dose of 60 mU/m2/minute for 180 minutes. Insulin was diluted in 50 ml 0.9% NaCl 
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with addition of 2 ml albumin, to a concentration of 1 U/mL. According to the clamp 
technique (25), plasma glucose concentration was kept at an euglycemic level by a 
variable infusion of glucose 20% solution, adjusted by arterial plasma glucose levels 
measured at 5 minutes intervals. All subjects were clamped at fasting glucose levels minus 
0.3 mmol/L. The glucose infusion rate was calculated as the given amount of glucose in 
mL/kg body weight per minute, which equals the whole body glucose uptake (M). The 
glucose uptake per plasma unit of insulin (I) (insulin sensitivity index, M/I) was calculated 
as an additional measure of insulin sensitivity. In addition, the concentrations of non-
esterified fatty acids (NEFA) were determined before and at the end. 
Forearm Blood Flow Measurement 
Forearm blood flow (FBF) was measured using mercury-in-silastic strain-gauge 
venous occlusion plethysmography on both arms as previously described (26). One minute 
before the start of the measurements (every 30 minutes), a wrist cuff was inflated to 100 
mmHg above the systolic blood pressure, to be sure that the measurement only referred to 
the forearm skeletal muscle vascular bed (27). The collecting cuff around the upper arm 
was inflated to a pressure of 45 mmHg during 8-10 heart cycles using a rapid cuff inflator 
(Hokanson E20 rapid cuff inflator, Hokanson Inc., Issaquah, Wa, USA). The strain 
gauges were connected to a Plethysmograph (Hokanson EC4 Plethysmograph, Hokanson 
Inc., Issaquah, WA, USA). Changes in FBF during the clamp procedure were calculated 
with the means of the left and right FBF. 
Analytical Methods 
Glucose concentrations were measured in duplicate using the oxidation method 
(Beekman®, Glucose Analyser2, Beekman Instruments Inc., Fullerton, CA 92634, USA). 
Plasma insulin concentrations were determined using an "in house" assay (double antibody 
method) with an inter-assay variability of 6%. C-peptide was determined using a 
commercially double antibody kit (Diagnostic Products Cooperation, cat no KPED1 
double antibody, CA 900455597, USA), with an inter-assay variability of 4.3%. 
Hemoglobin A,c was determined with a HPLC technique (BIORAD Laboratories B.V. 
Veenendaal, The Netherlands), with a reference range of 4.8-6.2%. The concentrations of 
NEFA's were determined using a commercially available ACS-ACOD method (Waco 
Chemicals GmbH cat. no. 994-75409, Neuss, Germany). Total plasma cholesterol and 
triglyceride concentrations were determined by commercially available, enzymatic reagents 
(Boerhinger-Mannheim, FRG, cat. no. 237574 and Sera Pak, Tournai, Belgium cat. no. 
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6639, respectively). VLDL was isolated from whole plasma by sequential 
ultracentrifugation at density 1.019 g/ml for 16 hours at 36,000 rpm in a fixed angle rotor 
(TFT 45.6 rotor, Kontron, Zürich, Switserland) in a Beekman L7-55 ultracentrifuge 
(Beekman, Palo Alto, USA). High density lipoprotein (HDL) cholesterol was determined 
with the polyethylene glycol 6000 method (28). LDL cholesterol was calculated by 
subtraction of VLDL and HDL cholesterol from total plasma cholesterol. Total plasma 
apolipoprotein-B was determined by immuno-nephelometry (29). To achieve accurate 
results in relation to the Center for Disease Control Standardization Program, the obtained 
plasma apo-B results were recalculated on the basis of exchange of sera with Dr. S. 
Marcovina (Northwest Lipid Research Laboratory, Seattle, WA, USA). LDL subfractions 
were detected by single spin density gradient ultracentrifugation according to a previously 
described method (30). LDL subfractions were detected by single spin density gradient 
ultracentrifugation, according to a method described elsewhere (31). After 
ultracentrifugation up to five LDL subfractions, stained with Coomassie Brilliant Blue R, 
were visible as distinct bands in the middle of the tube. Accurate documentation of the 
different LDL subfraction patterns was obtained by scanning slides of the tubes in 
triplicate on a LKB 2202 ultrascan laser densitometer (Pharmacia LKB). The mean peak 
heights (hl-h5) of the LDL subfractions (LDL1-LDL5) on the three scans were used to 
calculate a continous variable К (-1 < K < 1), as described elsewhere (32). This continuous 
variable К appeared to reflect appropriately the individual LDL subfraction proñles 
(32,33). A negative K-value (-1<K<0) reflects a LDL subfraction profile more or less 
predominated by small dense subfractions. A profile with a predominance of buoyant LDL 
subfractions reveals a positive К value (0<К < 1). 
Statistical Analysis 
Differences in baseline characteristics and baseline values for lipid, lipoproteins, 
glucose and HbA lc were tested by the nonparametric two-sample Wilcoxon signed rank 
test. The results of the glucose tolerance test were tested by comparing areas under the 
curve of both the glucose excursion curve and the insulin response. To compare the whole 
body glucose uptake and the insulin sensitivity index of the affected with that of the 
unaffected subjects, controlling for possible influence of confounding variables, an 
analysis of variance (ANOVA) was performed with age, body mass index and waist to hip 
ratio as covariates. To investigate differences in the time action of insulin on 
hemodynamic parameters between the two groups, the time/group interaction was 
calculated by repeated measures ANOVA with insulin as the dependent factor. All 
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statistical analysis were performed using the SPSS/PC + program (SPSS Ine, Chicago, 111, 
USA). Results in Tables and Figures are presented as mean+SEM unless otherwise 
indicated. Differences with a test value less than 0 05 were considered to be significant. 
RESULTS 
Baseline Characteristics 
Baseline characteristics, of both 11 FCH patients and their 11 non-affected relatives, 
are presented in Table 1 Age, BMI, waist to hip ratio and blood pressure were not 
different between both groups As a consequence of the selection procedure, all lipid and 
lipoprotein concentrations (except the LDL cholesterol concentration) were significantly 
higher in FCH patients compared with the unaffected relatives 
Table 1: Baseline anthropometric measurements, blood pressure, lipid, lipoprotein and apolipoprotein-B 
levels of the FCH patients and their non-affected relatives 
Affected Unaffected p-value 
Number 
Age (years) 
Body mass index (kg/m1) 
Waist/hip ratio 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Total cholesterol (mmol/L) 
Total triglycerides (mmol/L) 
VLDL cholesterol (mmol/L) 
VLDL triglycerides (mmol/L) 
LDL cholesterol (mmol/L) 




41 9 + 9 0 
24 9 ± 12 
0 99 ± 0 05 
122 7 ± 11 7 
79 5 ± 6 9 
7 70 ± 1 01 
3 73 ± 2 50 
1 90 ± 1 40 
2 80 ± 2 14 
4 90 + 1 39 
0 89 ± 0 17 
178 9 ± 45 3 
-0 62 ± 0 13 
11 
44 9 ± 115 
24 3 ± 1 5 
1 00 ± 004 
132 7 ± 16 5 
81 8 ± 8 4 
5 59 ± 0 85 
1 24 ± 0 43 
0 50 + 0 29 
071 ± 0 4 1 
4 03 ± 0 88 
1 20 ± 0 15 
122 8 ± 26 8 














All values are presented as means + SD, VLDL, very low density lipoproteins, LDL, low density 
lipoproteins, HDL, high density lipoproteins, Apo-B, apolipoprotein-B, ns, not significant 
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Total plasma apo-B was also higher in FCH patients than in unaffected relatives. The K-
value, as a description of the LDL subfraction profile, was more negative in FCH patients 
than in unaffected relatives, corresponding with the predominance of small dense LDL 
particles in FCH patients. 
Responses to Oral 75 gram Glucose Load 
Baseline values of fasting glucose, fasting insulin, HbA,c, C-peptide, and the 
calculated insulin to glucose ratio are presented in Table 2. C-peptide concentrations were 
significantly higher in FCH patients compared with their unaffected relatives. 
Concentrations of glucose, insulin, HbA,c, and insulin to glucose ratio all tended to be 
higher in FCH patients than in the unaffected, but these differences did not reach 
significant levels. 
Table 2: Baseline concentrations of parameters of glucose metabolism in 11 FCH patients and 11 non-
affected relatives. 





Insulin to glucose ratio 
NEFA 
All values, except the insulin to glucose ratio, are presented as means ± SEM; NEFA, non estenfied fatty 
acids; ns, not significant. 
Glucose excursions after oral glucose load were comparable in both groups (Figure 1), 
although a significant higher glucose concentration after 2 hours was observed in FCH 
patients as compared with the controls (5.73±0.52 mmol/L vs. 4.36+0.29 mmol/L, 
p=0.019). Plasma insulin responses during 2 hours after the oral glucose load, also 
presented in Figure 1, were significantly higher in patients than in controls. None of the 
participants had plasma glucose above 7.8 mmol/L, 2 hours after an oral 75 gram glucose 
load. 
5.45 ± 0.12 
8.55 ± 0.95 
5.45 ± 0.10 
0.65 ± 0.03 
1.57 ± 0.18 
0.86 ± 0.16 
5.22 ± 0.15 
7.00 ± 0.98 
5.36 ± 0.08 
0.47 ± 0.04 
1.35 ± 0.18 
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Time (min) 
Figure 1: Plasma glucose (top) and insulin (bottom) concentrations in response to the oral 75 gram glucose 
tolerance test in 11 FCH patients (•) and 11 unaffected relatives (•). For glucose response, calculated 
areas under the curve were not significantly different, hut mean glucose concentration at 120 minutes was 
significantly higher in patients than in controls. For insulin response, calculated areas under the curve were 
significantly higher in FCH. 
Metabolic Response to Clamp Procedure 
Plasma glucose values during the last 60 minutes of the clamp procedure were stable 
in patients and unaffected relatives (coefficient of variation 3.4+0.3% and 4.1+0.3%, 
respectively). Plasma insulin concentrations increased in all subjects and were similar after 
3 hours of insulin infusion in both groups (94.6±4.3 mU/L in FCH patients and 
93.8±4.8 mU/L in unaffected relatives). Whole body glucose uptake (M), calculated from 
the glucose infusion rate of both groups during the clamp procedure, is presented in 
Figure 2, and was significantly different over the last 60 minutes between FCH patients 
and unaffected relatives (6.89+0.31 vs. 8.94+0.76 mg/kg.min, respectively; p=0.01 
ANOVA). The mean M-value of the control relatives was very similar to previous 
obtained values of healthy volunteers (8.8±1.3 mg/kg.min) (34). The glucose uptake 
during the last 60 minutes of the clamp procedure per plasma unit of insulin (insulin 
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sensitivity index) also differed between both groups (M/I 7.46±0.50 vs. 9.51 ±0.53, 
respectively; p=0.009 ANOVA). 
30 60 90 120 140 160 180 
Time (min) 
Figure 2: Results of the euglycerruc hypennsuhneinic clamp procedure during 3 hours in 11 FCH patients 
and 11 unaffected relatives Lett Y-axis Mean glucose concentrations of FCH patients ( • ) and unaffected 
controls (D) presented in the upper lines Right Y-axis Significantly different mean glucose infusion rate 
(mg/kg nun) as measure tor glucose uptake during the clamp procedure of affected (closed bars) and 
unaffected (open bars) 
When the results of the related couples were compared it was found that in 9 FCH 
patients whole body glucose uptake was lower, in 1 FCH patient it was equal and in 1 
FCH patient it was higher than in their respective normolipidemic relatives (Figure 3). To 
avoid the possible confounding effect of smoking, the rates of uptake were also compared 
in non-smokers. In non-smokers the rates of whole body glucose uptake were also 
significantly lower in FCH patients (n=9) than in unaffected relatives (n=9) (6.90±0.66 
vs. 9.00±0.93 mg/kg min, respectively; p=0 019 ANOVA). Although fasting plasma 
NEFA concentrations were higher in the FCH patients than in controls, this difference 
appeared not to be significant (Table 2). Both NEFA concentrations were suppressed in a 
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similar manner during the clamp procedure (from 0.86+0.16 to 0.12+0.04 minol/L in 
FCH patients, p=0.003 and from 0.75+0.12 to 0.10+0.05 mmol/L in unaffected 


















FCH PATIENTS RELATIVES 
Figure 3: Companion of whole body glucose uptake during clamp procedure ot related couples (i.e., FCH 
patients and relatives) connected by lines. 
Effects on Forearm Blood Flow 
At baseline, the mean values of hemodynamic parameters (FBF and MAP) of both 
groups were similar. Only unaffected relatives exhibited a significant increase of 
31.8± 14.3% in forearm blood flow (FBF from 1.85+0.16 to 2.45±0.35 ml/dl.min, 
ANOVA p=0.025), whereas FCH patients showed no significant change in forearm blood 
flow (1.87±0.15 to 2.06±0.24). MAP did not change in either group (FCH patients: 
92.7+2.3 to 93.0±3.6 and relatives: 95.3+3.0 to 98.4+2.7 mmHg). The time course of 
the changes in FBF showed the major and statistically significant changes during the last 
hour of the clamp reflecting a phenomenon with slow-onset. 
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Relationship between LDL subfraction distribution and whole body glucose uptake 
The individual LDL subfraction profile, described as parameter K, correlated 
significantly with the glucose uptake during the clamp procedure (Pearson's r=0.51, 
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Figure 4: Correlation between glucose uptake during the clamp procedure and LDL density as determined 
by density gradient ultracentrifugation and described by parameter K. FCH patients are depicted by a closed 
box (•) and unaffected relatives by an open box (D) (r=0.51, p=0.008). 
When the groups were compared separately, FCH patients were more insulin resistant and 
exhibited a predominance of small dense LDL subfractions. The unaffected relatives, with 
the exception of one individual, were characterized by the presence of more buoyant LDL 
particles. 
DISCUSSION 
In this study, we demonstrated by means of the euglycemic clamp technique directly 
a reduced insulin sensitivity in well-defined male FCH patients as compared with one of 
their normolipidemic relatives. Since it has been established that insulin resistance is also 
associated with obesity, age and gender alone (35,36), it is important to emphasize that 
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these observations were not confounded by differences in gender or age, and were 
registered in the absence of obesity, hypertension and impaired glucose tolerance in the 
participants. Furthermore, we selected the affected and the unaffected participants in 
genetically related pairs, presuming that by this study design differences in environmental 
or genetic influences were reduced. Apart from the metabolic resistance to insulin 
(reduced glucose uptake), FCH patients also exhibited resistance to the vasodilator effects 
of insulin. Finally, diminished whole body glucose uptake correlated with the presence of 
small dense LDL subfractions. 
Because of the similarity in presenting lipid disturbances and the association with 
increased cardiovascular risk, diminished insulin sensitivity may be related to FCH. This 
observation is further supported by the finding that insulin resistance affects both hepatic 
VLDL production and lipoprotein lipase action features also met in FCH. Previous studies 
indicate that insulin resistance is associated with elevated concentrations of VLDL 
triglyceride (7,37,38). Recent studies, however, showed no improvement in insulin 
sensitivity after substantial reduction of plasma triglyceride levels with fibrate treatment in 
both non-diabetic men with type lib hyperlipidemia and in type II diabetic patients with 
hypertriglyceridemia (39,40). This may indicate that in some patients insulin resistance is 
of an inherited nature, not depending on plasma triglyceride concentrations, but probably 
preceding VLDL triglyceride overproduction. 
A proposed mechanism responsible for VLDL overproduction is the impaired 
postprandial suppression of NEFA release in adipose tissue due to resistance to the normal 
suppressive effect of insulin on hormone sensitive lipase (11,41). An elevated 
concentration of NEFA is associated with increased hepatic VLDL triglyceride secretion, 
possibly due to reduced intracellular apo-B degradation (12). Furthermore, when normal 
insulin mediated activation of lipoprotein lipase in adipose tissue is diminished, an 
impaired postprandial clearance of triglyceride-rich lipoproteins may occur (14). Several 
reports mentioned an impaired lipoprotein lipase activity as one of the factors contributing 
to FCH (42,43). 
A postprandial status with prolonged circulating triglyceride-rich lipoproteins is a 
provocating situation for the formation of small dense LDL particles (44). In the Kaiser 
Permanente Women Twin study and other studies small dense LDL was found to be an 
integral feature of the insulin resistance syndrome (15,16). Others, however, showed a 
significant correlation between LDL particle size and triglyceride levels, but not to insulin 
resistance in mildly hypertriglyceridemic subjects (17). Here, the authors considered small 
dense LDL a feature of the insulin resistance syndrome more as a consequence of 
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abnormalities in VLDL metabolism. Our observed correlation between glucose uptake as a 
measure of insulin sensitivity and LDL density is in accordance to these reports, but 
cannot discriminate between metabolic influences, such as the correlation with 
hypertriglyceridemia, causing a dense LDL subfraction profile, or primarily genetic 
effects related to diminished insulin sensitivity and small dense LDL in FCH. The recently 
reported major gene effect on LDL subfraction size in FCH (5,33), may possibly be found 
in mutations causing insulin resistance underlying hypertriglyceridemia and the formation 
of small dense LDL. On the other hand, reported linkage of small dense LDL to a locus 
near the LDL receptor and the insulin receptor gene on chromosome 19p (45) may 
indicate that the allele responsible for expression of small dense LDL also predisposes to 
insulin resistance. 
Disorders related to insulin resistance seems to exhibit their major defect on the 
level of glucose uptake in skeletal muscle, rather than at the level of the liver or the 
adipose tissue (46-48). Furthermore, several groups including ourselves have demonstrated 
the vasodilator effect of systemic hyperinsulinemia (19,34,49), which was reduced in non-
insulin-dependent diabetes (NIDDM) (50). It is hypothesized that decreased insulin 
sensitivity in humans may not only be due to lower insulin-mediated glucose extraction in 
insulin-sensitive tissues, but also to a lower blood flow to these tissues, due to a decreased 
ability of insulin to stimulate skeletal muscle blood flow (20). In accordance with other 
studies in which comparable systemic insulin concentrations were reached, we observed a 
30% increase in FBF in non-affected, but not in FCH patients. Although part of the 
present reported insulin resistance may be related to this diminished insulin-induced 
vasodilation, this could in fact only account for the last 60 to 80 minutes of the clamp, 
since differences in FBF between the groups became statistically significant in this period. 
The insulin-induced vasodilation seems to be endothelium-dependent (21). 
Noteworthy, reduced insulin-induced vasodilation may be due to direct endothelium 
disturbing action of elevated lipid levels (23). Therefore, in FCH patients the elevated 
lipoprotein concentration may directly influence the endothelium function, resulting in 
decreased nitric oxid release during hyperinsulinemia. Because insulin resistance itself 
may underlie VLDL overproduction, the reduced hemodynamic effects of insulin in 
hyperlipidemia can amplify metabolic disturbance as found in FCH patients. 
Recently, the Insulin Resistance Artherosclerosis Study demonstrated an inverse 
association between insulin sensitivity and atherosclerosis, as assessed by measures of the 
carotid artery wall (51). This association was eliminated, although not completely, by 
correction for traditional cardiovascular risk factors. The authors suggested that insulin 
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resistance is indeed associated with several established cardiovascular risk factors (51), 
however, the opposite conclusion of atherosclerosis underlying insulin resistance was not 
drawn. Therefore, insulin resistance in our FCH patients, exposed to elevated lipid levels 
for a relatively short period of time (mean age less than 42 year) and without signs of 
atherosclerosis, represents more likely a metabolic defect than being the consequence of 
atherosclerosis. 
In conclusion, this study suggests that FCH patients do exhibit a diminished insulin 
sensitivity. This insulin resistance may underlie the observed hyperlipidemia, characterized 
by elevated concentrations of VLDL cholesterol and triglycerides and a predominance of 
small dense LDL in the affected subjects, and may be partly explained by a reduced 
capacity of insulin to induce vasodilation in skeletal muscle of the patients. Therefore, 
interactions between insulin-action and lipid metabolism in FCH warrant further 
investigation. 
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Familial combined hyperlipidaemia (FCH) is one of the major genetic causes of 
coronary heart disease and is characterised by elevated levels of plasma cholesterol and/or 
triglycerides in individuals within a single family. Decreased lipoprotein lipase (LpL) 
activity has been found in some cases of FCH. A recent study revealed a common 
mutation in the LpL gene, LpL(Asn291-»Ser), with a frequency of 9.3% in Dutch FCH 
patients (Reymer et al., Circulation, 90 (1994) 1-998). This mutation was found in 3 out 
of 17 FCH families. Extensive family studies were subsequently performed to determine 
the effect of this mutation on the phenotypic expression of FCH. Using a pedigree-based 
maximum likelihood estimate, we demonstrated that the LpL(Asn291-»Ser) mutation 
significantly affects the levels of plasma and very low density lipoprotein (VLDL) 
triglycerides (2.03±0.21 versus 1.14+0.13 and 1.21+0.16 versus 0.62±0.09 mmol/1, 
carriers and non-carriers respectively) and VLDL- and high density lipoprotein cholesterol 
(0.83+0.10 versus 0.38±0.06 and 1.02+0.08 versus 1.29+0.05 mmol/1, carriers and 
non-carriers, respectively), but not those of plasma and low density lipoprotein (LDL) 
cholesterol. These findings indicate that the LpL(Asn291-»Ser) mutation is associated with 
elevated lipid levels, indicating it may be one of the genetic factors predisposing to FCH 
in the families studied. 
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INTRODUCTION 
Familial combined hyperlipidaemia (FCH) is commonly found among survivors of 
premature myocardial infarction. Goldstein et al. (1) were the first to show that the FCH 
syndrome was distinct from familial hypercholesterolaemia and familial hyper-
triglyceridaemia. FCH is one of the major genetic causes of coronary heart disease with 
an estimated frequency of 0.3-2% in the general population (1). FCH probands show 
elevated plasma levels of cholesterol, triglyceride, or both. The FCH phenotype may vary 
from time to time in a given patient or among affected relatives within a single family (2). 
In addition, characteristics such as increased very low density lipoprotein (VLDL) 
production, predominance of small dense low density lipoprotein (LDL), hypertension and 
insulin resistance have been described to be associated with FCH (3-5). Considering 
elevated levels of either VLDL, LDL or both as affected phenotype in family studies, 
FCH was initially suggested to be an autosomal dominant disorder (1,6). Recently, using 
complex segregation analysis, Cullen et al. (7) found evidence for a major gene acting on 
triglycerides in families with FCH. 
Several genes, including the apolipoprotein В (АРОВ) gene, the APOAI-CIII-AIV 
gene cluster, the LDL receptor and the lipoprotein lipase (LpL) genes (8-13) have been 
suggested to be associated with the appearance of FCH. However, despite extensive 
studies in FCH families, a major genetic defect underlying this heterogeneous and possibly 
polygenetic disorder has not been reported. 
Babirak et al. (12) showed in a study among relatives from homozygous LpL-
deficient probands that the heterozygous state for LpL deficiency, determined by 
measurement of posthepharin LpL activity and mass, often segregates with 
hyperlipidaemia and decreased levels of high density lipoprotein (HDL) cholesterol. In 
addition, decreased LpL activity has been found in one third of the cases with FCH (13). 
These results suggest that heterozygosity for LpL mutations may be one of the factors 
influencing the lipid phenotype of FCH. Recently, the LpL(Asn291-»Ser) mutation was 
identified in 9.3% of Dutch patients with FCH (14). The identification of this mutation in 
three unrelated FCH probands enabled us to study the inheritance of this mutation within 
FCH families and estimate its effect on the lipid levels. Statistical analysis showed that the 
LpL(Asn291-»Ser) mutation significantly affects lipid parameters, implying that this LpL 




SUBJECTS, MATERIAL and METHODS 
Subjects 
FCH probands were selected from patients, attending the lipid clinics in Nijmegen 
and Amsterdam for analysis of a lipoprotein disorder, when they fulfilled the following 
criteria: (i) elevated levels of both total cholesterol and triglycerides (at first 
measurement), (ii) a personal or family history of premature cardiovascular disease, and 
(iii) at least one first degree relative with elevated total cholesterol and/or triglycerides 
levels. None of the FCH probands had specific clinical signs, like tendon xanthomata, and 
none were homozygous for the APOE*2 allele. For all probands, a secondary cause of 
hyperlipidaemia was excluded by standard laboratory tests. Using these criteria 17 
probands were diagnosed to have FCH. The study protocol was approved by the ethical 
committee of the universities of Amsterdam and Nijmegen. 
Lipid and lipoprotein analysis 
Ethylenediamine tetraacetic acid (EDTA) blood samples were obtained from the 
three probands and family members after an overnight fasting. No lipid lowering drugs 
were administered to the subjects for 6 weeks at the onset of the study, except for 
individual II-5 of family A. This individual was still on medication when the blood 
samples were collected. Plasma was separated from cells by centrifugation at 500 g for 10 
min at room temperature, and was used for lipid and lipoprotein analysis. 
VLDL (d< 1.006 g/ml) was isolated by ultracentrifugation for 16 hours at 36,000 
rpm in an fixed-angle TFT 45.6 rotor (Kontron, Zurich) (15). Plasma and lipoprotein 
cholesterol and triglyceride concentrations were determined by enzymatic, commercially 
available reagents (No. 237574; Boehringer-Mannheim, FRG; Sera-рак, No. 6639; 
Tournai, Belgium). HDL-cholesterol was determined in whole plasma using the 
polyethylene glycol 6000 method (16). LDL cholesterol was subsequently calculated using 
the formula of Friedewald et al. (17). 
Detection of the LpL(Asn291-»Ser) mutation 
Genomic DNA was isolated from leucocytes according to Miller et al. (18). 
Identification of the LpL(Asn291-»Ser) allele carriers in probands and their families was 
performed by polymerase chain reaction (PCR) using a mutagenic amplification primer 
approach. Primer LpL291L: У-ATA ATA TAA AAT ATA AAT ACT GCT TCT TTT GGC 
TCT GAC- TG.TA-3' was designed with a nucleotide mismatch (underlined) as compared 
to the wild type LpL sequence (19). In the case of the mutant allele an Rsa\ restriction site 
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is introduced due to the germline missense mutation and the nucleotide mismatch in the 
primer. The primer was elongated with a TA-rich stretch (italics) at the 5' end to facilitate 
the subsequent electrophoretic screening (see below). PCR was performed using primer 
LpL291R 5'-GCC GAG ATA CAA TCT TGG TA-3' and primer LpL291L. The reaction 
mixture included 15 pmol of each primer, 0.5 μ% genomic DNA, 0.2 mM of each dNTP, 
10 mM Tris-HCl; pH 9.0, 1.5 Mm MgCl2, 50 mM KCL, 0.01% (w/v) gelatin, 0.1% 
Triton X-100, 0.1 unit Taq polymerase (Super Taq, HT biotechnology Ltd, UK), and 
10% dimethylsulphoxide (v/v) in a total volume of 50 μ\. Amplification was performed 
for 32 cycli of 30 s at 94 °C, 30 s at 53 °C and 1 min at 72 °C, with an initial 
denaturation period of 3 min. Some 20 μ\ of PCR products were digested with the 
restriction enzyme Rsal according to recommendations of the supplier (Pharmacia). 
Thereafter, fragments were separated on a 4% MP agarose gel (Boehringer Mannheim, 
FRG) and stained with ethidium bromide. Digestion of PCR product will reveal two 
fragments for the mutant allele of approximately 240 and 40 bp, and one fragment of 280 
bp for the normal allele. 
Statistics 
Studying three FCH families implies, in a strict sense, that there were only three 
independent observations which can be used for statistical analysis. To test for the 
statistical significance of the effect of the mutant LpL(Asn291-»Ser) allele on the 
lipoprotein traits in these three families, we used a pedigree-based maximum likelihood 
method developed by Lange et al. (20). Using standard statistical analyses would give 
similar results concerning the univariate statistical calculations but inappropriate standard 
errors due to fact that individuals are related. 
For a given pedigree of η individuals a vector of observations (x) is defined and a 
vector of expected values [E(x)], that can depend on measured variables such as gender or 
measured genotype. The covariance between the residual part of the observations, i.e., the 
part that is not accounted for by the measured genotype or other variables, depends on the 
relationship between the pedigree members and on the genetic model assumed for the 
observations. Throughout, we have modeled the variances not accounted for by the 
measured genotype as consisting of additive genetic and random environmental variance, 
recognizing that the genetic part may also reflect environmental influences shared by 
family members. However, our main interest is to test for the influence of the measured 
genotype. For a given E(x) and expected covariance matrix Σ, the log likelihood of 
obtaining the observation vector χ is: 
85 
Chapter 5 
L = -Άΐη Ι Σ I -'Л[х -E(x)]'£"'[x - E(x)] + constant, where ' denotes matrix transpose. 
The joint log-likelihood of obtaining all pedigrees is the sum of the log-likelihood of 
the separate pedigrees. Estimation involves selection of parameter values under a specific 
model that maximizes the joint likelihood of all pedigrees. The likelihood obtained for 
different models can be compared with chi-squared difference tests where λ2 = 2(L, - LQ) 
and L, and L0 denote the log-likelihood for the general (//,) and the constrained (Я0) 
hypothesis. The degrees of freedom (df) for this test are equal to the number of 
independent parameters between //, and H0 (21). The Fisher package (19) was used for 
genetic modelling. Ascertainment correction was carried out by conditioning on the 
probands. Extensive description of model definition: A: most general model allowing for: 
(i) age regression, (ii) gender-difference, and (iii) difference between carriers and non-
carriers; B: Equal to model A but no age differences; C: Equal to model A but no gender 
difference, except for the trait 'HDL-Chol' where model С is equal to model В but no 
gender difference; D: Equal to model С but no difference between carriers and non-
carriers, except for the trait 'VLDL-Tg' where model D is equal to model A but no 
difference between carriers and non-carriers and the trait 'HDL-chol' where model D is 
equal to model В but no difference between carriers and non-carriers. Testing procedure: 
(1), Model В is tested against model A. The data from the probands were omitted from 
statistical calculations in order to avoid possible ascertainment bias. 
RESULTS 
Probands and families 
As a part of an ongoing study aiming at the identification of genetic risk factors 
underlying FCH we screened 17 FCH probands for the presence of a common LpL 
mutation, LpL(Asn291-»Ser). Screening revealed three, apparently unrelated, carriers. The 
lipid parameters of these three probands, at their first visit to a lipid clinic, are shown in 
Table 1. Family members with total cholesterol and/or triglyceride levels above the 90th 
percentile using the age- and sex-related percentile levels of the PROCAM study are 
indicated in Figure 1. 
Family studies were performed for all three probands, including 67 relatives. During 
screening of these 3 families, 19 carriers for the LpL(Asn291-»Ser) mutation were found, 
including an individual related by marriage. One of the offsprings of this marriage proved 
to be homozygous for the mutation (Figure 1). 
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Figure 1: Pedigrees of the families of the three probands. Probands are indicated with an arrow. The symbol 
definitions are indicated in the figure. The homozygous carrier ot the LpL(Asn291-»Ser) mutation is relative 
number 22 of family A. Individual II-5 from family A was using lipid-lowenng drug. 
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This homozygous carrier of the LpL(Asn291-*Ser) mutation appeared to have 
hypertriglyceridaemia (total cholesterol: 4.8 mmol/1 and total triglycerides: 3.1 mmol/1) at 
the age of 22 despite very lean body constitution (BMI 21 kg/m2). Although total 
cholesterol levels are not elevated, the VLDL cholesterol is rather high, 1.44 mmol/1 
while HDL levels are decreased, 0.66 mmol/1. Screening 114 random individuals of a 
general Dutch population revealed no carriers suggesting that this mutation occurs with a 
low frequency in the general population. 
Lipid and lipoprotein levels in carriers versus non-carriers 
Plasma samples of the three probands and 67 additional family members were 
studied for lipid and lipoprotein parameters. The clinical details of allele carrying (n=19) 
family members, including the homozygous carrier, and non-carrying (л=48) family 
members are presented in Table 2. 
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Plasma samples were collected after an overnight fasting. 
The statistical analyses of these data are presented in Table 3. Compared to non-
carriers, the LpL(Asn291-»Ser) allele carriers exhibited markedly increased levels of 
plasma and VLDL-triglycerides (2.03±0.21 versus 1.14+0.13 and 1.21+0.16 versus 
0.62±0.09 mmol/1, respectively) and VLDL-cholesterol (0.83+0.10 versus 0.38+0.06) 
(Table 2). HDL-cholesterol was slightly decreased in carriers (1.02+0.08 versus 
1.29±0.05 mmol/1). As indicated in the Materials and Methods section, we considered 
allele carriers and non-carriers of three different families, implying that, in a strict sense, 
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there were only three independent observations. 



























Means and asymptotic standard errors were estimated trom the most general model using the maximum 
likelihood estimate procedures implemented in the Fisher program. Probands were excluded for these 
quantitative analyses. ' all levels are expressed in mmol/l. 
Therefore, to test for the effect of the mutant LpL(Asn291-»Ser) allele in these 
families, we used a pedigree-based maximum likelihood method (20). The principle of this 
statistical method is briefly described in the Materials and Methods section. The legend of 
Table 3 indicates the four different models that were considered for the quantitative 
variables. Model A is the most general model, estimating the effects of age, gender and 
carrier status. Models В, С and D subsequently leave out each of these effects and are 
tested for a significant decrease in likelihood. In this table we present, when significant, 
the percentage of the total variance that can be explained by age, gender or carrier status, 
respectively. BMI did not differ between the two groups. Therefore, it cannot explain the 
differences found between carriers and non-carriers and is not used for one of the models. 
Table 3 shows that age influences BMI and all lipid parameters measured except HDL-
cholesterol. In addition, gender influences levels of VLDL-triglycerides and HDL-
cholesterol. No significant effects of additional genetic or environmental variances could 
be detected on the residual variance (results not shown). 
Independently from the effects of age and gender, it is apparent that carrier status of 
the LpL(Asn291-»Ser) mutation significantly affects the levels of plasma and VLDL-
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triglycerides, VLDL- and HDL-cholesterol but not of plasma and LDL-cholesterol. In 
general, carrier status appears to explain approximately 14% of the total variance of these 
traits. 
Table 3 Log-likelihood for four different models testing the effects of age, gender, and carrier status for the 
quantitative traits and BMI in the LpL(Asn291-»Ser) pedigrees. 
Percent variance explained by 



















































Log-likelihoods for four models. Model definition: A: most general model allowing for: (ι) age regression, 
(li) gender-difference, and (ni) difference between earners and non-carriers; B: Equal to model A but no age 
differences; C: Equal to model A but no gender difference; D: Equal to model С but no difference between 
earners and non-carriers. Testing procedure: (1), Model В is tested against model A. When twice the 
difference in log-likelihoods of these models is higher than the X- corresponding to df= 1 this indicates a 
significant age difference (as indicated by " for Ρ < 0.05 (X :>3.84), * for Ρ < 0.01 (X :>7.88) or · for Ρ 
< 0.001 (X2> 10.83) (2) Model С (with dt= 1) is tested against model В as described above. When model 
В was significantly different trom model A, then model С was tested against model A. (3) Model D (with 
df= 1) is tested against model С or, in case of a significant effect of gender in model C, model B, or in case 
of a significant effect of age in model B, model A. 
DISCUSSION 
FCH is a frequently occuring lipid disorder in which multiple lipoprotein phenotypes 
occur within one family (1,6,7). Although, no major underlying defect has been found 
sofar, some studies suggested a link between heterozygosity for LpL deficiency and FCH 
(12,13). Therefore, we investigated the LpL gene as a candidate gene in Dutch FCH 
families. 
We have screened FCH families for a common mutation, LpL(Asn291-»Ser) which 
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occurs with a frequency of 9.3% among Dutch FCH patients (14). Moreover, in vitro 
site-directed mutagenesis revealed that the LpL(Asn291-»Ser) mutation affects the catalytic 
function of LpL by 50% reduction of LpL activity and mass (22), making it a feasible 
candidate gene for FCH. 
Three probands from our study carried the LpL(Asn291-»Ser) mutation. This 
allowed us to determine the effect of this mutation on lipid and lipoprotein parameters 
within FCH families. We have used a pedigree-based maximum likelihood method 
described by Lange et al. (20) allowing to study the influence of measured alleles on 
quantitative traits under different models since the subjects included are not unrelated and 
derive from only three families. Since age and gender effects have an considerable 
influence on interindividual variability (23), we have estimated the effects of age and 
gender on the quantitative lipid traits and BM1 for carriers and non-carriers. In addition to 
the influences of age and gender, the LpL(Asn291-»Ser) allele appeared to contribute 
considerably (14%) to the total variance in VLDL and HDL levels. Recently, a 
segregation analysis of 55 FCH families, predicted a model for FCH in which a major 
gene, predominantly acting on triglycerides, would explain 20% of the phenotypic 
variance in triglyceride levels (7). The influence found for the LpL(Asn291-»Ser) mutation 
on the variance in triglyceride levels and the absence of associations with total cholesterol 
levels, are in agreement with this predicted effect. 
Hamsten and co-workers (24) estimated in families for serum triglyceride 
concentration that the genetic (0.33) and cultural, i.e. smoking, alcohol intake and obesity, 
(0.23) inheritance was of similar significance. In our study, carrier status explains 
approximately 13% of the total variance in plasma triglycerides indicating that almost half 
of the genetic heritability is due to this mutation within the three families studied. For 
HDL cholesterol, carrier status explains a similar effect of the genetic heritability. This 
reduction of levels of HDL cholesterol was also observed in patients with premature 
atherosclerosis carrying the LpL(Asn291-*Ser) mutation (25). 
Sofar, only a few studies were performed on heterozygosity for LpL mutations and 
the effect of carrier status on the lipid parameters. Wilson et al. (26) found that 
heterozygotes for the LpL(Glyl88-»Glu) mutation showed moderate fasting 
hypertriglyceridaemia only after an age of 40. Secondary factors such as obesity, 
hyperinsulinaemia and lipid-raising drug use were aggravating factors on the genetic 
defect. Similar results were found with two Austrian families, carrying the 
LpL(Glyl88->Glu) mutation, in which pronounced postprandial lipidaemia was found (27). 
In contrast with the LpL(Glyl88-»Glu) mutation, homozygous carriers of the 
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LpL(Asn291-»Ser) mutation do not develop severe hyperchylomicronaemia (this study,28). 
Although the heterozygous carriers of both mutations seem to develop hyperlipidaemia in 
the presence of other predisposing factors, the homozygous carriers do differ in their 
phenotype. These differences in phenotypic effects of mutations in the LpL gene suggest 
different underlying mechanisms. 
Two studies, in which FCH patients with impaired LpL activity were screened for 
DNA changes in the LpL gene, showed that only polymorphisms but no mutations causing 
defective catabolic activity could be found in the LpL gene, implying that LpL is not a 
significant primary factor leading to FCH (29,30). Recently, Mailly and coworkers (31) 
showed, among 773 healthy men, that carriers of the LpL(Asp9-»Asn) substitution have an 
significantly higher triglyceride concentration compared with non-carriers. This study 
suggests that the common LpL(Asp9->Asn) variant is a mutation that has insufficient 
impact on its own to cause hyperlipidaemia. In combination with other predisposing 
factors LpL(Asp9-»Asn) is associated with the development of hyperlipidaemia. As a 
consequence, this mutation is also found among healthy individuals but its frequency is 
lower than in patients with hyperlipidaemia. 
Our study showed similar results for the LpL(Asn291-»Ser) mutation, association 
with a significant increase of triglycerides and VLDL-cholesterol and a decrease of HDL-
cholesterol in carriers. In addition, this mutation is found with an increased frequency in 
patients with premature atherosclerosis and FCH (14). Taken together, these findings 
suggest, that within the families described in this study, the LpL(Asn291-*Ser) mutation is 
one of the predisposing genetic factors to FCH but does not cause the disease on its own. 
Additional genetic and environmental factors are needed for complete expression of the 
FCH phenotype. 
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Apolipoprotein E Polymorphism Influences Lipid Phenotypic 
Expression, but not the Low Density Lipoprotein Subfraction 
Distribution in Familial Combined Hyperlipidemia 
Sebastian J.H. Bredie, Janine M. Vogelaar, Pierre N.M. Demacker, Anton F.H. 
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The impact of apo E polymorphism on interindividual variation in plasma lipid, 
lipoprotein concentrations, and LDL subfraction profiles was studied in 201 well-defined 
patients (88 men and 103 women) with familial combined hyperlipidemia (FCH). When 
corrected for the concomitant influences of age, gender and obesity, the allelic variation in 
the apo E gene was shown to explain a statistically significant portion of the variability in 
lipid and (apo)lipoprotein concentrations. Carriers of the apo e2 allele exhibited a 
substantial higher plasma triglyceride concentration and a lower low density lipoprotein 
(LDL) cholesterol level, while subjects with the apo ε4 allele had significant higher total 
plasma cholesterol and LDL cholesterol levels. In line with this observation, our FCH 
population was characterized by an over-representation of the apo E4 allele as compared 
with a Dutch standard population (χ2=55.2, p<0.0001). The contribution of apo E 
polymorphism to trait variability was different between sexes for plasma triglyceride, 
VLDL cholesterol, VLDL triglycerides, and high density lipoprotein (HDL) cholesterol 
levels. Apo E polymorphism had no impact on chemical composition of VLDL; for LDL 
particles the apo e2 allele was associated with a lower cholesterol to protein (C/P) ratio, 
whereas the opposite was true for the apo c4 allele. Despite the demonstrated impact of 
apo E polymorphism on plasma lipids and LDL chemical composition, in all phenotypic 
groups a dense LDL subtraction profile predominated. Thus, apo E polymorphism 
contributes to the lipid phenotypic expression in FCH, whereas further evidence was 
obtained that a dense LDL subfraction profile is an integral feature of FCH. 
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INTRODUCTION 
Familial combined hyperlipidemia (FCH) is a common heritable lipid disorder, in 
which affected individuals show elevations of plasma cholesterol, total triglycerides or 
both, with differing lipid phenotypes occurring within affected first-degree relatives, 
together with a high prevalence of premature cardiovascular disease (1-3). Originally, it 
was supposed that FCH was caused by the variable expression of a single autosomal 
dominant gene with primary action on plasma triglyceride levels and secondary on 
cholesterol levels (1). Nowadays, FCH is considered to be more heterogeneous, with on 
the one hand hepatic VLDL overproduction (4,5), possibly amplified by additional defects 
as insulin resistance, and on the other hand a deficiency in the clearance of circulating 
triglyceride-rich lipoproteins (6). To the latter molecular defects in the LpL gene may 
contribute (7). 
Apolipoprotein (apo) E, consisting of 3 common isoforms E2, E3 and E4, is one of 
the major protein constituents of chylomicrons and VLDL remnants, and is involved in the 
subsequent catabolism of these particles by allowing specific binding to hepatic receptors. 
Population studies have shown that the apo E polymorphism could explain a significant 
part of the inter-individual variability in plasma cholesterol and LDL cholesterol (8-10). In 
these studies, the apo ε2 allele was frequently associated with lower levels of total plasma 
cholesterol, LDL cholesterol and apo B, whereas for the apo e4 allele the opposite was 
observed, inherent to the different binding activities of apo E isoproteins to the hepatic 
receptor (11-13). Similar effects on lipid and lipoprotein concentrations due to apo E 
polymorphism were documented in a homogeneous sample of patients with familial 
hypercholesterolemia exhibiting the same LDL receptor mutation (14). These effects 
appeared to be dependent of age, gender, and body mass index (BMI), similar to reported 
epidemiological observations (15,16). Consequently, the effects of apo E polymorphism, 
age, gender and BMI may, at least in part, also explain the great inter-individual 
variability in lipid phenotypic expression in FCH, despite the probability of a common 
defect assumed by its inherited nature. 
Therefore, the objective of this study was to estimate the specific impact of apo E 
polymorphism on plasma lipids, lipoproteins and LDL subfraction profiles in well-defined 
FCH patients, taking concomitant influences of age, gender and BMI into account. 
SUBJECTS AND METHODS 
Families 
As a part of an ongoing study aiming at the identification of biochemical and 
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genetical aspects underlying FCH, extended FCH kindreds were recruited by family 
studies of probands attending the out-patient clinic of the Academic Hospital of Nijmegen. 
These probands repeatedly exhibited a combined hyperlipidemia with both plasma 
cholesterol and triglyceride concentrations above the 90th percentile for age and gender. 
Families were only included when they satisfied the following criteria: the presence of a 
multiple type hyperlipidemia in first-degree relatives with elevated levels of total plasma 
cholesterol and/or triglycerides using the age- and sex-related 90th percentile upper levels 
of the prospective cardiovascular Munster (PROCAM) study (17). Thus, besides a 
proband presenting a combined hyperlipidemia, the presence of at least one first-degree 
relative with hypertriglyceridemia or hypercholesterolemia was obligatory. Furthermore, 
at least one of the first-degree relatives should have cardiovascular disease before the age 
of 60 years. 
Families were excluded when first-degree family members had tendon xanthomata. 
All individuals were Caucasian with an age of 12 years or older. Information on medical 
status (i.e., diabetes, renal impairment and liver disease), medication use, alcohol intake, 
smoking habits, and hormonal status in women was collected by questionnaire. The study 
protocol was approved by the ethical committee of our Institute. None of the probands 
was homozygous for the apo ε2 allele or had hyperlipidemia due to a secondary cause 
(i.e., diabetes mellitus, hypothyroidism and hepatic or renal impairment), which was 
excluded by standard laboratory tests. Hypolipidemic drugs were discontinued at least 4 
weeks prior to drawing of the blood. 
Plasma 
Overnight fasted venous blood samples were drawn by vein puncture into K3EDTA 
containing vacutainer tubes. Non-local participants were visited at their homes, and blood 
was transported directly to the laboratory. On arrival at the laboratory within 2 hours, 
plasma was isolated for determination of the lipid and lipoprotein levels, and the LDL 
subfraction profile. 
Plasma lipid and lipoprotein assays and apo E phenotype determination 
VLDL was isolated from whole plasma by ultracentrifugation at density 1.006 g/ml 
for 16 hours at 36,000 rpm in a fixed angle rotor (TFT 45.6 rotor, Kontron, Zurich), in a 
Beekman L7-55 ultracentrifuge (Beekman, Palo Alto, USA). High density lipoprotein 
(HDL) cholesterol was determined by the polyethylene glycol 6000 method (18). LDL 
cholesterol was calculated by subtraction of VLDL cholesterol and HDL cholesterol from 
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total plasma cholesterol. For determination of its chemical composition LDL was isolated 
by seguential ultracentrifugation of the VLDL infranatant for another 20 hours. Total 
cholesterol and triglyceride concentrations were determined by enzymatic, commercially 
available reagents (Boehringer-Mannheim, FRG, cat. no. 237574 and Sera Pak, Miles, 
Italy cat. no. 6639, respectively). To obtain the chemical composition data of VLDL and 
LDL additional unesterified cholesterol and phospholipids were determined using 
commercial available reagents (Boehringer-Mannheim, FRG, cat. no. 310328, 691844). 
The protein content of VLDL and LDL was determined using the Lowry method (19) 
with chloroform extraction to remove turbidity due to lipids. From these data the mean 
ratio of cholesterol (unesterified cholesterol plus cholesterol moiety of cholesterol ester 
[ = 0.59* weight of cholesterol ester]) to protein was calculated. The chemical composition 
of each VLDL or LDL particle is expressed in percentage of dry mass of each 
contributing component (i.e., free cholesterol, cholesterol esters, triglycerides, 
phospholipids and proteins). Total plasma apo В concentrations were determined by 
immunonephelometry (20). To achieve accurate results in relation to the Center for 
Disease Control Standardisation Program, the obtained values were recalculated on the 
basis of an exchange of sera with Dr. S Marcovina (Northwest Lipid Research 
Laboratory, Seattle WA, USA). Apo E phenotypes were determined after iso-electric 
focusing of VLDL lipoproteins, as described previously (21). Results obtained for 534 
samples agreed with two exceptions well in comparison to apo E genotyping according to 
Hixson et al (22) (performed by Dr. M.J.V. Hoffer, MGC-Department of Human 
Genetics, Leiden University, Leiden; data not shown). 
Low density lipoprotein subfractionation 
LDL subfractions were detected by single spin density gradient ultracentrifugation 
(23). After ultracentrifugation up to five LDL subfractions could be distinguished as 
distinct bands in the middle of the tube concentrated in the following density ranges: 
LDL1 (1.030-1.033g/ml), LDL2 (1.033-1.040 g/ml), LDL3 (1.040-1.045 g/ml), LDL4 
(1.045-1.049 g/ml), and LDL5 (1.049-1.054 g/ml). The ultracentrifugation tubes, 
containing the LDL subfractions stained with Coomassie Brilliant Blue R, were placed in 
a specially designed rack and photographed. Accurate documentation of the different LDL 
subfraction patterns was obtained by scanning the obtained slides in triplicate on a LKB 
2202 ultrascan laser densitometer (Pharmacia LKB, Uppsala, Sweden). The mean peak 
heights (hl-h5) of the LDL subfractions (LDL1-LDL5) on the three scans were used to 
calculate the variable К as a continuous variable, that best describes each individual LDL 
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subfraction pattern (24). The contribution of each LDL subfraction, expressed by its peak 
height (%hl-%h5) relative to the total LDL subfraction profile, (total LDL [100%] = 
%hl + %h2+%h3+%h4+%h5), was calculated. The relative peak heights of LDL3 and 
the less frequently occurring LDL4 and/or LDL5 were added to give %h3' = (%h3+%h4-
+ %h5), where LDL[100%] = LDLl[%hl] + LDL2[%h2] + LDL3[%h3']. When a 
subfraction profile was characterized by a predominance of buoyant LDL particles (hl-
h3>0), variable К was calculated by K=(%hl-%h3')/(%h2-%h3' + l). In case of a 
predominance of heavy, dense LDL subfractions (hl-h3<0), variable К was calculated 
by: K = (%hl-%h3')/(%h2-%hl + l). A negative value (-1<K<0) reflects a dense LDL 
subfraction profile and a positive К value (0< K< 1) a buoyant profile. 
Statistical methods 
All statistical analyses were performed for affected FCH relatives as a group and 
because of different frequency distributions in men and women for plasma lipids, 
lipoproteins, and concomitant effects (i.e., age and BM1), shown by epidemiological 
studies (15,25), also an additional analysis was performed for men and women separately. 
Differences between men and women for the quantitative trait means depicted in Table 1 
were evaluated by Student's τ test. Allele frequencies were determined by the gene-
counting method under the hypothesis of a Hardy-Weinberg equilibrium. Differences in 
apo E phenotype frequencies between FCH relatives and either spouses or a representative 
sample of the Dutch population (8) were evaluated by the χ2 test. Multiple regression 
analysis was used to estimate on the parameters the possible concomitant effects of age, 
gender, BMI, smoking habits, and hormonal status in women. Initially, affected FCH 
subjects were distinguished from unaffected relatives on the basis of elevated lipid 
concentrations (total plasma cholesterol >6.5 mmol/1 and/or plasma triglycerides >2.0 
mmol/1). By this classification age, gender and BMI significantly contributed to the 
variation of a majority of the parameters, whereas smoking habits and hormonal status in 
women did not. When percentile data (total plasma cholesterol and/or total plasma 
triglycerides >90th percentile for age and gender) were used to identify affected relatives, 
age and BMI did not contribute anymore to the variation in the parameters, since these 
concomitant effects appeared to be incorporated in the percentile data itself. Therefore, the 
actually presented analyses were performed with data of relatives classified by using the 
percentile data. A two-way ANOVA with independent variables 'apo E phenotype' and 
'sex' towards dependent lipid parameters followed by Scheffe's post-hoc multiple 
comparison test was performed to determine the effects of apo E polymorphism on plasma 
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lipids, (apo)lipoproteins, the chemical composition of VLDL and LDL and the LDL 
subfraction profile, for each sex separately. Statistical analyses were performed by the 
Department of Medical Statistics using procedures available in the Statistical Analysis 
System software package (SAS Institute Inc., Сагу, N.C.). A trait difference with a p-
value less than 0.05 was considered to be significant. 
RESULTS 
Subjects 
In total, 40 multi-generational FCH kindreds including 660 individuals (558 FCH 
relatives and 102 spouses) were used in this study. Based on percentile data, 201 
individuals were found to be affected by exhibiting a total plasma cholesterol and/or a 
plasma triglyceride concentration above the 90th percentile for age and gender. The 
anthropometric measurements of the affected subjects, as well as the plasma lipid and 
lipoprotein levels (88 men and 113 women) are shown in Table 1. 













Women (n= 113) 
47.3 ± 16.8 
26.3 ± 3.9 
6.91 ± 1.35 
2.75 ± 1.75 
1.19 ± 0.93 
1.86 ± 1.46 
1.14 ± 0.34 
4.58 ± 1.26 
168.8 ± 35.3 
-0.41 ± 0.27 
Men (n = 88) 
45.1 ± 15.5 
26.7 ± 3.2 
7.12 ± 1.25 
4.03 ± 3.16 
1.85 ± 1.44 
3.04 ± 2.70 
0.90 ± 0.26 
4.39 ± 1.33 
181.1 ± 38.7 












Values are presented as mean ± S.D.; n.s. not significant, "in mmol/l. 
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Both in men as well as in women mean age and BMI were similar. Men exhibited higher 
concentrations of plasma triglycerides, VLDL cholesterol, VLDL triglycerides and apo B, 
and lower concentrations of HDL cholesterol. Total plasma cholesterol and LDL 
cholesterol concentrations were not different between both sexes. Despite lower 
triglyceride levels in women, both sexes had on the average a substantial negative K-
value, which represents a LDL subfraction profile in which small dense LDL particles 
predominate. In men, this feature was more pronounced. 
Phenotype and allele frequencies 
Table 2 depicts the phenotype and allele frequencies in our sample of Dutch FCH 
patients and unaffected relatives compared to a standard Dutch control population (8). Apo 
E phenotype and apo ε allele frequencies in spouses (n = 102) were similar compared to 
the Dutch control population, but differed significantly from those in affected and 
unaffected FCH relatives (Table 2). The apo ε2 allele frequency was comparable in both 
FCH relatives and controls, but the apo ε4 allele frequency in FCH relatives, especially in 
FCH patients, was higher. 
Effects of apo E polymorphism on lipids and (apo)lipoproteins 
The impact of apo E polymorphism on trait means in the 88 male and 113 female 
affected FCH relatives is summarized in Table 3. Reported average alcohol intake and 
smoking habits appeared to be similar among the apo E phenotype groups. Of all 558 
FCH relatives 6 individuals had an apo E2/2 phenotype without exhibiting a 
hyperlipidemia. With the whole group of affected relatives differences related to gender 
were observed for plasma triglycerides, VLDL cholesterol, VLDL triglycerides and HDL 
cholesterol. The significance of the overall difference for the traits between the 5 apo E 
phenotypes is depicted by the p-value in Table 3. When phenotype means were compared 
mutually for both sexes, significant differences between the phenotypes could be observed 
for plasma triglycerides (phenotype E3/2 vs. E4/4, Scheffé's test ρ <0.05), VLDL 
triglycerides (phenotype E3/2 vs. E4/4, Scheffé's test ρ <0.05) and LDL cholesterol 
(phenotype E3/2 vs. E3/3 and E4/4 Scheffé's test ρ < 0.001, and vs. E4/3 and E4/2 
Scheffé's test ρ<0.05). Within this sample, specific differences between apo E 
phenotypes for total plasma cholesterol concentration could not be distinguished. 
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Table 2: Apo E phenotype and allele frequencies in our FCH population (affected and unaffected subjects), 
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X = 9.4 
df=2 
P= : 0.009 
Spouses" 














AThe apo E phenotype and allele frequencies in 2018 
"Represents the apo E phenotype and allele frequencies in 
different population samples were analyzed by χ analysis; 
randomly selected 35-year-old Dutch males (8); 
the spouses of FCH relatives, Differences between 
n.s. not significant. 
Effects of apo E polymorphism on VLDL and LDL composition 
Apo E polymorphism had no detectable effect on VLDL chemical composition (data 
not shown), except that men exhibited an overall lower protein content, and therefore a 
higher cholesterol to protein (C/P) ratio in all phenotype groups (data not shown), in 
agreement with the slightly lower K-values in the males. On the contrary, apo E 
polymorphism had a significant effect on chemical composition data of LDL particles 
(Table 4). The relative cholesterol ester content was lower in subjects with phenotype 
E3/2 compared with those with E4/3 (Scheffé's test p<0.05). The same was true when 
compared with subjects with E4/4 (Scheffé's test p<0.01). The triglyceride content was 
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higher in individuals with phenotype E3/2 compared with those with E3/3 and E4/3 
(Scheffé's test ρ < 0.01). The phospholipid content was significantly lower in subjects with 
phenotype E4/4 compared with those with E3/3 (Scheffé's test p<0.01) (Table 4). 
Table 3: Plasma concentrations of lipids, lipoproteins and apolipoproteins according to apolipoprotein E 

































5 88±1 27 
7 15±2 13 
3 49 ± 2 34 
6 13 ± 4 29 
1 25 ± 0 82 
2 84 ± 2 20 
2 37+1 97 
4 97±3 83 
1 15 + 0 40 
0 91+0 38 
3 49±1 08D D 
3 40 ± 1 24D D 
0 50+0 16 
0 52±0 21 
161 2±55 4 
187 0±41 0 




7 10±1 38 
7 3 2 ± 0 89 
2 88±2 05 
3 49 ±3 25 
1 30±1 09 
1 55±1 34 
2 03±1 97 
2 58±2 84 
1 14±0 40 
0 9 6 ± 0 22 
4 6 6 ± 1 12 
4 79±І 22 
0 44±0 12 
0 4 6 ± 0 17 
169 7±31 9 




6 5 1 ± 0 8 1 
6 00±0 82 
2 89±2 08 
4 08 ±2 50 
1 43±1 18 
] 83±1 12 
2 13±1 77 
3 10±1 97 
1 04+0 38 
0 86 + 0 19 
4 01 + 1 47F 
3 31±0 45F 
0 36±0 19 
0 3 5 ± 0 11 
151 6 + 31 8 




6 99±1 36 
6 77 ± 0 92 
2 5 9 ± 1 13 
4 05 ± 2 97 
1 14±0 83 
1 75±1 19 
1 6 6 ± 0 95 
3 0 4 ± 2 37 
1 11 ± 0 25 
0 8 9 ± 0 21 
4 74±1 25F 
4 14+1 0 9 Е 
0 4 8 + 0 14 
0 4 4 ± 0 12 
174 1±33 7 




7 5 1 ± 0 84 
7 30±1 34 
1 84 + 0 93 е 
2 70±1 74 г 
0 7 6 ± 0 58 
1 42 ± 0 93 
1 15 ± 0 84' 
1 92 + 1 21' 
1 2 7 ± 0 30 
0 85±0 36 
5 49±1 04с< 
5 І0±1 5 6 " 
0 43±0 12 
0 5 9 ± 0 25 
168 0+19 6 










Values are presented as inean + SD in mmol/l for lipids and lipoproteins and in mg/1 for apoprolein-B, TC total plasma 
cholesterol, TG total plasma triglycerides, différentes between 5 phenotypes if both men and women are considered 
together, t sex difference p<0 01 Scheffé's posi hoc tests <p<0 05, c rp<0 001 E3/2 vs E4/4 "Dp<0 001 E3/2 vs 
E3/3,Ep<0 05 E3/2VS E4/3,Fp<0 05 E3/2 vs E4/3. η s nol significant 
A sex difference was observed for the free cholesterol content and for the cholesterol to 
protein (C/P) ratio. This C/P ratio was lower in subjects with E3/2 compared with 
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subjects with E3/3 (Scheffé's test ρ < 0.05) and higher in subjects with E4/4 compared 
with those with E3/2 (Table 4). 
Table 4: Chemical composition of low density lipoproteins (in percentage of dry mass) according to 






















7 8 ± 1 4 
7 0 ± 1 8 
35 6 ± 5 6 
33 7 ± 8 0 
10 4 ± 3 5 " 
14 2 ± 7 9 с с 
20 8 ± 1 4 
18 4+.6 6 
25 4 ± 3 3 
26 7 ± 2 7 
I 17±0 26 с 
1 04±0 29' 
Apoli|K>protein E phenotypes 
ЕЗ/3 
7 9 ± 1 5 
7 6 ± 1 2 
37 2 ± 8 6 
40 3 ± 4 5 
8 І ± 3 0 
8 5 ± 5 5 
20 4 + 3 3 
20 1+2 0 
26 5 ± 7 0 
23 5 ±2 4 
I 22±0 31 
1 37±0 27 
Е4/2 
8 8 ± 1 9 
6 6 ± 0 5 
41 7 ± 6 3 
38 8 ± 3 1 
7 4 ± 2 6 
8 3 ± 3 2 
160 + 7 2 
1 8 6 ± 0 7 
26 2 ± 4 6 
27 8 ± 0 2 
1 32±0 30 
1 07+0 08 
Е4/3 
7 9 ± 0 9 
7 3 ± 1 0 
40 2 ± 3 9D 
39 9 ± 4 6" 
8 3 ± 2 4DD 
8 5±Э 4DD 
18 3 ± 5 2 
17 7 ± 4 8 
25 3±2 4 
26 6 ± 2 4 
1 27±0 16 
1 18±0 20 
Е4/4 
8 6 ± 0 8 
8 0 + 1 6 
43 4 ± 4 0СЕ 
41 Э±7 9 г с 
7 3 ±2 8 
9 8 ± 5 5 
17 l ± 6 4 r F 
14 2 ± 8 4FF 
23 8 ±2 2 
26 7 + 3 3 
1 45 ± 0 15' 








Values arc presented as mean±SD, FC free cholesterol. CE cholesterol ester, TG triglycerides, PL phospholipids, 
PROT proteins, C/P ratio, ihe ratio of cholesterol (i e . FC plus cholesterol moiety of CE ( « 0 59*wciglu of CE]) to 
protein, ADifferences between 5 phenotypes if bolh men and women are considered together, % sex difference p < 0 05 -
Scheffé's post hoc tests c p < 0 05, c c p < 0 01 E3/2 vs E3/3. D p<0 05. n D p<0 01 ЕЗ/2 vs F4/3,'p<0 05, E E p < 0 01 
E3/2 vs E4/4,F Fp<0 01 ЕЗ/Э vs E4/4, η s not significant 
Effects of apo E polymorphism on LDL subfraction distribution 
The distribution of LDL subfractions in a LDL subfraction profile were both 
described by the amount of cholesterol measured in each separated LDL subfraction 
(Figure 1), and by the continuous variable K, taking the relative contribution of each LDL 
subfraction into account (Table 5). Data of 12 affected subjects were missing due to 
technical errors or lack of sufficient amount of plasma. As a consequence of the effect of 
apo E polymorphism on total plasma LDL cholesterol, highest individual LDL subfraction 
cholesterol concentrations were observed in patients with the apo E4/4 phenotype and 
lowest with apo E3/2 phenotype (Figure 1). However, no effect of apo E polymorphism 
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on the distribution of LDL subfractions pattern was observed, despite the established 
quantitative effect on lipid and (apo)lipoprotein concentrations. Affected FCH relatives 
exhibited a predominance of heavy LDL particles as described by negative К values in all 
apo E phenotype groups (Table 5). Men showed more dense LDL subfraction profiles 
(i.e., more negative К values) than women. 
Table 5: Distribution of low density lipoprotein subfraction profiles, described by a continuous variable К 
according to apohporotein E phenotypes in 189 affected subjects of a sample of Dutch familial combined 
hyperlipidemia families. 
Аро1і|торгоіеіп E phenotypes 
Trait Sex ЕЭ/2 E3/3 E4/2 E4/3 E4/4 p-valueA 
Number ? 15 39 5 40 11 
i 12 31 3 23 10 
K-value 9 -0 34±0 06 -0 44±0 05 -0 36±0 13 -0 46±0 04 -0 25±0 08 ns 
it -0 45±0 07 -0 52±0 05 -0 67±0 07 -0 52±0 04 -0 45±0 12 
Values are presented as mean + SEM; differences between 5 phenotypes if both men and women are 
considered together; % sex difference p=0,004. 
Additionally, each apo E phenotype showed a predominance of dense LDL3 particles, as 
measured by the cholesterol content in the subfractions both for men and women (Figure 
1). In the general picture there was one exception in women with apo E4/4. Only in this 
group the distribution of LDL subfractions showed a buoyant profile with highest 
concentration in LDL1 (Figure 1). 
DISCUSSION 
Although the genetic nature of FCH seems obvious, it remains to be established 
whether different affected subjects represent the same metabolic defect or whether 
additional genetic factors (e.g., gender and apo E polymorphism), or concomitant 
influences of age and BMI could amplify the lipid phenotypic expression of FCH. 
Population based studies have documented the genetic variance of plasma lipids both 
in normolipidemic subjects (8-10,12) and in hypercholesterolemic subjects (14), associated 
with the apo E phenotype. In the present study, we could demonstrate that the apo E 
polymorphism also contributes to the magnitude of lipid and lipoprotein concentrations 
among affected subjects of 40 well-defined FCH families. 
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LDL t L e t I LOL 1 LDL 4 LOL I LDL 1 LDL I LOL 4 LOL · 
Figure 1: Cholesterol content of 5 isolated LDL subtractions contributing to the total LDL subtraction 
profile according to the apolipoprotein E phenotypes of 189 affected FCH patients. The black and the 
hatched bars represent men and women, respectively. Mean sex-difference if all apo E phenotypes are 
considered together for LDLI p=0.006, for LDL2 p = 0.016, for LDL3 p = 0.026, for LDL4 n.s., and for 
LDL5 n.s.; *p<0.05, **p<0.01 when equivalent LDL subfractions are compared with E4/4, (tfp<0.05 
E3/2 vs. E3/3 or E4/3; all differences are observed both for men and women. 
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Like familial dysbetalipoproteinemia (FD) in which other factors next to the apo 
E2/2 phenotype contribute to the expression of the hyperlipidemia (26), a similar 
coincidence of factors may appear in FCH. Clearly, the presumed overproduction of 
VLDL particles as a primary cause of FCH, would be exaggerated by the differential 
effect of the apo ε2 allele on VLDL remnants and of the apo ε4 allele on LDL 
cholesterol. The effect of the apo ε2 allele was confirmed by the observed accumulation of 
beta-VLDL in FCH subjects with extensive premature atherosclerosis related to a 
heterozygote apo E3/2 pattern (27), which was independent of the LDL receptor status as 
reported by others (28). In our FCH sample, indeed, higher VLDL cholesterol and 
triglycerides concentrations were observed in subjects with apo E3/2. The observed 
elevated LDL levels in subjects with the possession of an apo E4 allele hypothetically 
results from the more efficient uptake of chylomicrons and VLDL remnants by the liver 
increasing intracellular cholesterol, thereby reducing LDL receptor activity and thus 
elevating plasma LDL cholesterol levels (11). 
When apo E alleles effects are primarily related to FCH, the allele frequency would 
deviated from normal. In a comparative study between hypercholesterolemic patients and 
non-obese patients with combined hyperlipidemia (serum cholesterol >7.5 mmol/1 and 
serum triglyceride >2.0 mmol/1) the apo ε2 allele, together with smoking habits and 
fasting insulin concentrations explained 30% of the hypertriglyceridemia and the low 
HDL-cholesterol levels (29). Besides specific apo ε2 related differences on plasma lipids, 
also the frequency of the apo ε2 allele was higher in the combined hyperlipidemic group, 
which confirms that the apo ε2 allele has a plasma triglyceride raising effect in primary 
hypercholesterolemic patients. We observed, however, a similar allele frequency of apo 
ε2, but a significant increase in the presence of apo ε4 in our sample of FCH patient as 
compared with a representative Dutch control population (8) and the spouses in this study. 
The apo ε2 frequency similar to the representation in the control population is in 
agreement with the report of Lussier-Cacan et al. confirming the presence of a normal apo 
E2 frequency in FCH (30). Consequently, this may imply that apo E2 isoform has only 
secondary modulating effects on a the expression of FCH. The over-representation of apo 
E4 in our sample corresponds with results in strictly unrelated patients with primary 
combined hyperlipidemia (31), and also with the frequency found in patients with 
coronary heart disease (32,33). Moreover, the normal apo E allele distribution in the 
spouses of our FCH families suggests that the over-representation of apo ε4 is not simply 
explained by a high apo ε4 allele frequency in spouses. Therefore, Houlston et al. 
suggested that the possession of the apo E4 allele is one of the predisposing genetic factors 
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to the development of the combined hyperlipidemic phenotype of FCH (31). 
Although affected subjects with hypertriglyceridemia and the apoE3/2 phenotype 
may exhibit a relative increase of triglyceride in VLDL particles, on average VLDL 
particles were not affected in their composition by qualitative differences in the apo E 
isoprotein content. Furthermore, no increase of cholesterol content as seen in so called 
VLDL remnants could be observed with the apo E 3/2 phenotype. This apparent 
homogeneity of VLDL particles in FCH comparable with VLDL of normolipidemic 
subjects has been reported several times (4,34,35). Our results affirm that the produced 
VLDL particles maintain their normal composition irrespective of the apo E isoprotein 
component. So, the accumulating effects of apo E2 on VLDL particles may be subordinate 
to the overproduction. Furthermore, diminished catalytic LpL activity in FCH (6) may 
prevent increased VLDL remnant formation. The effects of apo E phenotypes on LDL 
particle composition reflect the effects as observed on plasma lipids. These compositional 
changes are potentially associated with alterations in LDL heterogeneity (36). A high 
cholesterol ester content and high C/P ratio is usually associated with large buoyant LDL 
particles, whereas a high triglyceride content and low C/P ratio coincides with small dense 
LDL particles (36,37). Only in women with apo E4, exhibiting elevated LDL cholesterol 
and low plasma triglyceride concentrations the buoyant LDL1 and LDL2 subfractions 
predominated. Surprisingly, no significant differences in the overall dense LDL 
subfraction profiles between the various apo E phenotype groups were observed. Thus, the 
affected FCH subjects in this sample could be distinguished by the presence of a small 
dense LDL subfraction profile, as reported previously (38-41), despite the documented 
variation in plasma lipids. We considered several explanations for this apparent 
contradiction: (i) the compositional differences in LDL due to apo E polymorphism may 
be too small to cause identifiable changes in LDL subfraction profiles, (ii) it has to be 
noted that all LDL C/P ratios were below 1.45, which is usually associated with dense 
particles (36). (iii) pharmacological studies in FCH patients showed the persistence of 
small dense LDL particles in FCH patients despite substantial reduction of plasma 
triglyceride concentrations by gemfibrozil administration (39,40). This is in line with the 
identification of a major gene effect on the small dense LDL subfraction distribution in 
these FCH families (41). 
In conclusion, in the genetically and metabolically heterogeneous lipid disorder FCH 
we demonstrated that the apo E polymorphism by itself contributes significantly to the 
lipid and lipoprotein concentrations of affected subjects, independent of its allele 
frequency. It is likely that in FCH populations the apo ε4 allele is slightly over-
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represented. However, apart from this, apo E polymorphism itself has no distinct effect on 
the distribution of LDL subfractions. This finding provides further evidence that a LDL 
subfraction profile consisting of small dense LDL particles is a characteristic feature in 
FCH patients, irrespective of apo E related impact on plasma lipid and lipoprotein 
concentrations. 
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Chapter 7 
ABSTRACT 
Familial combined hyperlipidemia (FCH) is characterized by a familial occurence of 
a multiple-type hyperlipidemia, associated with coronary risk. The latter may be related to 
increased levels of small dense low-density lipoprotein (LDL) particles which have been 
found to be more prone to oxidative modification. We isolated total LDL, as freshly as 
possible from: 12 normolipidemic relatives with a buoyant LDL subfraction profile (group 
1), 7 normolipidemics with a dense LDL subfraction profile (group 2), and 16 
hyperlipidemic FCH subjects with a dense LDL subfraction profile (group 3). In these 
non-obese and normotensive men, we studied the resistance of total LDL against Cu2+-
oxidation in vitro. In addition, we analyzed the α-tocopherol and the coenzyme Q10 
contents of LDL and determined their relation with LDL oxidizability. LDL, isolated from 
group 3 subjects, was more susceptible to oxidative modification than LDL from group 1 
subjects (lag time: 60.4 + 8.1 vs. 70.4 ± 11.4 min; p<0.05). For the combined groups, 
the ratio ubiquinol-10/polyunsaturated fatty acids in LDL together with the basal amount 
of dienes in LDL, were good predictors of the rate of LDL oxidation (R2=0.73, 
p=0.0001). In both groups 2 and 3, the redox status of coenzyme Q10 (ubiquinol-
10/ubiquinone-10) and the ratio ubiquinol-10 to α-tocopherol in LDL were reduced when 
compared with group 1 (p<0.05). The K-value, a measure of the LDL density, correlated 
with the the redox status (r=0.37, ρ<0.05). We conclude that in subjects with FCH total 
LDL is more prone to oxidation, due to the predominance of dense LDL particles. In 
addition, the decreased redox status of coenzyme Q10 in LDL from subjects with a dense 
LDL subfraction profile suggests that the LDL in the circulation is already modified due 
to lipid peroxidation. 
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INTRODUCTION 
Familial combined hyperlipidemia (FCH), first identified by Goldstein et al. (1), is a 
genetically and metabolically heterogeneous common lipid disorder, associated with an 
increased risk for cardiovascular disease (1,2). The trait is characterized by a multiple 
type hyperlipidemia in first degree relatives. Affected persons exhibit elevated plasma 
concentrations of cholesterol or triglycerides, or both. In addition, elevated concentrations 
of apolipoprotein B, and reduced concentrations of high density lipoprotein (HDL) 
cholesterol are observed. Furthermore, FCH has shown to be associated with a 
predominance of dense low-density lipoprotein (LDL) subfraction profiles (3,4). Small 
dense LDL was generally found to be prevalent in patients with coronary heart disease 
(CAD) (5-10). 
Studies on LDL oxidation revealed that small dense LDL particles are more prone to 
oxidative modification than buoyant LDL (11,12). Oxidation of LDL is supposed to play 
an important role in early atherosclerosis (13). After being oxidatively modified in the 
intima, LDL is probably taken up by scavenger receptors of macrophages (14). As a result 
of uncontrolled uptake of oxidized LDL, macrophages are converted into cholesterol-rich 
foam cells, a hall-mark of early atherosclerotic lesions (15). Evidence in humans to 
support the oxidation hypothesis has been provided by studies which showed an 
association between plasma autoantibodies against oxidatively modified LDL and the 
progression of cardiovascular disease (16,17). Epitopes of oxidized LDL were also 
detected in human fatty streaks (18,19). 
According to the oxidation hypothesis, LDL is protected against oxidative stress by 
antioxidants, thereby delaying the formation of modified LDL. The lipophilic antioxidants 
α-tocopherol, ubiquinol-10, ß-carotene, and lycopene are present in LDL (20). 
Epidemiological studies suggested that high (>100 mg/day) α-tocopherol intake 
contributes to reduced risk of atherosclerosis (21,22). Although α-tocopherol is supposed 
to be the major antioxidant in LDL responsible for the protection against oxidation in vivo 
(20), extensive work by Stocker and coworkers (23) suggest that the determination of the 
LDL ubiquinol-10 content is more relevant to assess the initial state of LDL peroxidation 
in vivo. 
Ubiquinol-10 (or reduced coenzyme Q) is an endogenous product of the mevanolate 
pathway, having coenzymeatic activity in the enzyme system of mitochondria, where it 
functions as an essential electron carrier in the respiratory system (24). This antioxidant is 
also present in foods as soy beans, walnuts, almonds, oils, fruits and spinach (25). Despite 
low concentrations in LDL (0.5-0.8 mol/LDL particle), compared to LDL α-tocopherol 
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content (8-15 mol/LDL particle), ubiquinol-10 has shown to be the first line defence 
against oxidative stress in LDL (26). In volunteers, a long term supplementation with Q10 
resulted in a two-fold increase in the plasma concentration of ubiquinol-10 (27). This was 
accompanied by an increased resistance of LDL against oxidation, initiated by aqueous 
peroxyl radicals, in vitro (27). Beside the contribution of antioxidants, LDL oxidizability 
in vitro was found to be influenced by the fatty acid composition (28) and the chemical 
composition of LDL (11). 
Although a specific marker to definitively ascertain the diagnosis FCH is still 
lacking, a recent study shows that a predominance of small dense LDL particles is 
characteristic for affected FCH relatives (4), especially when accompanied by 
hyperlipidemia. Regarding the observations on the relatively constancy of the LDL 
subfraction profile in relation to that of plasma lipid concentrations, especially that of 
plasma triglycerides (unpublished observations, S.J.H. Bredie, P.N.M. Demacker, A.F.H. 
Stalenhoef, 1995), we assume that the presence of dense LDL is a helpful metabolic 
marker for identifying affected relatives of FCH kindreds characterized by variability in 
plasma concentrations of lipids and cholesterol. Therefore, FCH families offer an unique 
opportunity to investigate the oxidation characteristics of both dense LDL from subjects 
with with or without hyperlipidemia and buoyant LDL from normolipidemic subjects, all 
present in these families. 
METHODS 
Chemicals 
Ubiquinone-10, D.L-a-tocopherol, and butylated hydroxytoluene (BHT) were from 
Sigma; ubiquinone-10 was reduced to ubiquinol-10, essentially as described by Frei et al. 
(29). All reagents and HPLC solvents were of high analytical grade. 
Subject selection 
All participants were selected from 40 well-defined FCH families, consisting of both 
affected and non affected relatives (4). The diagnosis FCH was based on the following 
criteria: (i) the presence in first-degree relatives of a multiple type hyperlipidemia with 
elevated levels of total plasma cholesterol and/or triglycerides using the age- and sex-
related 90th percentile upper levels of the prospective cardiovascular Münster (PROCAM) 
study (30), and (ii) a family history of premature cardiovascular disease before the age of 
60 years. Families were excluded when first-degree family members had tendon 
xanthomata. None of the probands was homozygous for the apo E2 allele, and for all 
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probands, a secondary cause (i.e., diabetes mellitus, hypothyroidism and hepatic or renal 
impairment) for the presence of the hyperlipidemia could be excluded by standard 
laboratory tests. 
On basis of the density of the LDL subfraction profiles and plasma lipid 
concentrations, 35 subjects from 13 families were selected to participate in this study. 
Twelve subjects were characterized by a buoyant LDL subfraction profile, and 23 subjects 
by a dense LDL subfraction profile. The method of LDL subfractionation is described 
elsewhere in this paper. All subjects with a buoyant LDL subfraction profile had normal 
lipids. From the subjects with a dense LDL subfraction profile, 7 subjects were 
normolipidemic and 16 subjects were hyperlipidemic. This resulted in three groups of 
subjects; basal characteristics are summarized in Table 1. None of the subjects were on 
drug treatment or on a special diet, and none of the subjects used vitamin supplements. 
Plasma measurements 
Fasting blood samples were collected into vacutainer tubes containing K3-EDTA (1 
mg/ml). The tubes were immediately placed on ice in the dark. Thirty non-local 
participants were~visited at their homes. At two hours after blood sampling, plasma was 
separated from blood cells by centrifugation at 3600 rpm for 8 min at 4°C. Prior to the 
measurement of α-tocopherol and ubiquinol-10 concentrations in plasma, saccharose as 
cryopreservative (final concentration 6 mg/ml), and BHT as antioxidant (final 
concentration 250 μg/ml) were added. 
VLDL and intermediate density lipoprotein (IDL) (d< 1.019 g/ml) were isolated by 
ultracentrifugation. After removal of VLDL and IDL, cholesterol and triglycerides were 
measured in the infranatant and in total plasma. HDL was isolated from whole plasma by 
the polyethylene glycol 6000 method (31). Cholesterol and triglycerides were determined 
by enzymatic methods (Boehringer-Mannheim, Germany (cat. no. 237574), and Sera Pak, 
Miles Tournai, Belgium (cat. no. 6669), respectively). LDL cholesterol was calculated by 
subtraction. 
Analysis of low-density lipoprotein subfraction profiles 
Each individual LDL subfraction profile was defined by a continous variable K, as 
described in detail by de Graaf et al. (32). Briefly, LDL subfractions were separated by 
single spin density gradient ultracentrifugation, according to an earlier described method 
(33). After ultracentrifugation the LDL subfractions were visible as distinct bands in the 
middle of the tube. Up to five LDL subfractions could be distinguished. The tubes were 
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photographed. Accurate documentation of the LDL subfraction distribution was obtained 
by scanning the slides on a LKB 2202 ultrascan laser densitometer (Pharmacia LKB, 
Uppsala, Sweden) (32). The relative peak heights of the LDL subfractions on the scans 
were used to calculate parameter К as a continuous variable, which best describes each 
individual LDL subfraction profile. A negative value (K<0) reflects a more dense 
subfraction profile, and a positive К value (K>0) a more buoyant profile (32). 
Oxidation of low-density lipoproteins 
Plasma isolation was immediately followed by LDL isolation by density gradient 
ultracentrifugation (40,000 rpm for 18 h at 4°C) using a SW40 rotor (Beekman, Palo 
Alto, California, USA) (34). After isolation of total LDL, the protein content of LDL was 
measured by the method of Lowry et al., with chloroform extraction to remove turbidity, 
using bovine serum albumin as a standard (35). The oxidation experiments were 
performed as described by Esterbauer et al. (36) as modified by Princen et al. (34). 
Briefly, the oxidation of LDL (60 μg apolipoprotein/ml) was initiated by the addition of 
CuS04 to a final concentration of 18 μΜ at 37°C. The kinetics of the oxidation of LDL 
was determined by monitoring the change of the 234-nm diene absorption in a thermosta-
ted UV spectrophotometer (Lambda 12, Perkin Elmer GmbH, FRG), equipped with a 
nine-position automatic sample changer. Each LDL preparation was oxidized twice in two 
separate oxidation runs on the same day. Every oxidation run was controlled by analyzing 
one reference LDL, prepared from a pooled plasma stored at -80°C. The interassay coef­
ficients of variation for the oxidation parameters lag time, oxidation rate and the maximal 
amount of conjugated dienes formed per milligram of protein of the reference LDL 
amounted to 1.2%, 5%, and 4.7%, respectively (n=10). To guarantee a high 
reproducibility of the oxidation assay, it appeared to be necessary to clean the quartz 
cuvettes thoroughly after each 3 oxidation runs. For this purpose, cuvettes were immersed 
into 2% (v/v) Hellmanex (Hellma, Germany, cat no. 329.001) for 30 min under 
continuous stirring at a hotplate at 80°C. Subsequently, cuvettes were thoroughly washed 
with deionized water for 15 min, followed by drying in a stream of filtered air. 
Determination of α-tocopherol, ubiquinol-10 and ubiquinone-10 in plasma and LDL 
To exclude any oxidation of ubiquinol-10, antioxidants were determined in material 
as freshly as possible. Consequently, plasma separation was immediately followed by LDL 
isolation by density gradient ultracentrifugation (40,000 rpm for 18 h at 4°C). LDL was 
isolated by cautious aspiration. Before extraction, BHT was added to the LDL 
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preparations to a final concentration of 2S0 ^g/ml. 
The concentrations of ubiquinone-10 (oxidized form of coenzyme Q10) in plasma 
and LDL were determined by high performance liquid chromatography (Spectra Physics 
model 8800, Breda, the Netherlands) with UV detection at 275 nm, sequentially followed 
by electrochemical detection (Decade, Antee, Leiden, The Netherlands) for the 
determination of α-tocopherol and ubiquinol-10 (37). In each run, samples obtained of 
group 2 and/or group 3 subjects were blindly analyzed together with samples obtained of 
group 1 subjects. Deoxygenated and transition-metal-free aquous solvents were used. All 
treatments were performed on ice, in the dark and under nitrogen. 
Immediately after isolation, plasma or LDL (200 μ\) were mixed with 2.0 ml of ice-
cold methanol. Subsequently, 4.0 ml of ice-cold n-hexane was added and the mixture was 
vortex-mixed for 2 min. To exclude artefacts due to instability, samples were extracted in 
series of maximal 10. After centrifugation for 2 min at 3600 rpm at 4°C, the hexane 
upper layer was collected and the extraction procedure was repeated. Both hexane layers 
were pooled and dried under a flow of nitrogen within 45 min at room temperature. The 
residue was stored at -20°C until injection within 4 h. Just before injection onto the HPLC 
column, the residue was dissolved in the mobile phase, consisting of 22.5% (v/v) metha­
nol and 77.5% (v/v) ethanol/isopropanol (95:5) with 20 mM lithiumperchlorate as elec­
trolyte. Twenty μΐ of sample were injected onto an Inertsil ODS-2 column (200 χ 3.0 mm; 
5-/im particle size) equipped with a reversed phase guard column (10 χ 2 mm) (both from 
Chrompack, Middelburg, the Netherlands). α-Tocopherol and ubiquinol-10 were eluted 
isocratically with the mobile phase at a flow rate of 0.35 ml/min. The eluate was moni­
tored with an electrochemical detector. A VT-03 flow cell with GC working electrode 
(Antee, Leiden, the Netherlands) was used. The applied potential was 600 mV (vs. 
Ag/AgCl in saturated LiCl). The interassay coefficients of variation for the determination 
of plasma and LDL concentrations of α-tocopherol were 1.3% and 4.5% (n=6), 
respectively; of ubiquinol-10: 5.9 and 4.4% (n = 8), respectively, and of ubiquinone-10: 
3.1% and 5.6% (n=8), respectively. 
Stability of ubiquinol-10 
Because of the suggested instability of ubiquinol-10 in plasma and especially in LDL 
(26,38) we performed stability experiments to warrant the validity of our results. In whole 
blood, ubiquinol-10 was found to be stable for at least 4 h in the dark at 4°C (99.6+3.1% 
to initial concentrations (n=6)). Ubiquinol-10 concentrations in plasma were stable during 
storage in presence of 250 μg BHT/ml for up to 1 week at -80°C (98.0 + 3.0% to initial 
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concentrations (n=3)). In order to use similar LDL preparations both for the oxidation 
and antioxidant experiments we isolated LDL by density gradient ultracentrifugation in the 
absence of BHT. Ubiquinol-10 concentrations in LDL were 104.1 ± 4.6% (n = 8) to those 
concentrations measured in LDL isolated in the presence of BHT. Prior to all extractions 
we added 250 /ig BHT/ml. Ubiquinol-10 concentrations in LDL, however, were similar to 
those received at extraction without BHT (99.0 ± 2 . 1 % (n=3) vs. BHT method). Until 
extraction of the LDL preparations, LDL was stored in 2 ml of methanol at -20°C after 
mixing. Under these conditions, ubiquinol-10 was found to be stable for at least 24 h 
(100.4+3.8% to initial concentrations (n=6)). Consequently, ubiquinon-10 concentrations 
during the described storage conditions were stable. After the lipid extraction the 
combined hexane layers were evaporated under N2(g) and residues were stored at -20е С 
until analysis within 4 h. During this time, ubiquinol-10 concentrations were stable (98.0 
±2.0% to initial concentrations (n=6)). However, storage of the lipid residues for 24 h at 
-20°C resulted in a 43.5 + 8.7% loss of the ubiquinol-content. Consequently, the 
ubiquinone-10 content was increased. 
Determination of fatty acids in LDL 
The concentrations of polyunsaturated (CI8:2; C20:4) and of monounsaturated 
(C18:l) fatty acids in LDL were determined essentially as described in detail by de Graaf 
étal. (11). 
Statistical analysis 
Prior to statistical testing, plasma TG and VLDL-TG were transformed 
logarithmically because of skewing of the distributions. Differences in smoking and 
drinking habit, and personal history of coronary artery disease was calculated by a chi-
square test. A oneway analysis of variance (ANOVA) was used to analyze the differences 
in the studied parameters between the three groups, followed by additional Tukey's 
multiple comparison tests. All values are presented as mean ± S.D. Associations between 
variables were calculated with Pearson's correlation coefficients. All statistical analyses, 
including logistic regression analysis, were performed using SPSS/PC software (SPSS 
Inc., Chicago, IL, USA). 
RESULTS 
Plasma lipids, lipoproteins and К values 
Mean concentrations of plasma lipids and lipoproteins and the characterization of the 
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LDL subfraction profiles of the respective groups are presented in Table 1. With regard to 
age, body mass index, smoking and drinking habits, groups 1, 2 and 3 did not differ from 
each other. The personal history of coronary heart disease increased from 0% to 31% in 
groups 1 to 3, respectively. As compared to groups 1 and 2, group 3 subjects had, by 
selection, higher concentrations of total cholesterol, LDL cholesterol, VLDL cholesterol, 
total triglycerides and VLDL triglycerides, lower concentrations of HDL cholesterol, and 
more negative К values (Table 1). 
Table 1: Characteristics of sub|ects, plasma concentrations of lipids and lipoproteins and the LDL 
subfraction profile (i.e., К value). 
Age (yr) 
BM1 (kg/m2) 
smokers ( > 10 cigarettes/day) 
personal history of CAD· 
total cholesterol (mmol/l) 








41.4 ± 12.7 
23.5 ± 2.2 
16.7% 
0% 
5 16 ± 0.96 
1 30 ± 0.53 
0.36 ± 0.17 
0.76 ± 0 41 
3.28 + 0.82 
1.34 ± 0 28 
0.06 ± 0.07 
Group 2 
(n=7) 
39.4 ± 12.9 
24.8 ± 2.7 
14.3% 
14.3% 
5.59 ± 0.64 
I 60 ± 0.26 
0.64 ± 0 18 
1.01 ± 0.22 
3.87 ± 0.61 
1.04 ± 0.22 
-0.30 ± 0.20' 
Group 3 
(n=16) 
46.2 ± 11.8 
25.8 ± 2.8 
18.8% 
31.2% 
6.67 ± 1.34f 
3.66 + 1 15** 
1.51 ± 0 52« 
2.86 ± 1.05« 
4.25 ± І.30 
0.87 ± O.I4f 
-0.64 ± 0.16« 
Group 1, buoyant LDL aubtraction profile, normolipidemic relatives; Group 2, dense LDL subfraction 
profile, normolipidemic relatives; Group 3, dense LDL subfraction profile, FCH sublets; ', p<0.0001 (chi-
square test), ' , ρ ί 0.005 vs. group 1, *, ρ 5 0.005 ч group 2, BMI, body mass index. 
Oxidation characteristics of LDL and LDL antioxidant contents 
The mean lag time of LDL for oxidation was shorter in group 3 than in group 1 
(Tukey, ρ<0.05) (Table 2). In group 2, an intermediate mean lag time was measured 
which, probably due to the small group size, did not differ significantly from both other 
groups. When we considered groups 2 and 3 as one group, on the basis of characterization 
of the LDL subfraction profile, we observed that the mean lag time of LDL to oxidation 
was shorter than that in group 1 (Table 3), Exclusion of the smokers in the respective 
groups did not affect the present results. The lag time of the total LDL to oxidation 
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correlated with the density of the LDL subfraction profile of the subjects, expressed as the 
continuous variable К (r=0.35, ρ< 0.05). The maximal amount of dienes formed per 
milligram of LDL protein during oxidation of LDL isolated from FCH subjects were 
lower than the amount of dienes formed in LDL from group 1. Oxidation rates of LDL 
and basal amounts of dienes in LDL were similar in the three studied groups (Table 2). 
Table 2: Oxidation characteristics of LDL isolated from normolipidemic and FCH subjects. 
lag time (min) 
oxidation rate (nmol dienes/mg protein/rrun) 
dienes (t=0) (nmol/mg LDL protein) 
dienes„. (nmol/mg LDL protein) 
Group 1 
(n=12) 
70.4 ± 1 1 . 4 
22.5 ± 2.3 
175 ± 12 
710 ± 70 
Group 2 
(n = 7) 
66.6 ± 14.1 
23.6 ± 2.0 
178 ± 1 1 
738 ± 59 
Group 3 
(n = 16) 
60.4 ± 8.1* 
21.4 ± 2.5 
167 ± 12 
646 ± 61« 
Group 1, buoyant LDL subfraction profile, normolipidemic relatives; Group 2, dense LDL subfraction 
profile, normolipidemic sub|ects; Group 3, dense LDL subtraction profile, FCH sublets; f, ρ < 0.05 vs 
group 1; *, ρ < 0.05 vs group 2 . 
We examined whether the oxidation characteristics of LDL could be attributed to 
differences in the basal α-tocopherol and ubquinol-10 concentrations. Plasma 
concentrations of ubiquinol-10 were related to plasma concentrations of total cholesterol 
(r=0.41, p<0.01), and α-tocopherol (r=0.41, p<0.01). The absolute and relative 
concentrations of α-tocopherol, ubiquinol-10 and ubiquinone-10 in plasma and LDL are 
given in Table 4, while the most important results are presented in Fig. 1. No differences 
were found between the three groups in the LDL α-tocopherol content, quantitated 
relatively to cholesterol, apolipoprotein or PUFA (Table 4). While the LDL QH2-10, 
quantitated relatively to apolipoprotein and PUFA, tended to be lower in group 2 when 
compared with group 1 (Tukey, p=0.07), the Q10 content was significantly increased 
(Table 4). The fatty acid composition of LDL was similar in all three groups (Table 4). 
Remarkably, for all subjects with a dense LDL subfraction profile, both the LDL 
QH2-10 to α-tocopherol ratio and the redox status of coenzyme Q10 in LDL (QH2-10/Q10 
ratio) were lower than the ratios in LDL from subjects having a buoyant LDL subfraction 
profile (Figure 1). In line with this, the redox status of coenzyme Q10 correlated with the 
density of the LDL subfraction profile (r=0.37, p<0.05). Even when groups 2 and 3 are 
considered as one group, characterized by a dense LDL subtraction profile (n=23), both 
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ratios were significantly lower than those in group 1 (data not shown). 
Table 3: Oxidation characteristics of LDL isolated from normolipidenuc and FCH subjects 
Dense LDL2 
(η = 23) 
К value 0 Об ± 0 07 -О 54 ± 0 24* 
lag time (min) 70 4 ± 1 1 4 62 3 ± 10 4* 
nmol QHj-10/g apolipoprotein 700 ± 138 578 ± 223* 
nmol QlO/g apolipoprotein 191 ± 99 304 ± 144* 
μιηοΙ QlO/mol cholesterol 32 9 ± 14 0 52 3 ± 24 0* 
QH,-10/Q10 3 2 ± 1 0 1 9 ± 1 0* 
QHj-10/αΤΟΗ 0 05 ± 0 01 0 04 ± 0 01' 
'LDL isolated from group 1 subjects, 'LDL isolated trom group 2 and 3 subjects., α-ТОН, or-tocopherol, 
QH2-10, ubiquinol-10, Q10, ubiquinone-10, *0 0005<p< 0 005, *0 01 < p < 0 05 
Regarding our stability experiments (see Methods section), it is unlikely that the observed 
differences m the ratios were due to oxidation ex vivo A second indication that the shift 
in the redox status of coenzyme Q10 was not an artefact appeared from the similarity of 
the redox ratios in total plasma versus the indicated LDL fraction in the various groups. 
In the combined groups, we observed that 53% of the variability in oxidation rate 
could be predicted by the basal amount of dienes tn LDL together with the basal LDL 
QH2-10 to LDL PUFA content (p<0 0001) 
DISCUSSION 
Total LDL in FCH subjects (group 3) was less well protected against copper-
mediated oxidation than total LDL from normohpidemic relatives with a buoyant LDL 
subfraction profile (group 1) Even when the subjects of groups 2 and 3, all characterized 
by dense LDL subfraction profile, were combined, LDL was more prone to oxidation than 
LDL of group 1 (p<0.05) To our knowledge, this is the first time a reduced oxidation 
resistance of total LDL, in stead of isolated LDL subfractions, is presented for subjects 
characterized by a dense LDL subfraction profile Possibly, the conformation of dense 
LDL particles facilitates the accessibility of copper to the apolipoprotein В100, or the 




Table 4: Concentrations of α-tocopherol and ubiquinol-10 in plasma and lipoproteins. 
Group 1 Group 2 Group 3 
(n=12) (n=7) (n=16) 
Plasma 
α-ΤΟΗ (uM)1 
mmol a-TOH/mol cholesterol 
ΟΗ,-ΙΟ (nM) 
μιηοΙ QH,-10/mol cholesterol 
Q-10 (nM)1 
μηκ>1 Q-10/mol cholesterol' 
LDL 
mmol a-TOH/mol cholesterol 
μιηοΙ a-TOH/g apolipoprotein 




nmol QHi-10/g apolipoprotein 
/imol QH,-10/moI PUFA 
/»mol Q-10/mol cholesterol' 
nmol Q-10/g apolipoprotein' 
PUFA/C18:! 
C18:2/C18:l 
See Table 1 for definition of groups; +p<0.05 vs. group 1; α-ΤΟΗ, α-tocopherol; QH;-10, ubiquinol-10; 
Q10, ubiquinone-10; PUFA, sum of C18:2 and C20.4. 
Quantitatively, α-tocopherol is an important antioxidant in LDL (20). However, in 
line with observations of other groups with subjects on a normal diet, the susceptibility of 
LDL to oxidative modification was not related to the α-tocopherol content of LDL 
(34,40-43). From in vitro oxidation studies, ubiquinol-10 is shown to be an antioxidant of 
the first line (26). LDL, isolated from normolipidemic subjects with dense LDL tended to 
have a lower ubiquinol-10 content, relatieve to that of apolipoprotein B100 or PUFA 
content, than LDL from subjects with a buoyant profile. In addition, the redox status of 
coenzyme Q10 (ratio of reduced form to oxidized form of coenzyme Q10) was 
substantially reduced in dense LDL particles, independently whether LDL was isolated 
from normolipidemic or hyperlipidemic subjects (Figure 1). The oxidation of ubiquinol-10 
27.6 ± 10.3 
5.3 ± 1.7 
1035 ± 600 
193 ± 81 
350 ± 101 
69 ± 32 
1.9 ± 0.4 
14.3 ± 3.1 
7.0 + 1.6 
95.3 ± 18.0 
700 + 138 
342 ± 88 
32.9 ± 14 
191 ± 99 
2.9 ± 0.5 
2.6 + 0.5 
27.5 ± 5.5 
5.0 ± 1.1 
1020 ± 569 
180 ± 95 
461 ± 161 
85 ± 35 
2.1 ± 0.6 
14.5 ± 2.6 
6.8 ± 2.1 
69.6 ± 38.0 
480 ± 252 
227 ± 88 
62.7 ± 25f 
351 ± 136+ 
3.2 ± 0.4 
2.8 ± 0.4 
42.5 ± 9.0» 
6.5 ± 1.4 
1159 ± 479 
177 ± 69 
593 ± 228f 
91 ± 34+ 
2.3 ± 0.5 
15.2 ± 3.3 
7.5 ± 1.5 
92.2 ± 32.0 
621 ± 204 
308 ± 100 
47.7 ± 22 
284 ± 147 
3.0 ± 0.4 
2.6 ± 0.3 
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within LDL particles was reported to be accompanied by the formation of lipid 
hydroperoxides within LDL (26). Our data on the redox status of coenzyme Q10 and the 
consequences concerning the initial degree of lipid peroxidation concur with data of Alleva 
et al. (44). For normolipidemic subjects these authors showed that hydroperoxide 
concentrations were increased in dense LDL compared to buyoant LDL particles. An 
increased lipid hydroperoxide content in dense LDL may also explain the observed 
increased susceptibility of dense LDL to copper-mediated oxidation, in vitro (45). In 
healthy subjects elevated concentrations of plasma lipid hydroperoxides were measured, in 
vivo, when the redox status of coenzyme Q10 was reduced (46). Thus, the redox status of 
coenzyme Q10 in dense LDL appears to be a sensitive marker for oxidative changes 
which take place in LDL in vivo. By careful analysis, we have shown that the reduced 
redox status of coenzyme Q10 in groups 2 and 3, versus that in group 1, can not be 







Group 1 Group 2 Group 3 
Figure 1: Relative ubiquinol-10 (QH,-I0) concentrations in LDL. LDL QH,-10 content was quantitated 
relatively to the α-tocopherol content (left y-axis, open bars), and the ubiquinone-10 content (QH-10, redox 
status) (right y-axis, filled bars). Groups 1 indicates normolipidemic subjects with a buoyant LDL 
subfraction profile (n=12); Group 2, normolipidemic sub|ects with a dense profile (n = 7), and Group 3, 
FCH subjects with a dense profile (n= 16); *, p<0.05 vs. Group 1. 
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In this respect it is interesting to note the 3- to 30-fold lower ubiquinol-10 concentration in 
dense LDL of normolipidemic subjects (38) as compared to concentrations measured in 
other studies (26,27), and in the present study. We ascribe this to the lengthy isolation 
procedure of 3 days, including the dialysis step. To prevent loss or oxidation of LDL 
ubiquinol-10, LDL was not dialyzed in our study. This may explain that we did not find 
any relation between lag time and ubiquinol-10 content. In agreement with Kontush et al. 
(47), we found that the basal LDL ubiquinol-10 to PUF A content was negatively 
correlated with the rate of oxidative modification of LDL. Ubiquinol-10 may indirectly 
protect the PUFA's against lipid peroxidation, by efficient reduction of a-tocopheroxyl 
radicals (reviewed in reference 23). In line with results of Stocker and co-workers (26,27) 
our results stress the promissing role of ubiquinol-10. 
Whether a decrease of the redox status of coenzyme Q10 in LDL, due to oxidation 
of ubiquinol-10, results in minimally oxidized LDL needs to be studied. Compared to 
native LDL, mildly oxidized LDL exerts important biological effects, at least in vitro. It 
is believed that these are involved in the early stages of atherosclerosis (48). Minimally 
oxidized LDL was shown to stimulate the endothelial cell-mediated release of monocyte 
chemoattractant protein (49) and monocyte colony-stimulating factor (50). On the other 
hand it may be possible that the radicals which result in oxidation of coenzyme Q10 can 
also induce tryptophan residue destruction (51). This process occurs in two phases; the 
earliest phase is independent of α-tocopherol and plays an initial role in LDL lipid 
peroxidation (51). 
In conclusion, dense LDL particles from subjects with FCH are less resistant to 
oxidation in vitro than buoyant LDL from normolipidemic relatives. Compared with 
subjects with an overall buoyant LDL subfraction profile, the redox status of coenzyme 
Q10 was reduced in subjects with an overall dense LDL subfraction profile, independently 
of the plasma concentration of cholesterol or triglycerides. This suggests that ubiquinol-10 
is an important indicator of oxidative modification in vivo. Future investigations to assess 
oxidative stress in subjects at risk for coronary heart disease should include the redox 
status of coenzyme Q10. 
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Chapter 8 
ABSTRACT 
Familial combined hyperlipidemia (FCH) is a heritable lipid disorder, which is 
associated with an increased risk of premature cardiovascular disease. An elevated plasma 
apolipoprotein-B (apoB) concentration is reported to be a diagnostic feature of the 
disorder. Recently we demonstrated a strong relation between plasma apoB concentrations 
and the cholesterol concentration in very low density lipoproteins (VLDL) plus low 
density lipoproteins (LDL), both elevated in FCH families. Therefore, examination of the 
inheritance of elevated plasma apoB levels in FCH families may reveal important 
information about the mechanism responsible for the aggregation of elevated plasma lipids 
in FCH. This study included 663 Dutch family members in 40 families ascertained 
through FCH-probands. Plasma apoB concentration correlated significantly with apoB-
related cholesterol both in the probands and in the relatives (r=0.83 and r=0.90, 
respectively). Adjustment for age, gender, BMI and smoking habits accounted for 35.7% 
of the variation in apoB levels, and there was strong familial aggregation in adjusted apoB 
levels in these families. Complex segregation analysis was performed to determine the 
mechanism of inheritance behind this familial aggregation. The aggregation of elevated 
apoB levels was best explained by a major gene effect inherited by a codominant 
mechanism. Estimated mean apoB levels for the three supposed genotypes A A, AB and 
BB were 111.5, 126.7 and 165.7 mg/dl, respectively, with relative frequencies of 43.5%, 
44.9% and 11.6%, respectively. In conclusion, despite assumed metabolic and genetic 
heterogeneity of FCH, there is clear evidence for a single gene effect on apoB 
concentrations in families ascertained through FCH. Linkage studies based on this analysis 
may further clarify the molecular basis of the apoB regulation in these families. 
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INTRODUCTION 
Familial combined hyperlipidemia (FCH) is the most common form of heritable lipid 
disorders, and is associated with cardiovascular disease (1). This multiple phenotype 
hyperlipidemia is characterized by elevations of the total plasma cholesterol concentration 
and/or the plasma triglyceride concentration, consequently resulting in the presence of 
different lipid phenotypes in first-degree relatives. Furthermore, an elevated plasma 
apolipoprotein-BlOO (apoB) concentration, a decreased high density lipoprotein (HDL) 
concentration, and a preponderance of small dense low density lipoprotein (LDL) particles 
are observed. Initially, FCH was thought to be inherited as a single gene disorder with a 
major gene effect on triglyceride levels (1). Recently this was supported by a segregation 
analysis in 55 British FCH families (2). Other studies, however, have shown FCH to be a 
more heterogeneous lipid disorder, comprising features of the insulin resistance syndrome, 
hyperapobetalipoproteinemia and familial dyslipidemic hypertension (3-5), which in turn 
are all associated with the presence of small dense LDL (6). Still, the absence of a 
specific metabolic or genetic marker complicates the diagnosis of FCH in individual 
patients. 
In FCH, the hyperlipidemia is caused by hepatic overproduction of very low density 
lipoprotein (VLDL)-apoB100 (7,8). Consequently, elevated levels of apoB containing 
lipoproteins (i.e., intermediate density lipoprotein [IDL] and LDL particles) are observed. 
A delayed clearance of the triglyceride-rich apoB containing lipoproteins, in part caused 
by impaired lipoprotein lipase activity may modify the lipid phenotypic expression (9,10). 
Elevated lipid levels in FCH reflect elevated VLDL and LDL cholesterol concentrations 
which correspond with an increase in respective particle numbers (8,11,12). Since each 
VLDL and LDL particle always contains one apoB molecule per particle, a strong 
correlation can be expected in FCH between total plasma apoB and its related cholesterol 
in VLDL and LDL particles. Based on this, the individual plasma apoB concentration 
represents the actual VLDL and LDL concentrations, which may show some variability in 
time in FCH patients (13). 
Studies have also shown the association between elevated apoB levels and 
cardiovascular disease, which is a feature of FCH as well (14-16). Some studies show that 
the apoB level is a better predictor of premature cardiovascular disease than the plasma 
lipids are (17,18). Complex segregation analyses demonstrated familial aggregation of 
elevated apoB levels in families presenting premature cardiovascular disease, in families 
with familial hyperlipidemia, and in healthy volunteers (19-26), but conclusions about the 
specific genetic mechanism were contradictory to date. This may be the reason that 
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linkage studies could not identify conclusively the locus responsible for the elevation of 
apoB levels (20,27-30), although some gene markers showed some association (31) 
Before further linkage analyses with candidate genes can be undertaken, it is critical to 
have a better model of inheritance 
In the present study, segregation models were examined to explain the familial 
clustering of elevated apoB levels measured m individuals from 40 well-defined Dutch 
FCH families. Single gene effects and polygenic components were tested by using class D 
regressive models of Bonney et al (32), as implemented in the Statistical Analysis for 
Genetic Epidemiology (SAGE) package 
MATERIALS AND METHODS 
Study Population 
The FCH pedigrees considered here have been studied for inheritance of LDL 
subfraction profiles (33) The families were ascertained through probands exhibiting a 
combined hyperlipidemia with both plasma cholesterol and triglyceride concentrations 
above the 90th percentile, adjusted for age and gender, as obtained from the Prospective 
Cardiovascular Munster (PROCAM) Study (34) These values were consistent over 
several measurements in which the probands had not been given any lipid-lowenng drugs 
Families were included when a multiple type hyperlipidemia with levels of total plasma 
cholesterol and/or triglycerides above the 90th percentile was present Thus, besides the 
proband presenting with combined hyperlipidemia, at least one first-degree relative 
exhibited hypercholesterolemia or hypertriglyceridemia 
All probands were tested for an underlying cause or their hyperlipidemia (ι e , 
diabetes mellitus, hypothyroidism and hepatic or renal impairment) The presence of one 
of these causes excluded them and their families from further analysis None of the 
probands in these families was homozygous for the apo έί allele and none of the first-
degree relatives had tendon xanthomata In addition, to refine the selection procedure, the 
95th percentile for plasma cholesterol and triglycerides was used if the body mass index 
exceeded 30 kg/m2, or an alcohol consumption of more than two units (one unit=one 
consumption) per day was present 
In total, 40 multi-generational families (2 to 4 generations) were included in this 
study, containing 40 FCH probands and 623 family members All individuals were 
Caucasian above the age of 10 years Everyone filled out a questionnaire in order to 
collect information on medical status, medication use, alcohol intake and smoking habits 
The study protocol was approved by the ethical committee ot the University Hospital of 
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Nijmegen. 
Plasma 
After an overnight fast and a withdrawal of lipid-lowering medication for at least 
four weeks, blood was drawn by venipuncture into EDTA containing vacutainer tubes. 
Non-local participants were visited at their homes, and blood was transported directly to 
the laboratory. Plasma was isolated within 3 hours for determination of the lipid and 
lipoprotein levels. 
Measurement of Lipid, Lipoprotein and Apolipoprotein levels 
VLDL was isolated from whole plasma by ultracentrifugation at density = 1.006 g/ml 
for 16 hours at 36,000 rpm in a fixed rotor (TFT 45.6 rotor, Kontron, Zurich), in a 
Beekman L7-55 ultracentrifuge (Beekman, Palo, U.S.A.). High density lipoprotein (HDL) 
cholesterol was determined by the polyethylene glycol 6000 method (35). LDL cholesterol 
was calculated by subtraction of VLDL cholesterol and HDL cholesterol from total plasma 
cholesterol. Respective cholesterol and triglyceride concentrations were determined by 
enzymatic, commercially available reagents (Boehringer-Mannheim, Germany, cat. 
No.237574 and Sera Pak, Miles, Italy cat. No. 6639, respectively). Total plasma apoB 
concentrations were determined by immunonephelometry (36). To achieve accurate results 
in relation to the Center for Disease Control Standardization Program, obtained values 
were recalculated on the basis of an exchange of sera with Dr. S. Marcovina (Northwest 
Lipid Research Laboratory, Seattle WA, U.S.A.). 
Statistical Analysis 
Pearson correlations coefficients were calculated for the relation between crude 
plasma apoB values and apoB related cholesterol in VLDL plus LDL. Subsequently, 
multiple linear regression was used to examine the association between the apoB level and 
age, gender, BMI, smoking habits, and alcohol intake, as conforming to other reports 
(19,21,23-26). Based on the results of this analysis, those covariates that significantly 
influenced apoB level were selected. Given this regression model, predicted apoB levels 
were calculated and residual values were computed by subtracting each individual's apoB 
level from their predicted value. These residuals represent the fraction of the apoB level 
that is not predicted by the selected environmental variables but may represent the genetic 
contribution to the apoB level. Because these residuals can be positive or negative, the 





To investigate the role of genetic and environmental influences on apoB levels, a 
series of class D regressive models (32) available in the Statistical Analysis for Genetic 
Epidemiology (SAGE) program (release 2.2) was used. The models assume that variation 
among individuals for a quantitative trait is the result of a major gene effect and residual 
variation which may reflect both familial correlations and individual variation (24). A 
'general model' describes the distributions of apoB levels in terms of the independent 
contribution of a single factor with a major effect, residual familial correlations and non-
genetic effects (22). This 'general model' emanates from two alleles at a single locus 
(denoted A and B) resulting in three possible 'types' of individuals (AA, AB and BB), 
termed 'ousiotypes' (37). The mean apoB value associated with each 'type' is denoted 








. The 'ousiotype' effects may be 
attributable to a genetic or an environmental factor. The parameter ρ is defined as the 
frequency of allele A; q= (1-p) equals the frequency of allele B. Founder individuals are 
assumed to come from a population in Hardy Weinberg equilibrium. Individuals 
characterized by the 'types' AA, AB and BB are assumed to transmit the allele A with 
probabilities т
АА
, rAB and rBB, respectively. These transmission probabilities are used to 
calculate the probabilities of all three 'types' for individuals whose parents are in the 
pedigree. In addition, the parameters p,p, p^, pmo, pfo and p s s denote spouse, parent-
offspring, mother-offspring, father-offspring and sib-sib correlations, respectively. In this 




, is the total variance and <r is the variance conditional on 
the restricted model (assuming p^, =p„). Hypotheses were tested by comparing the 
'general model' to various submodels, in which certain parameters were restricted to 






=р. In this model 
the prior probability of an offspring having a certain Ousiotype' is completely independent 
of parental 'ousiotypes'. Mendelian models constrain these segregation probabilities τ ^ , 
TAD and rBB to be 1.0, 0.5 and 0.0, respectively. The most general Mendelian model is a 










containing pp,,, p ino, p fo and p„ equal to zero are equivalent to restricting the 'polygenic 
component' to zero. Restricted models are compared to the general model by using the 
likelihood ratio test (LRT). For non-hierarchical models, Akaike's information criterion 
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(AIC) was used to compare the fit of the models. For a given model AIC=-21n(L)+2*x 
(x=number of parameters estimated in the model). The model with the lowest AIC is 
considered the most parsimonious model (38). 
Segregation analysis was performed on 40 families which included 825 individuals, 
although 162 individuals had missing date (primarily these included dead family members 
linking other relatives) In this study no normalizing transformation was performed 
because analysis of untransformed data is easier to interpret and can be compared more 
easily to the published studies. In addition, normalizing transformations of a biologically 
skewed variable may lead to a large reduction in the power to detect a major gene when 
one exists (39). Families were selected through two affected probands Consequently, the 
lipid inclusion entena (ι e , both plasma cholesterol- and triglyceride levels) of probands 
versus non-probands showed large differences (Table 1) Therefore, ascertainment 
correction was undertaken by conditioning the phenotypes of family members on those of 
the affected pnmary probands and that of one extra individual with elevated lipid levels 
per pedigree (33) 
RESULTS 
Study population 
The study included 663 individuals with an age between 10-88 years old The 
correlation between crude plasma apoB concentration and apoB related cholesterol 
concentration (ι е., VLDL plus LDL cholesterol), both for the 40 probands plus 40 extra 
affected subjects of each family and for the remaining relatives is presented in Figure 1 
Table 1: Characteristics of the Study Population 
Probands Family members Total 
( η = 80 ) ( η = 583 ) ( η = 663 ) 
Characteristics Mean SD Mean SD Mean SD 
Age (years) 
BMI (kg/m2) 
Crude apo-B (mg/dl)A 

























"Crude apoB levels were missing tor 7 probands and 72 family members, BAd|usted apoB levels were 
missing for 13 probands and 78 family members 
137 
Chapter 8 
In both groups, a significant correlation was observed (0.83, ρ<0.0001 and 0.90, 
ρ <0.0001, respectively). Characteristics of the study population are presented in Table 1. 
BMI values varied between 13.6 and 40.9 kg/m2, crude apoB levels between 60 and 298 
mg/dl and the adjusted apoB levels between 42.3 and 277.7 mg/dl. Significant differences 
between probands and family members were seen in mean values of both the crude and 
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Figure 1: The correlation between plasma apoB and ils related cholesterol m VLDL plus LDL fractions m 
ail 80 probands (top) and in the remaining FCH relatives (botlum). 
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Adjustment of the apoB level 
Non-hpid covanates (i.e , age, age2, gender, BMI, smoking habits [0=not smoking, 
l=one or more cigarettes/day] and alcohol consumption [0=no alcohol consumption, 
1 =one or more units/day] were examined in association with plasma apoB level. Table 2 
shows the covanates and their regression coefficients used in the adjustment of the apoB 
levels. Age2 and alcohol consumption were excluded from the adjustment procedure 
because they did not contribute significantly. Although m this study gender was not 
significantly associated with apoB, it was included in the adjustment procedure to make 
our results more comparable with other studies. The variables combined explained 35 1% 
of the variation in apoB levels 
Table 2: Regression coefficients (β) and standard error (S E ) tor the four variables used in a multiple 
lineair regression model to adjust the crude plasma apoB level 
Variables β S E P-value 
Age (years) I 05 0 09 0 0001 
BMI (kg/m:) 2 73 0 40 0 0001 
Gender (female) -3 27 2 74 0 2334 
Smoking ( > 1 cigarette/day) 13 55 3 00 0 0001 
Segregation Analysis 
In a first segregation analysis on the total study population the data were consistent 
with two different models ot inheritance a) a codominant major gene effect explaining 
44% of the variance in apoB levels with an insignificant polygenetic component of h 2 =l-
%, and b) an environmental model explaining 16% of the apoB level variance with a 
polygenetic component of h, = 38% (data not shown) This ambiguous result may have 
been caused by either genetic heterogeneity among these 40 pedigrees, yielding a mixture 
of different mechanisms influencing apoB levels, or by extreme apoB levels in certain 
families or particular individuals. 
In order to evaluate the extent to which each family supported one model over the 
other, the -21n(L) scores of both an environmental model (-21n[L]L) and a codominant 
model (-21n[L]J were calculated for each family. The ratio -21n(L,/L
c
) measures the 
extent to which each family favored one or the other model (19,24,40,41) Families which 
favored an environmental model would hava a -21n(L,/L<) ratio <0, and families with a 
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-21n(LE/Lc) >0 favored a codominant model. As shown in figure 2, the distribution of the 
likelihood ratio's was centered around zero, suggesting most families cannot discriminate 
definitively between these models. The procedure separated 19 families more favoring an 
environmental model and 21 families more favoring a codominant model. One family, 
however, seemed to give an extreme preference to the environmental model (-
21n[LE/Lc]=-13.5). This particular family (containing twelve subjects in three generations) 























-14 -13 -12 -11 -10 -9 -8 -7 -6 - 5 - 4 - 3 - 2 - 1 1 2 3 4 5 
Figure 2: Relative likelihood of the environmental model -2ln(L, ) and the codominant model -2^(1^.). The 
ratio -21п(І_,/Ц,) measures the extent to which each family biipported one model over the other. 
The results of a second series of analyses testing the different genetic models on the 
39 remaining pedigrees are shown in Table 3. All models assumed a single correlation 
among parents and offspring (p^), which appeared to be equal to the sib-sib correlation 
(pM). Therefore, all submodels were assumed to have a single correlation for first-degree 
relatives (ppo=p„). The best fitting one distribution model (model 4) showed insignificant 
spouse correlations (р
чр
=-0.14±0.07) and significant residual familial correlations 
(Pp„=P„=0.15±0.03). Using this familial correlation, the polygenetic heritability was 
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 =0.29, which is compatible with published estimates from 
other studies. The non-Mendelian two distribution model (model 6) showed a significant 
improvement of the -21n(L). The three distribution non-Mendelian model (model 7) gave 
no further improvement of the fit. Inclusion of a two distribution Mendelian mechanism 
(model 9) showed a significant improvement of the -21n(L), compared with model 4. The 
two distribution Mendelian models (models 8 and 9) looked very similar to the two 
distribution non-Mendelian models (models 5 and 6) with p4,=-0.11±0.10 and PpO=ps,=0-
.22±0.05. Extension of a two distribution Mendelian model (model 9) to a three 
distribution Mendelian model (model 11) revealed a significant improvement of the -
21n(L). The analysis presented a general model very similar to the best fitting codominant 
model (model 11). Although the excluded family had a substantial influence on the -21n(L) 
used to select the most parsimonious model, no major differences were seen in the 
parameter estimates. Comparison of the -21n(L) scores of submodels against the general 
model (model 12) showed that models 1, 2, 3, 4, 7, 8, and 9 could be strongly rejected 
(p<0.001), while models 5, 6, and 10 could only be weakly rejected (p<0.05). Only 
model 11 could not be rejected. Rejected environmental models 5, 6 and 7 did not 
contradict the most parsimonious model (model 11) because they showed that variation in 
apoB levels was strongly explained by a genetic component (p[K,=p,s=0.24±0.05 to 
0.25±0.05). Comparison of model 5, 6 and 7 to model 11, demonstrated that the 
significant familial correlation in apoB levels was absorbed by the inclusion of a 
codominant mechanism of inheritance. Therefore, the segregation of elevated apoB levels 
in 39 of the 40 FCH families was best explained as the result of a codominant major gene 
effect. 
DISCUSSION 
In the present study, a segregation analysis was performed to examine genetic 
mechanisms that could explain the familial clustering of elevated apoB levels as observed 
in 663 individuals from 40 well-defined Dutch families. These families were ascertained 
through FCH, a common hyperlipidemia associated with premature cardiovascular disease. 
The observed Mendelian mechanism with a codominant mode of inheritance for the 
segregation of elevated plasma apoB levels in this study agrees very well with the reported 
inheritance of apoB levels in other populations containing families of patients with 
coronary artery disease and families with familial dyslipidemic hypertension 
(20,21,24,25). Such families most probably also contain patients who satisfy the criteria 
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with the previous reported major gene effect on plasma triglyceride levels (1,2), because 
VLDL particles, which carry most of the total triglycerides, show a consistent 
composition of lipids and apoB protein in FCH (8,11,12). 
Total plasma apoB was determined by immunonephelometry and obtained values 
were adjusted for variation due to age, gender and smoking habits prior to the segregation 
analyses (19-26). In the present study also BMI was shown to be highly correlated with 
apoB levels. 
Because a first segregation analysis could not discriminate conclusively between two 
models of inheritance, a more detailed analysis was performed on each family. In contrast 
with other 39 families, one family seemed to have an extreme preference to a two 
distribution non-Mendelian model. The exclusion of this single outlying family in a second 
segregation analysis, only influenced the -21n(L) scores and through these the selection of 
the most parsimonious model, whereas estimates of model specific parameters were 
remarkably consistent. Therefore, this family can be seen as an indication of rare 
heterogeneity, also observed in other family samples (23-25). 
Both our first and second segregation analysis showed a significant familial 
correlation of ppo=pM=0.24 (model 7), which appeared not to be influenced by the 
excluded family. This estimated correlation is comparable to that reported by others (0.13 
to 0.47) (23,24). Although examined in completely different study populations, most 
studies reported a codominant model as the most parsimonious fit on their apoB data 
(20-22,24,25,31). A few studies preferred, however, a dominant or recessive model 
(19,23,26). The estimated relative frequency of the 'low' apoB allele at 66% is in 
agreement with other reports (20-22,24,25,31). These consistent findings suggest that 
genetic control on apoB levels is comparable in subjects with different dislipidemia 
phenotypes. Some of the remaining differences in the results may be explained by the 
large differences in ascertainment criteria of the analyzed study populations, since studies 
ascertained families through probands who suffered from CAD (19,21,25), who were 
patients of a lipid clinic (22,23), who were submitted to elective coronary angiography 
(24) or after a coincident detection of CAD in the family (20,31). This study analyzed its 
sample after correction on ascertainment. Although the influence of ascertainment bias on 
the segregation analysis is still a subject of debate, inadequate correction for ascertainment 
bias can provide misleading results, suggesting the presence of a major locus when one is 
absent (42). 
FCH is caused by hepatic overproduction of VLDL-apoBlOO, subsequently leading 
to elevated levels of apoB containing IDL and LDL particles, of which the latter are 
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predominantly smaller and denser compared to normolipidemic subjects (11,14). The 
finding of a genetic mechanism for elevated apoB levels in this FCH population suggests 
that there is genetic control of hepatic VLDL-apoB production and that additional 
metabolic processes responsible for diminished clearance of apoB-containing particles, 
associated with mutations in the lipoprotein lipase gene (9,10) and the apoAI/CIII/AIV 
gene cluster (43,44), are subordinate to this VLDL-apoB overproduction. Thus, metabolic 
processes associated with VLDL-apoB overproduction, such as increased delivery of free 
fatty acids to liver cells (45) or dysregulation of the action of microsomal triglyceride 
transfer protein required for assembly and secretion of hepatic VLDL-apoB (46), may 
have a genetic basis. 
Recently, we demonstrated Mendelian inheritance of dense LDL subfraction profiles 
in these same FCH families (33). It appeared that the LDL subfraction profile was 
strongly related to the plasma apoB concentration, which raises the question whether the 
observed inheritance of the LDL subfractions more likely reflects the segregation of a trait 
in which affected subjects have elevated concentrations of apoB, as demonstrated in the 
present study. The few available reports, however, suggest that LDL subfraction profile 
phenotype and plasma apoB level genotype are separate Mendelian traits in FCH (2,47). 
Further analysis in which the LDL subfraction profile is considered independently of the 
genetic influence of apoB may elucidate this complicated issue. 
In conclusion, there is a clear familial aggregation of elevated apoB concentrations 
that significantly correspond with the lipid phenotype in FCH families. Segregation 
analysis provides evidence that this aggregation is well explained by a single major gene 
effect with a codominant expression. Using these findings, linkage analysis can be used to 
explore the molecular defect involved in apoB regulation in FCH families. 
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Chapter 9 
ABSTRACT 
Familial combined hyperlipidemia (FCH) is a heritable lipid disorder, in which 
dense low-density lipoprotein (LDL) subfraction profiles due to a predominance of small 
dense LDL particles are frequently observed. These small dense LDL particles are 
associated with cardiovascular disease. Using segregation analysis, we investigated to what 
extent these LDL subfraction profiles are genetically determined; also, the mode of 
inheritance was studied. Individual LDL subfraction profiles were determined by density 
gradient ultracentrifugation in 623 individuals of 40 well-defined Dutch FCH families. 
The individual LDL subfraction profile was defined as a quantitative trait by the 
continuous variable K, a reliable estimate of the relative contribution of each LDL 
subfraction to the overall profile. Variation in parameter К due to age, sex, and hormonal 
status was taken into account by introducing liability classes. Segregation analysis was 
performed by fitting a series of class D regressive models, implemented in the Statistical 
Analysis for Genetic Epidemiology (SAGE) program, after which genetic models were 
compared using log-likelihood ratio tests. Our data show that 60% of the variability of 
parameter К could be explained by lipid and lipoprotein levels and that a major autosomal 
locus, recessively inherited, with a population frequency of 0.42+0.07, and an additional 
polygenic component of 0.21 best explained the clustering of atherogenic dense LDL 
subfraction profiles in these FCH families. Therefore, dense LDL subfraction profiles, 
associated with elevated lipid levels, appear to have a genetic basis in FCH. 
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INTRODUCTION 
Familial combined hyperlipidemia (FCH) is the most common form of heritable lipid 
disorder and is accompanied by an increased incidence of cardiovascular disease (1). The 
trait is characterized by a multiple type hyperlipidemia in first-degree family members, 
with elevations of either total plasma cholesterol concentration, plasma triglyceride 
concentration, or both (2-4). Classically, FCH was thought to be inherited as a 
homogeneous single-gene disorder (1). Recent additional data, however, suggest that FCH 
is actually a more heterogeneous disorder. Overproduction of very-low- density 
lipoprotein (VLDL) apolipoprotein-B (apo-B) is supposed to be the primary cause (5). 
Delayed clearance of postprandial triglyceride-rich lipoproteins seems to be an aggravating 
metabolic defect in FCH (6). Mutations within the LpL gene, associated with a reduced 
hydrolytic capacity and elevated lipid levels (7,8), and in the apo-CI/AIV/CIII gene 
cluster (9) were genetically linked to the hyperlipidemia. Therefore, the expressed 
phenotypes may have a different etiology among families. The absence of a specific 
metabolic or genetic marker, combined with the characteristic variability of lipoprotein 
phenotypes among affected relatives complicates the diagnosis FCH in an individual 
patient, and still necessitates family investigation. 
The increased risk of premature cardiovascular disease in FCH relatives is not 
completely explained by the sometimes mild elevation of VLDL and low density 
lipoprotein (LDL) alone. The predominance of small dense LDL particles, which are less 
rapidly processed by the LDL receptor (10) and more susceptible to oxidative modification 
(11-13), may also play a role. Although LDL heterogeneity is markedly influenced by 
age, gender, and environmental factors (14,15), an additional genetic influence controls 
the variability of LDL subfractions (14,16). Recently, evidence for linkage of the 
predominance of small dense LDL and a gene cluster near the LDL receptor locus on the 
short arm of chromosome 19 was reported (17) but has not yet been confirmed by others. 
Segregation analyses confirmed that the distribution of the qualitative LDL subfraction 
pattern in a FCH population has a genetic basis (18). LDL subfraction patterns could be 
classified as pattern A, consisting of large buoyant LDL particles, and pattern B, 
consisting of small dense LDL subfractions. Pattern В appeared to be inherited as a 
single-gene trait with a dominant or additive mode of inheritance in the FCH population. 
When LDL subfractions were separated by density gradient ultracentri f ligation, a 
dichotomous classification of the LDL subfraction profile into pattern A and В could not 
fully reflect the great inter-individual variation in the LDL subfraction profiles (14). To 
describe the specific individual LDL subfraction distribution more accurately, we 
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introduced a continuous variable, parameter K, characterized by the relative contribution 
of the three major LDL subfractions LDLl, LDL2, and LDL3 to total LDL (14). 
Performing segregation analysis by using this parameter K, both inherited susceptibility 
and "environmental" factors (i.e., age, gender, body mass index [BMI], smoking habits, 
hormonal status in women, and lipid and lipoprotein levels) determined the LDL 
subfraction profile in 19 healthy Dutch families (14). In addition, longitudinal studies 
showed a remarkable consistency in time in the composition of the LDL subfraction 
profile both in untreated participants of the Framingham offspring study (19) and in FCH 
patients after drug treatment that substantially lowered particularly the plasma triglyceride 
concentrations (20,21). This predominance of subfractions containing small dense LDL 
particles irrespective of adequate lipid-lowering suggests that genetic factors may control 
LDL subfraction profiles in FCH subjects. It may therefore be questioned whether the 
LDL subfraction profile is a better metabolic marker for identifying affected relatives of 
FCH kindreds than are plasma lipids and lipoproteins. 
Our study aimed to examine the inheritance of small dense LDL subfraction profiles 
in FCH on the basis of LDL particle density, as described by the quantitative parameter 
K. For this, a segregation analysis in a large sample of well-defined Dutch FCH families 
was performed using the Statistical Analysis for Genetic Epidemiology (SAGE) program. 
This approach may confirm that the LDL subfraction profile can be used as an additional 
diagnostic marker, which best reflects the metabolic and genetic influences of the lipid 
disorder in individual affected relatives of FCH families. 
SUBJECTS and METHODS 
Families 
The recruitment of FCH kindreds took place via known affected probands who were 
attending the out-patient clinic of the University Clinics of Nijmegen (η =36) and 
Amsterdam (n=4). These probands exhibited a combined hyperlipidemia with both plasma 
cholesterol and triglyceride concentrations >90th percentile for age and gender during 
several periods in which they were not treated with lipid-lowering drugs, and despite 
dietary advice. In total, 40 multi-generational FCH kindreds containing 194 nuclear 
families with 687 individuals were used in this study. Families were included when a 
multiple type hyperlipidemia with elevated levels of total plasma cholesterol and/or 
triglycerides using the age- and sex-related 90th percentile upper levels of the prospective 
cardiovascular Münster (PROCAM) study (22) was present in first-degree relatives. Thus, 
besides the proband presenting a combined hyperlipidemia, the presence of one first-
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degree relative with hypertriglyceridemia, hypercholesterolemia, or a combined 
hyperlipidemia was obligatory. 
Families were excluded when first-degree family members had tendon xanthomata. 
None of the probands was homozygous for the apo E2 allele, and for all probands, a 
secondary cause (i.e., diabetes mellitus, hypothyroidism, and hepatic or renal impairment) 
for the presence of the hyperlipidemia could be excluded by standard laboratory tests. In 
addition, to refine the selection procedure, the 95th percentile for total plasma cholesterol 
and triglycerides was used if the BMI exceeded 30 kg/m2 or an alcohol intake of more 
than two daily consumptions was present. All individuals were Caucasian above the age of 
12 years. They all filled out a questionnaire about their medical status (i.e., diabetes, 
renal impairment and liver disease), medication use, alcohol intake, smoking habits, and 
hormonal status in women (pre- or postmenopausal, postmenopausal hormonal 
supplements, and oral contraceptive use). The study protocol was approved by the ethical 
committee of our institute. 
Plasma 
After an overnight fast and after withdrawal of lipid-lowering medication for at least 
4 weeks, venous blood was drawn by venipuncture into K,EDTA containing Vacutainer 
tubes. Non-local participants were visited at their homes, and blood was transported 
directly to the laboratory. Plasma was isolated within 3 h for determination of the lipid 
and lipoprotein levels, and the LDL subfraction profile. 
Plasma lipid and lipoprotein assays 
VLDL was isolated from whole plasma by ultracentrifugation at density =1.006 g/ml 
for 16 h at 36,000 rpm in a fixed angle rotor (TFT 45.6 rotor, Kontron), in a Beekman 
L7-55 ultracentrifuge. High-density lipoprotein (HDL) cholesterol was determined by the 
polyethylene glycol 6000 method (23). LDL cholesterol was calculated by subtraction of 
VLDL cholesterol and HDL cholesterol from total plasma cholesterol. Total plasma 
cholesterol and triglyceride concentrations were determined by enzymatic, commercially 
available reagents (Boehringer-Mannheim, Germany, catalog, no. 237574 and Sera Pak, 
Miles, Belgium, catalog, no. 6639, respectively). Total plasma apo-B concentrations were 
determined by immunonephelometry (24). To achieve accurate results in relation to the 
Center for Disease Control Standardization Program, the obtained values were 
recalculated on the basis of an exchange of sera with Dr. S. Marcovina (Northwest Lipid 
Research Laboratory, Seattle WA, USA). 
153 
Chapter 9 
Low density lipoprotein subfractionation 
LDL subfractions were detected by single spin density gradient ultracentrifugation, 
according to a method described elsewhere (25). After ultracentrifugation the LDL 
subfractions were visible as distinct bands in the middle of the tube. Up to five LDL 
subfractions could be distinguished concentrated in the following density ranges: LDL1 
(1.030-1.033g/ml), LDL2 (1.033-1.040 g/ml), LDL3 (1.040-1.045 g/ml), LDL4 (1.045-
1.049 g/ml), and LDL5 (1.049-1.054 g/ml). The ultracentrifugation tubes, containing the 
LDL subfractions stained with Coomassie Brilliant Blue R, were placed in a specially 
designed rack and photographed. Accurate documentation of the different LDL subfraction 
patterns was obtained by scanning the obtained slides in triplicate on a LKB 2202 
ultrascan laser densitometer (Pharmacia LKB). The mean peak heights (hl-h5) of the LDL 
subfractions (LDL1-LDL5) on the three scans were used to calculate the variable К as a 
continuous variable, that best describes each individual LDL subfraction pattern (14). The 
relative contribution of each LDL subfraction, expressed by its peak height (%hl-%h5) 
relative to the total LDL subfraction profile, (total LDL [100%] = 
%hl + %h2+%h3+%h4+%h5), was calculated. The relative peak heights of LDL3 and 
the less frequently occurring LDL4 and/or LDL5 were added to give 
%h3'=(%h3+%h4+%h5), where LDL[100%] = LDLl[%hl] + LDL2[%h2] + 
LDL3[%h3']. When a subfraction profile was characterized by a predominance of buoyant 
LDL particles (hl-h3>0), variable К was calculated by K=(%hl-%h3')/(%h2-%h3' + l). 
In case of a predominance of heavy, dense LDL subfractions (hl-h3<0), variable К was 
calculated by: K=(%hl-%h3')/(%h2-%hl + l). A negative value (-1<K<0) reflects a 
dense subfraction profile, an intermediate subfraction profile is described by K=0, and a 
complete buoyant profile by a positive К value (0<K< 1). 
Statistical methods 
To determine the difference in lipid and lipoprotein values in individuals with the 
buoyant (K^O) and dense (K<0) LDL subtraction profiles, these values were corrected 
for the influence of gender, age, BMI, smoking, and OC use. Adjusted lipid and 
lipoprotein values were standardized for 50-year-old, nonsmoking men with a BMI of 24 
kg/m2, and the difference between a buoyant and dense LDL subfraction profile in lipid 
and lipoprotein values was tested by using analysis of covariance. Pearson correlation 
coefficients were computed to determine correlations between parameter К and the 
variables age, BMI, and smoking. Partial correlation coefficients, controlling for the effect 
of age, BMI, smoking, and OC use, were computed to determine correlations between 
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parameter К and the variables total plasma cholesterol, plasma triglycerides, VLDL 
cholesterol and VLDL triglycerides, LDL cholesterol, HDL cholesterol, and apo-B. 
Multiple linear-regression analysis was performed to determine the influence of 
gender, age, BMI, smoking, and ОС use (independent variables) on parameter К 
(dependent variable). Stepwise multiple linear-regression was used to examine significant 
contributions of the independent variables (total plasma cholesterol, plasma triglycerides, 
VLDL cholesterol and VLDL triglycerides, LDL cholesterol, HDL cholesterol, and apo-
B) to the prediction of the parameter K. Any influence of gender, age, smoking habits, 
BMI, and OC use was taken into account by forcing them in the models. Statistical 
analysis were performed by using the Statistical Analysis System computer programs (SAS 
Institute). 
Segregation analysis 
The segregation of the LDL subfraction profiles in FCH families was investigated by 
fitting a series of class D regressive models as implemented in SAGE release 2.2 (26), as 
described elsewhere (27). These models assume that variation among individuals for a 
quantitative trait is the result of a major gene effect and residual variation which may 
reflect both familial correlations and individual variations. Hypotheses were tested by 
fitting a general model and comparing its likelihood to that of reduced models representing 
specific modes of inheritance. 
The general model used allows for two alleles at a single locus (denoted "L" for low 
and "H" for high) resulting in three types of individuals (LL, HL, and HH). The mean 
value of parameter К associated with each type is denoted μ ( ί ί ) , /*(HL) and μ(ΗΗ). The 
within-type variance, σ2, was assumed to be equal among all three types. The frequency 
of allele L is denoted q(L). The distribution of types in the population is assumed to be a 
Hardy-Weinberg equilibrium. Individuals of the LL, HL, and HH type are assumed to 
transmit the L allele with probabilities T(LL), T(HL), and τ(ΗΗ), respectively. In addition, 
the parameters p(SP), p(PO), and p(SS) denote the spouse, parent-offspring and sib 
correlations of parameter K, respectively. The class D models assume that correlations 
among all siblings are equal, but not necessarily because of common parentage alone. In 
case of equal parent-offspring and sibling correlations the class D models used have been 
shown to be mathematically and numerically equivalent to the conventional "mixed model" 
of inheritance in nuclear families (28). In this setting, the parent-offspring correlation 
provides an estimate of the polygenic heritability, i.e., h2 = 2ρ(ΡΟ)*σ2 /σ
τ
2
, where a T
2 is 
the total variance and <r4s the variance conditional on the restricted model. 
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The general model was fitted and compared to various submodels by fixing certain 
parameters to specific values. For example, under a Mendelian model, transmission 
parameters are restricted to: r(LL) = l, r(HL)=0.5 and т(НН)=0, reflecting Mendelian 
segregation at a single locus with two alleles. A dominant model restricts / I H L = / Í L L , 
while a recessive model restricts / ÍHL=/¿HH. A restricted model is compared to the 
general model using the likelihood ratio test. When models are not hierarchical, the 
Akaike's information criterion (AIC) can be used to compare the fit of different models. 
For a given model, AIC=-21n(L)+2*p (p=number of parameters estimated), and the 
model with the lowest AIC is considered to be the most parsimonious model (29). 
To increase the power of the segregation analysis, the variation in the LDL 
subfraction profile (i.e., parameter K) was first standardized (mean=0, SD=1) within 
each of five liability classes (for men < 50 years or > 50 years, and for women pre- or 
postmenopausal, and for women using hormones), using the mean values obtained from 
spouses (n=93), to control for parameter К variation due to age, gender, and hormonal 
status. Initially, the segregation analysis was performed using these standardized values of 
K. Subsequently, also the unadjusted or crude К value with extra parameters for age, 
gender, pre- and post menopausal status were used in the segregation analysis as a check 
for the adjustment procedure. 
In this study a correction for ascertainment bias was made because of a positive 
family-selection via known affected probands. The correction was made by conditioning 
the phenotypes of family members on those of the affected proband plus one extra affected 
(based on lipid levels) individual per kindred. 
RESULTS 
Study population 
In total, 566 family members and 121 spouses in 40 FCH kindreds including 2 to 4 
generations participated. Thirteen subjects of a non-informative branch of family #201 
were excluded. Because of lack of the required volume of plasma (n=23) and technical 
errors (n=28), the LDL subfraction profiles of 51 subjects (23 FCH relatives and 28 
spouses) could not be determined. However, plasma lipid and lipoprotein levels of these 
51 subjects were taken into account in order to support the diagnosis FCH. In total, 623 
subjects (299 men and 324 women) were included in the segregation analysis of 
parameter K. 
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Analysis of LDL subfraction profiles 
In ail sera, Three to five distinct LDL subfraction bands, contributing to the 
individual LDL subfraction profiles could be distinguished. The frequency distribution of 
the various LDL subfraction profiles in spouses and in FCH relatives, described by 








Figure 1 Frequency distribution of values tor the standardized parameter К among FCH relatives (n=530) 
and spouses (n=93). A buoyant LDL subfraction profile is defined by K>0, and a dense LDL subfraction 
profile by K<0. 
FCH relatives showed a skewed distribution with a predominance of dense (i.e., more 
negative values of parameter K) LDL subfraction profiles, while in spouses more buoyant 
profiles were observed. The mean value of parameter К was different in each liability 
class, underlining a relation with age, gender, and hormonal status in women (table 1). In 
all 5 liability classes the value of К was lower, or tended to be, in the FCH relatives than 
in the spouses, reflecting the predominance of dense LDL subfraction profiles in FCH 
subjects independent of age, gender, and female hormonal status (table 1). Further, the 
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Inherited LDL subfraction profiles in FCH 
Women using OC and postmenopausal women using hormonal replacement (both 
presented in one liability class) had a lower mean value of К than premenopausal women 
not using ОС (table 1). 
Interrelation of the LDL subfraction profile with anthropometric measurements 
The mean age, BMI, and percentage of smokers among all FCH relatives (men and 
women) are presented in table 2. The values of parameter К correlated significantly with 
age and BMI and weakly with smoking habits. These data indicate that with increasing age 
and BMI and with smoking, a denser LDL subfraction profile was observed (table 2). 
Multiple regression analysis of parameter K, including age, BMI, smoking habits, gender 
and OC use, revealed that these variables together contributed 24% to the variation of 
parameter K. The prevalence of more dense LDL subfraction profiles in the FCH 
population is higher (figure 1), and in accordance with the findings in the spouses, the 
prevalence in this FCH population also increases with age, BMI, the gender and OC use 
(table 1). 
Interrelation of the LDL subfraction profile with lipid and lipoprotein levels 
The lipid and lipoprotein levels of all FCH relatives, adjusted for age, gender, BMI, 
and smoking habits, and stratified by buoyant and dense LDL subfraction profiles are 
presented in table 2. Within FCH relatives, parameter К was found to be negatively 
correlated with apo-B, plasma triglycerides, VLDL triglycerides, VLDL cholesterol and 
total plasma cholesterol and positively with HDL-cholesterol concentrations. Therefore, 
with decreasing parameter К values, a lipoprotein profile is observed, characterized by 
higher concentrations of total apo-B, plasma triglyceride, and total plasma cholesterol, and 
by a lower HDL cholesterol concentration. These associations are also observed if buoyant 
LDL subfraction profiles are compared with dense LDL subfraction profiles (table 2). The 
LDL cholesterol concentration itself did not differ between buoyant and dense LDL 
subfraction groups. 
Because we anticipated strong intercorrelations between lipid and lipoprotein levels, 
stepwise multiple regression analysis was performed to evaluate which combination of 
lipids and lipoproteins could be used to predict the LDL subfraction profile both in 
spouses and in FCH relatives (table 3). In order to be able to compare our results with 
those from the literature, where data from VLDL cholesterol, VLDL triglycerides 
and.LDL cholesterol are frequently unavailable, the multiple regression analysis was 
performed twice, once excluding VLDL and LDL concentrations (model I) and once 
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including values of VLDL and LDL (model II). 
Table 2: Adjusted lipids and (apo)lipoproteins for FCH relatives stratified by buoyant (KbO) and dense 
(K<0) LDL subfraction profiles. 
Age (years) 
BMI (kg/m2) 










(η = 530) 
41.1 ± 16.9 
24.5 ± 3.7 
27.2% 
6.03 ± 0.09 
2.82 + 0.02 
0.98 ± 0.06 
0.91 ± 0.06 
3.98 ± 0.08 
1.10 ± 0.02 
140.2 ± 2.6 
Buoyant (КSO) 
(n=139; 26.2%) 
36.4 ± 16.6 
22.6 ± 3.0 
16.3% 
5.68 ± 0.13 
0.97 ± 0.06 
0.62 ± 0.10 
0.22 ± 0.08 
3.80 ± 0.12 
1.29 ± 0.03 
118.6 ± 3.7 
Dense (K<0) 
(n = 391; 73.8%) 
42.7 ± 16.6 
25.3 ± 3.8 
31.9% 
6.12 ± 0.13 
3.69 ± 0.04 
1.05 ± 0.06 
1.26 ± 0.05 
4.03 ± 0.08 
1.06 ± 0.02 

























Values are presented as mean ± SE. Values are adjusted to those of 50-year-old, non-smoking men with a 
BMI of 24 kg/nr; "concentrations in mmol/l; 'concentration in mg/dl; NS = not significant 
Both models included age, gender, BMI, smoking habits, and OC use as covariates. 
In spouses, a significant contribution of plasma triglycerides, HDL cholesterol, and apo-B 
to the prediction of parameter К (R2=0.64) was found. VLDL cholesterol, VLDL 
triglycerides, and LDL cholesterol (entered into model II) did not contribute to the 
prediction of parameter К in spouses (table 3). In FCH relatives, a significant contribution 
of plasma triglycerides, HDL cholesterol and apo-B to the prediction of К was found as 
well (model I). However, these parameters accounted for 58% of the variability of 
parameter K. When VLDL triglycerides, VLDL cholesterol, and LDL cholesterol were 
included in the analysis (model II), VLDL triglycerides and VLDL cholesterol 
significantly contributed to predicting parameter К of FCH relatives, but LDL cholesterol 
did not. So, inclusion of VLDL in the model provided little additional information in the 
prediction of the LDL subfraction profile of FCH relatives. 
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Segregation analysis was carried out using the standardized parameter К (table 4). 
Analysis using the unadjusted parameter К yielded the same results (data not shown). 
Table IV presents parameter estimates for 11 different modes of inheritance. 
In a sporadic or unimodal model, the spouse, parent-offspring, and sibling 
correlations were examined to determine multifactorial or polygenic influences. The 
spouse correlation (p(SP)) was found to be negligible (0.04+0.11) and was therefore fixed 
at 0 in all models. The parent-offspring correlation (p(PO)) and sibling correlation were 
found to be equal (0.22+0.04). Therefore, in order to estimate a possible polygenic 
component, all subsequent models assumed a single correlation among first-degree 
relatives (p(SS)=p(PO)). The sporadic models (model 1 and 2) fitted the data significantly 
worse than the unrestricted general model. This general model (model 11), with all 
variables unrestricted, revealed strong evidence for inheritance of parameter K, with 
transmission parameters r(LL)=0.93, T ( H L ) = 0 . 5 2 and T ( H L ) = 0 . 10, almost equal to 
values expected under Mendelian transmission (T(LL) = 1, T ( H L ) = 0 . 5 and T ( H L ) = 0 ) . 
Therefore at least a bimodal distribution of parameter К was inferred. To consider non-
genetic transmission, models 9 and 10, in which transmission parameters were set equal to 
q(L), were examined. These models fit poorly and could be rejected. In order to examine 
the mode of inheritance, dominant models (models 3 and 4), recessive models (models 5 
and 6), and codominant models (models 7 and 8) were fitted by fixing the transmission 
parameters at their Mendelian expectations (i.e., r(LL) = l, T ( H L ) = 0 . 5 and T ( H L ) = 0 ) . 
Dominant models of inheritance could be rejected against the general model (p<0.01). 
The fit of the recessive model of inheritance was found to be equal to the general model. 
This was true, however, only if the residual correlation was considered (model 6). This 
residual correlation is equivalent to the polygenic component within the nuclear familiy, 
and represents 2ρ(ΡΟ)*σ2 /σ
τ
 г
 (=21%) of the variation in adjusted LDL subfraction 
profiles. A codominant major gene model of inheritance (trimodal distribution of values 
for parameter K) as well as a single recessive model (models 5 and 7) fit the data worse 
than the general model. However, when residual correlations were considered neither the 
codominant nor the recessive model could be rejected (i.e., models 6 and 8). Model 6 has 
the lowest AIC value and appears to be the most parsimonious model, although model 8 is 
a close second. 
Table 5 presents the predicted К values under model 6 (recessive mode) and model 8 
(codominant mode). The predicted values for the LH type are very similar to those for the 
HH type, indicating that the most parsimonious model is the recessive one. 
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-0.59 ± 0.07 
-0.69 ± 0.07 
-0.33 ± 0.06 
-0.40 ± 0.04 






-0.04 ± 0.03 
-0.19 ± 0.02 
0.10 ± 0.02 
-0.08 ± 0.01 
-0.15 ± 0.02 
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Table 5 Unadjusted (i.e., crude) К values of models 6 and 8 in table 4 for the five liability classes 
Genotype: LL LH HH 
Model 6 (Recessive): 
Men < 50 years 
Men a 50 years 
Women premenopausal, not taking ОС 
Women taking hormones* 
Women postmenopausal 
Model 8 (Codominant): 
M e n < 5 0 y r s -0.57 ± 0.04 -0.05 ± 0.03 0.04 ± 0.06 
Men 250 yrs -0.67 ± 0.03 -0.21 ± 0.03 -0.12 + 0.05 
Women premenopausal, not taking ОС -0.31 ± 0.03 0.09 ± 0.02 0.17 + 0.05 
Women taking hormones" -0.38 ± 0.02 -0.09 ± 0.02 -0.03 ± 0.03 
Women postmenopausal -0.64 ± 0.04 -0.19 ± 0.03 -0.08 ± 0.05 
Values are presented as mean ± SE; L and H are two alleles at a single locus; allele L is associated with the 
deviant phenotype; allele H is associated with a normal phenotype; 'including premenopausal women using 
ОС (η=77) and postmenopausal women taking hormonal replacement (n = 5) 
DISCUSSION 
To examine a possible genetic basis for the LDL subfraction profile distribution in 
patients with FCH, we investigated the segregation of individual LDL subfraction profiles 
(parameter K), in a large sample of well-defined Dutch FCH families. The results of our 
study show that the observed clustering of the dense, probably atherogenic, LDL 
subfraction profiles in this FCH population indeed has a genetic basis, best described by a 
common, major autosomal gene with a population frequency of 0.42+0.07 and a recessive 
mode of inheritance with a polygenic heritability component of 0.25. 
Several studies have suggested possible genetic control of LDL heterogeneity, using 
a variety of techniques to detect LDL heterogeneity and to analyze its genetic 
susceptibility (14,30,31). We performed a segregation analysis in a FCH population, using 
LDL subfraction profiles obtained by density gradient ultracentrifugation, and described 
by a continuous parameter K. Most reports on LDL subfractions, including the only paper 
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published thus far about the inheritance of LDL subfractions in FCH, distinguish only 2 
distinct LDL subfraction patterns, denoted "A" (parameter K>0) and "B" (parameter 
K<0), on the basis of LDL particle size of the major LDL subfraction, obtained by 
gradient gel electrophoresis (18). Additional analysis by Austin et al. using the LDL peak 
particle diameter as continuous trait was not superior to that of the dichotomous 
classification in determining the mode of inheritance of LDL subfraction patterns in 
primarily healthy families, probably because it was based only on the major LDL 
subfraction of a profile (32). The quantitative parameter K, which allows the contribution 
of all LDL subfractions to be taken into account, reflects better the great inter-individual 
variation in the LDL subfraction profile (14). When a quantitative trait such as the LDL 
subfraction profile is reduced to a dichotomy, i.e., LDL subfraction profile "A" and "B", 
much information is lost, since it is unknown whether an individual is close or far from 
the threshold. In addition, the general or mixed model was originally formulated in terms 
of quantitative traits. Indeed, we have shown in a normolipidemic population that 
segregation analyses on the basis of the quantitative parameter К discriminated better than 
on the basis of a dichotomous A or В classification, with regard to models of inheritance 
of LDL subfraction profiles (14). 
The only study to which we could compare our data is a segregation analysis of 
LDL subfraction patterns in seven FCH kindreds using the binary trait classification (18). 
They found that the heavy pattern "B" was inherited as an autosomal trait with either a 
dominant or an additive mode of inheritance, and a small multifactorial inheritance 
component. The population frequency for the proposed pattern "B" allele in FCH was 
0.30, which was very similar to the frequency in a healthy Mormon population (0.25) 
(33). Our results more strongly suggest inheritance of LDL subfraction profiles through a 
single major locus. However, in contrast to Austin et al. our data indicate a recessive 
mode of inheritance with a polygenic component with a gene frequency of 0.42. This gene 
frequency is higher than the 0.19 found in a healthy Dutch population with a recessive 
mode of inheritance (14). 
In assessing the validity of our conclusions from this study, several factors must be 
considered. First, we transformed the parameter К in order to increase the power of the 
segregation analysis. The classification by introducing five liability classes can be 
criticized. The analysis with an unadjusted K-value, however, revealed similar results. 
Inadequate correction for ascertainment bias can also provide misleading results, 
suggesting the presence of a major locus when one is absent (34). The way in which 
adequate correction for ascertainment bias should be carried out is still under debate. We 
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conditioned the phenotypes of family members on two affected individuals per family. 
It appeared that 60% of the variation in parameter К could be explained by gender, 
age, BMI, smoking habits, hormonal status in women, and lipid and lipoprotein levels. 
This rate confirms the results of previous reports, where »60% of the variability of the 
LDL subfraction profile could be explained by anthropometric measurements and 
metabolic influences (14,33,35). Therefore, the findings of a strong interaction between 
plasma lipids and lipoproteins (i.e., plasma triglycerides, apo-B, and LDL subfraction 
profiles), is very consistent. This raises the question whether the observed inheritance of 
LDL subfractions is more likely the segregation of a trait in which affected subjects have 
elevated concentrations of plasma triglycerides and apo-B, a diagnostic feature in FCH 
families. This hypothesis, however, is not supported by recent reports. Cullen et al. 
provide evidence for a major gene acting on serum triglyceride levels in 55 British FCH 
families (36). From their data, they also presumed the presence of exacerbating genes, 
such as a major gene acting on LDL subfraction profiles. This gene would have an allele 
that confers high triglyceride levels on those subjects with FCH. Jarvik et al. observed 
Mendelian segregation of a major locus for apo-B in seven FCH families, which was not 
eliminated by adjustment for dichotomously classified LDL subfraction pattern (37). They 
concluded that LDL subfraction phenotype and apo-B level genotype are separate 
Mendelian traits in FCH. Hokanson et al. recently reported that the physical and chemical 
properties of LDL particles in FCH differ from those of normolipidemic controls. Many 
of these properties appear to be independent of plasma triglyceride concentrations and are 
only found in FCH patients (38). In addition, we have demonstrated Mendelian 
transmission of LDL subfraction profiles in healthy normolipidemic Dutch families, using 
the same LDL subfraction isolation technique. In this normolipidemic population, a 
significant intercorrelation between lipids, lipoproteins, and LDL subfraction profiles was 
observed, comparable to that in the present FCH population. So, the distribution of LDL 
subfraction profiles in healthy Dutch normolipidemic families is the result of a 
combination of underlying genetic traits and environmental or behavioral traits. Our 
analysis indicates that the appearance of a dense LDL subfraction profile is not unique for 
affected FCH patients, but in the latter group it is more frequently observed. 
There are several arguments, obtained from this study and previous work, for 
considering small dense LDL as an additional metabolic marker for FCH. First, we 
observed the same mode of inheritance of a major locus for the LDL subfraction profile in 
a healthy population (14) and a FCH population (present study). The twice-as- high gene 
frequency of the proposed allele for the trait suggests a higher frequency of the allele for a 
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dense LDL subfraction profile in FCH. Also, the fact that the LDL subfraction profile in 
FCH subjects is reasonably refractory to lipid-lowering therapy (20,21), suggests that it is 
an underlying metabolic marker. A third argument is the observed Mendelian transmission 
of dense LDL subfraction profiles in these FCH kindreds, although selection of the 
families took place on the basis of elevated lipid level. At the same time, we demonstrated 
that these lipid concentrations could only explain 60% of the variation in the profiles. 
In conclusion, a constant individual LDL subfraction profile controlled by a major 
recessive locus is associated with the elevated and intra-individual fluctuating lipid levels 
in FCH. The predominance of dense LDL subfraction profiles appears to reflect both the 
metabolic and genetic influences on the lipid disorder. Therefore, additional determination 
of the LDL subfraction profile may be more informative in the search for affected FCH 
relatives than is lipid phenotyping alone. 
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ABSTRACT 
Familial combined hyperlipidemia (FCH) is a common heritable lipid disorder, 
characterized by elevations of plasma cholesterol and/or triglycerides within first-degree 
relatives and an elevation of plasma apolipoprotein-B (apoB). Furthermore, a 
predominance of small dense atherogenic low density lipoprotein (LDL) particles, 
consistently associated with the elevated plasma lipid levels, is frequently observed. 
Previously, we demonstrated a major recessive locus control of dense LDL profiles 
inheritance and a codominant mechanism involved in the aggregation of elevated plasma 
apoB levels in 623 individuals of 40 well-defined FCH families. Elevated plasma apoB is 
metabolically associated with dense LDL in FCH. To establish whether distinct genetic 
mechanisms express both traits, we now evaluated the inheritance of small dense LDL 
subfraction profiles after correction for the predicted genetic influence of a putative apoB 
locus. By means of a segregation analysis of apoB, individual apoB genotypes (i.e., AA, 
AB, or BB) could be assigned to 85% of all individuals. LDL subfraction profiles 
expressed by a continuous variable К differed significantly between apoB genotypes, 
supporting the metabolic relation between apoB and LDL subfraction profile. 
Subsequently, LDL subfraction profiles were adjusted for predicted apoB influence by 
subtracting the apoB genotype specific mean К value from the individual К values. These 
apoB genotype specific mean К values were obtained from those individuals with their 
apoB genotype probability >70%. Segregation analysis of residual LDL subfraction 
profiles provided substantial evidence for a major locus inheritance pattern. Therefore, it 
is concluded that two distinct genetic mechanisms influence the appearance of elevated 
plasma apoB and the predominance of dense LDL in these FCH families. 
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INTRODUCTION 
Familial combined hyperlipidemia (FCH) is the most common form of heritable 
lipid disorders with an estimated population frequency of 1 to 2%. At least 10% of all 
premature cardiovascular disease can be ascribed to this lipid disorder (1,2). The 
hyperlipidemia is characterized by elevations of the total plasma cholesterol concentration 
and/or the plasma triglyceride concentration in first-degree relatives and is therefore also 
known as 'multiple type hyperlipidemia'. Other characteristics of the disorder are an 
elevated plasma apolipoprotein-BlOO (apoB) concentration, a decreased high density 
lipoprotein (HDL) concentration, and a preponderance of small dense low density 
lipoprotein (LDL) particles (2-4). 
Originally, FCH was thought to be inherited as a homogeneous single gene 
disorder with a major effect on triglyceride levels and a secondary effect on plasma 
cholesterol levels (1). Although recently evidence has been provided for such a major 
locus effect on triglyceride levels, it was considered that a number of different loci may 
affect the expression of the FCH phenotype and that the major genes involved still have to 
be identified (5). Other studies also have shown FCH to be a heterogeneous lipid disorder, 
comprising features of the insulin resistance syndrome, hyperapobetalipoproteinemia and 
familial dyslipidemic hypertension (3,6-8). Interestingly, all of these entities are associated 
with the presence of small dense LDL (9). Still, the absence of a specific metabolic or 
genetic marker complicates the diagnosis of those entities which are probably lumped 
together under the rubric of FCH. 
FCH is considered to be caused by hepatic overproduction of very low density 
lipoprotein (VLDL)-apoB (10,11), resulting in elevated levels of apoB-containing 
lipoproteins in the density range of VLDL, intermediate density lipoprotein (IDL) and 
LDL particles. A delayed clearance of the triglyceride-rich apoB-containing lipoproteins, 
in part caused by impaired lipoprotein lipase activity may modify the lipid phenotypic 
expression (12,13). Using segregation analysis, the variation in age- and sex-adjusted 
apoB levels has been ascribed to a yet unmapped codominant mendelian locus (14,15). 
This locus was later found to be predictive of FCH (16,17). It is noteworthy that elevated 
plasma apoB levels, corresponding with elevated VLDL and/or LDL levels in FCH, have 
been metabolically associated with the predominance of small dense LDL (18-20). Both 
elevated plasma apoB and small dense LDL are associated with the occurrence of 
cardiovascular disease (21-24), although there may be some overlap in the reported 
respective cardiovascular risks related to each entity. 
Also the distribution of small dense LDL subfraction profiles appears to have a 
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genetic basis in FCH (4,25). Because the mechanisms reported for the inheritance of 
plasma apoB levels were different from those reported for the inheritance of LDL 
subfraction profiles in FCH, one may wonder whether the presumed inheritance of LDL 
subfractions is actually caused by the segregation of a trait responsible for elevated plasma 
apoB concentrations. After all, with two traits involved in the same metabolic pathway, 
the major locus controlling one phenotype may have a carryover effect on the other 
phenotype. In order to investigate whether distinct genetic mechanisms underlie the 
familial aggregation of elevated plasma apoB levels and the predominance of dense LDL 
subfraction profiles observed in FCH, we conducted a segregation analysis of LDL 
subfraction profiles adjusted for the inferred genotypic influence of a putative apoB locus. 
Elucidation of the relation between these two traits and depiction of their genetic basis in 
FCH would be helpful in the search for molecular defects involved. 
MATERIALS AND METHODS 
Study Population 
The FCH pedigrees considered here have been studied for inheritance of LDL 
subfraction profiles (25) and plasma apoB levels (26). The families were ascertained 
through probands exhibiting a combined hyperlipidemia with both plasma cholesterol and 
triglyceride concentrations above the 90th percentile, adjusted for age and gender, as 
obtained from the Prospective Cardiovascular Münster (PROCAM) Study (27). These 
values were consistent over several measurements in which the probands had not been 
given any lipid-lowering drugs. Families were included when a so called 'multiple type 
hyperlipidemia' (2) with levels of total plasma cholesterol and/or triglycerides above the 
90th percentile was present. This means that besides the proband, at least one first-degree 
relative exhibited hypercholesterolemia or hypertriglyceridemia. 
All participants completed a questionnaire on medical status, medication use, 
alcohol intake and smoking habits. All probands were tested for an underlying cause of 
the hyperlipidemia, i.e., diabetes mellitus, hypothyroidism and hepatic or renal 
impairment. The presence of one of these causes excluded them and their families from 
further analysis. None of the probands in these families was homozygous for the apo e2 
allele and none of the first-degree relatives had tendon xanthomata. In addition, to refine 
the selection procedure the 95th percentiles for plasma cholesterol and triglycerides were 
used if the body mass index exceeded 30 kg/m2, or an alcohol consumption of more than 
two drinks per day was present. All individuals were Caucasians above the age of 10 
years. The study protocol was approved by the ethical committee of the University 
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Hospital Nijmegen. 
Plasma 
After an overnight fast and a withdrawal of lipid-lowering medication for at least 
four weeks, blood was drawn by venipuncture into EDTA-containing vacutainer tubes. 
Non-local participants were visited at their homes, and blood was transported directly to 
the laboratory. Plasma was isolated within 3 hours for determination of the lipid and 
lipoprotein levels and LDL subfraction profiles. Remaining plasma was stored at -80°C for 
plasma apoB determination. 
Measurement of Lipid, Lipoprotein and Apolipoprotein levels 
VLDL was isolated from whole plasma by ultracentrifugation at density =1.006 
g/ml for 16 hours at 36,000 rpm in a fixed angle rotor (TFT 45.6 rotor, Kontron, 
Zürich), in a Beekman L7-55 ultracentrifuge (Beekman, Palo Alto, CA, U.S.A.). High 
density lipoprotein (HDL) cholesterol was determined by the polyethylene glycol 6000 
method (28). LDL cholesterol was calculated by subtraction of VLDL cholesterol and 
HDL cholesterol from total plasma cholesterol. Cholesterol and triglyceride concentrations 
were determined by enzymatic, commercially available reagents (Boehringer-Mannheim, 
Germany, cat. No.237574 and Sera Pak, Miles, Italy cat. No. 6639, respectively). Total 
plasma apoB concentrations were determined by immunonephelometry (29). To achieve 
accurate results in relation to the Center for Disease Control Standardization Program, 
obtained values were recalculated on the basis of an exchange of sera with Dr. S. 
Marcovina (Northwest Lipid Research Laboratory, Seattle, WA, U.S.A.). 
Low density lipoprotein subfractionation 
LDL subfractions were detected by single spin density gradient ultracentrifugation, 
according to a method described in detail elsewhere (30). Up to five LDL subfractions 
could be distinguished concentrated in the following density ranges: LDL1 (1.030-
1.033g/ml), LDL2 (1.033-1.040 g/ml), LDL3 (1.040-1.045 g/ml), LDL4 (1.045-1.049 
g/ml), and LDL5 (1.049-1.054 g/ml). The ultracentrifugation tubes, containing the LDL 
subfractions stained with Coomassie Brilliant Blue R, were placed in a specially designed 
rack and photographed. Accurate documentation of the different LDL subfraction patterns 
was obtained by scanning the obtained slides in triplicate on a LKB 2202 ultrascan laser 
densitometer (Pharmacia LKB). The mean peak heights (hl-h5) of the LDL subfractions 
(LDL1-LDL5) on the three scans were used to calculate the variable К as a continuous 
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variable, that best describes each individual LDL subfraction pattern (31,32). A negative 
value (-1<K<0) reflects a dense subfraction profile, whereas a complete buoyant profile 
reveals a positive К value (0<K< 1) (31). 
Statistical Analysis 
To determine the difference in lipid and lipoprotein values in the FCH probands, 
the remaining FCH relatives and the spouses, these values were first adjusted for the 
influence of gender, age, BMI, and smoking by lineair regression. Differences in mean 
adjusted lipid and lipoprotein values were tested by analysis of variance. Because of a 
skewed distribution of both variables, a Spearman correlation coefficient was calculated to 
depict the relation between plasma apoB concentrations and crude К values. 
Segregation analyses 
The preceding segregation analyses of LDL subfraction profiles and standardized 
plasma apoB levels (25,26), as well as the present segregation analysis of LDL subfraction 
profiles adjusted for the inferred genotypic influence of a putative apoB locus were all 
performed by fitting a series of class D regressive models (33) implemented in the 
Statistical Analysis for Genetic Epidemiology (SAGE) release 2.2 software package (34). 
These models assume that variation among individuals in a quantitative trait is the result 
of a major gene effect and residual variation which may reflect both familial correlations 
and individual variations (35). Hypotheses were tested by fitting a general model and 
comparing its likelihood to that of reduced models representing specific modes of 
inheritance. The general model used allows for two alleles at a single locus (denoted "L" 
for low and "H" for high) resulting in three types of individuals (LL, HL, and HH). The 
mean value of adjusted parameter К associated with each type is denoted ¿¿(LL), ¿i(HL) 
and μ(ΗΗ), and the mean value of standardized plasma apoB associated with each type is 
denoted μ(ΑΑ), μ(ΑΒ) and μ(ΒΒ) (26). The within-type variance, σ2, was assumed to be 
equal among all three types. The frequency of allele L is denoted q(L). Individuals of the 
LL, HL, and HH type are assumed to transmit the L allele with probabilities r(LL), 
T(HL), and τ(ΗΗ), respectively. In addition, the parameters p(SP), p(PO), and p(SS) 
denote the spouse, parent-offspring and sib correlations of the adjusted parameter K, 
respectively. The class D models assume that correlations among all siblings are equal, 
but not necessarily because of common parentage alone. In case of equal parent-offspring 
and sibling correlations the class D models have been shown to be mathematically 
equivalent to the conventional "mixed model" of inheritance in nuclear families (36). In 
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this case, the parent-offspring correlation provides an estimate of the polygenic 
heritability, i.e., h2 = [2ρ(ΡΟ)]*[σ2/σ
τ
 2 ] , where a T 2 i s the total variance and σ2 is the 
variance conditional on the restricted model. 
The general model was fitted and compared to various submodels by fixing certain 
parameters to specific values. For example, under a Mendelian model, transmission 
parameters are restricted to: T ( L L ) = 1 , T ( H L ) = 0 . 5 and т(НН)=0, reflecting Mendelian 
segregation at a single locus with two alleles. A dominant model restricts μΗΙ.=μΙΧ, 
while a recessive model restricts μΗί=μΗΗ. The distribution of types in the population 
was assumed to follow a Hardy-Weinberg equilibrium. A restricted model was compared 
to the general model using the likelihood ratio test. When models were not hierarchical, 
the Akaike's information criterion (AIC) was used to compare the fit of different models. 
For a given model, AIC=-21n(L)+2*p (p=number of parameters estimated), and the 
model with the lowest AIC is considered to be the most parsimonious model (37). 
Because of family selection through affected probands, correction for ascertainment 
bias was made by conditioning the phenotypes of family members on those of the affected 
probands and that of one extra affected individual per pedigree, so each pedigree contains 
two probands (i.e., 80 probands in 40 pedigrees) (25). 
Segregation of apoB levels and LDL subfraction profiles in FCH 
Previous segregation analyses on this data set demonstrated that both the 
distribution of dense LDL subfraction profiles (25) and the aggregation of elevated plasma 
apoB levels (26) appeared to have a genetic basis in these FCH families. The segregation 
of dense LDL subfraction profiles was most consistent with an autosomal recessive locus 
with a population frequency of 0.42 (data not shown) (25). In a separate segregation 
analysis of plasma apoB, the apoB concentrations were adjusted by linear regression for 
the influence of age, age2, gender, BMl, smoking habits, and alcohol intake prior to the 
segregation analysis, comparable with procedures reported by others (35). Subsequently, a 
codominant model of inheritance plus family correlations p(PO)=p(SS) =0.15±0.03 and 
spouse correlation p(SP)=0.14+0.07, best explained the segregation of adjusted plasma 
apoB levels (data not shown) (26). 
Correction of LDL subfraction profile for putative apoB genotype influence 
To allow a more quantitative assessment of the impact of a putative Mendelian 
locus on a secondary trait, Hasstedt and Moll proposed to compute for each individual the 
probabilities for all possible genotypes under a Mendelian model for the primary trait, and 
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subsequently to use these probabilities to compute genotypic-specific means for the 
secondary trait (38). 
In order to apply this method on the present data set, each individual was classified 
into their most probable genotype at the apoB locus (i.e., AA, AB, or BB) by segregation 
analysis of plasma apoB levels. The mean К value of those individuals with one of the 
apoB genotype probabilities ^70% were used to condition the К values for the predicted 
influence of apoB genotypes. By this arbitrary criterium (39), 53 individuals were 
assigned to represent apoB genotype AA, 144 to apoB genotype AB and 95 to apoB 
genotype BB (n=292 assigned, representing 47% of all subjects), with mean adjusted К 
values of 0.41, -0.46 and -1.69, respectively. Subsequently, the К values of all 623 
subjects were conditioned by subtracting these apoB genotype specific mean К values of 
the individual К values. For subjects with prob(AA)=prob(AB) (0.41-0.46)/2 was 
subtracted from their К value, and for those with prob(AB)=prob(BB) (-0.46-1.69)/2 was 
subtracted. For those with missing plasma apoB values, (0.41-0.46-1.69)/3 was subtracted 




566 Family members (i.e., 80 probands and 486 relatives) and 121 spouses from 
40 FCH kindreds (consisting of 2 to 4 generations with pedigree size ranges from 7 to 104 
family members, including spouses) participated. Because of lack of the required plasma 
volume (n=28) or technical errors (n=23), the LDL subfraction profiles of 51 subjects 
could not be determined. For an additional 13 subjects the apoB concentration was missing 
due to plasma sample unavailability. However, plasma lipid and lipoprotein levels of these 
subjects with missing apoB or LDL subfraction profile data were taken into account in 
order to support the diagnosis FCH. The present segregation analysis involved data of 623 
subjects (299 men and 324 women). The mean lipid, (apo)lipoprotein levels and К values 
of the 80 probands, the FCH relatives and the spouses, adjusted for age, gender, BMI, 
and smoking habits are presented in Table 1. Due to the inclusion criteria, probands 
exhibited higher plasma lipid and lipoprotein levels than relatives and spouses. Also the 
plasma apoB concentration was higher and the К value was more negative in the probands 
compared with relatives and spouses. FCH relatives differed significantly from spouses on 
all parameters except for the LDL cholesterol concentration. 
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ApoB genotype assignment and effects on lipids, (apo)lipoproteins and К values 
Of all 662 individuals (original 687 individuals minus 25 with missing data for 
apoB standardization) used in the segregation analysis of plasma apoB, one putative apoB 
genotype was more likely than the other two in 524 subjects (79%), whereas in 37 
subjects (6%) two genotypes were equally likely. 101 Subjects (15%) could not be 
classified. 
Table 1: Mean (±SD) adjusted' lipid and (apo)lipoprotein concentrations and К values in probands, FCH 














54.6 ± 11.4 
26.7 ± 3.8 
6.43 ± 1.40 
2.58 ± 2.54 
1.16 ± 1.32 
1.85 ± 2.19 
1.12 ± 0.27 
4.16 ± 1.15 
157.3 ± 42.9 
-0.32 ± 0.29 
FCH relatives 
480 
38.9 ± 16.8 
24.2 ± 3.7 
5.84 ± 1.07 
1.86 ± 1.47 
0.77 ± 0.67 
1.23 ± 1.21 
1.18 ± 0.29 
3.85 ± 0.98 
133.4 ± 29.5 
-0.24 + 0.26 
Spouses 
102 
50.0 + 11.9* 
25.5 ± 3.5* 
5.58 ± 1.13* 
1.18 ± 0.80* 
0.45 ± 0.41* 
0.67 ± 0.67* 
1.31 ± 0.33* 
3.91 ± 0.99 
117.4 + 27.1* 
-0.09 + 0.23* 
'values, except for age and BMI, were adjusted for the influence of age, gender, body mass index and 
smoking habits; *in mmol/l; "in mg/dl; BMI = body mass index; VLDL=very low density lipoprotein; 
HDL=high density lipoprotein; LDL=low density lipoprotein; *significant difference between FCH relatives 
and spouses. 
The distribution of assigned apoB genotypes (i.e., AA, AB, or BB) for probands, relatives 
and spouses is presented in Table 2. In FCH probands and FCH relatives the 'high' apoB 
level genotype BB and the 'intermediate' apoB level genotype AB were more frequently 
assigned compared with spouses, whereas the 'low' apoB level genotype AA was more 
frequently assigned to spouses. Table 3 presents the lipids, (apo)lipoproteins and К value 
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79 (16 5%) 
26 (5 4%) 
225 (46 9%) 





42 (41 2%) 
2 (2 0%) 
29 (28 4%) 
0 (0 0%) 
3 (2 9%) 
26(25 5%) 
genotypes. Compared with the apoB AA genotype, the apoB BB genotype corresponded 
with the highest plasma cholesterol, triglyceride, VLDL cholesterol, VLDL triglyceride 
and LDL cholesterol levels, and the lowest HDL cholesterol level. 
Table 2: Distribution (n, (%)) of the assigned apohpoprotein-B level genotype (i.e , AA, AB, or BB), as 
provided by segregation analysis, for the probands, FCH relatives and spouses of 40 FCH families. 
Total number 
ApoB AA genotype 
ApoB AA = AB genotype 
ApoB AB genotype 
ApoB AB = BB genotype 
ApoB BB genotype 
Unclassified 
ApoB=apolipoprotein-B, apoB AA genotype is associated with 'low' apoB levels, apoB AB genotype is 
associated with 'intermediate' apoB levels and apoB BB genotype is associated with 'high' apoB levels 
Interestingly, the apoB BB genotype was also significantly associated with the lowest К 
value, representing more dense LDL subfraction profiles. The apoB AB genotype 
represented values for the parameters in between apoB AA and BB genotypes. Thus, the 
apoB BB genotype corresponded with a FCH lipid phenotype with elevated plasma lipids 
and lipoproteins, a decreased HDL cholesterol and a dense LDL subfraction profile. In the 
entire FCH population without spouses, the variability in crude plasma apoB concentration 
could account for 42% of the variability in LDL subfraction profiles, revealing a strong 
correlation (Spearman's correlation r=-0.65) between crude values for both variables 
(Figure 1). After adjustment for 'environmental' influences (see methods) of both apoB 
concentrations and К values, this correlation was still significant (r=-0.47) However, 
after adjustment of standardized К values for the predicted influence of apoB genotype, 
the correlation was completely disappeared (Spearman's correlation r=-0.08) This 
implicates that LDL subfraction profiles were adequately corrected for inferred genetical 
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influence of plasma apoB concentration. 
Table 3: Mean (±SD) lipids, (apo)lipoproteins and К value by apoB level genotypes (ι e , AA, AB, or BB) 












ApoB AA genotype 
130 
44 6 ± 16 0 
24 9 ± 4 3 
5 04 ± 1 00 
1 08 ± 0 51 
0 35 ± 0 21 
0 59 ± 0 40 
1 33 ± 0 35 
3 36 ± 0 95 
106 1 ± 24 5 
-0 05 ± 0 21 
ApoB AB genotype 
276 
40 6 ± 17 4 
24 3 ± 3 7 
5 67 ± 1 14 
1 51 ± 1 29 
0 57 ± 0 54 
0 96 ± 1 16 
1 21 ± 0 36 
3 90 ± 1 06 
127 1 ± 30 0 
-0 20 ± 0 29 
ApoB В В genotype 
118 
45 2 ± 15 3/C 
24 8 ± 3 0 
7 17 ± 1 21* 
2 95 ± 2 05* 
1 38 ± 1 20* 
2 02 ± 1 71* 
1 05 ± 0 28* 
4 73 ± 1 16* 
180 8 ± 34 7* 
-0 46 ± 0 24* 
See 'Methods' for apoB level genotype designation procedure, *in mmol/l, Bin mg/dl, VLDL=very low 
density lipoprotein, HDL=high density lipoprotein, LDL=low density lipoprotein, #signiticantly different 
from apoB AB genotype, *sigmficantly different from apoB AA and AB genotype 
Segregation of LDL subfraction profiles corrected for apoB genotype 
Segregation analysis was earned out using the primary standardized variable К (25) 
adjusted for the genetic influence of apoB genotype. Table 4 presents parameter estimates 
for 13 different models of inheritance In a sporadic or unimodal model, the spouse, 
parent-offspring, and sibling correlations were examined to determine multifactorial or 
polygenic influences (models 1 to 4) The spouse correlation (p(SP)) was found to be 
insignificant (0.16 ± 0 12) and was therefore fixed at 0 m all subsequent models The 
parent-offspring correlation (p(PO)) and sibling correlation (p(SS)) were found to be equal 
(0 16+0 05) Therefore, all subsequent models assumed a single correlation among first-










-1.00 ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι 
0 40 80 120 160 200 240 280 320 
Plasma apoB concentration (mg/dl) 
Figure 1: Correlation between crude plasma apoB concentrations and LDL density (i.e., the crude К value) 
observed in FCH relatives of 40 FCH families. 
The sporadic models (models 1 to 4) and the non-genetic transmission models (models 11 
and 12) fitted the data significantly worse than the unrestricted general model 13. This 
general model, with all variables unrestricted, provided evidence for major locus 
inheritance of parameter K, because transmission parameters r(LL) = {1.00}, 
T(HL) =0.85±0.15 and r(HL)=0.09±0.07, were roughly in accordance with values 
expected under Mendelian transmission: (T(LL) = 1, r(HL)=0.5 and T ( H L ) = 0 ) , 
respectively, although T(LL) had to be fixed at boundary. In order to examine the mode of 
inheritance, dominant models (models 5 and 6), recessive models (models 7 and 8), and 
codominant models (models 9 and 10) were fitted by fixing the transmission parameters at 
their Mendelian expectations. None of the Mendelian models could be rejected, because 
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their -21n(L) values were very similar to that of the general model. Of the Mendelian 
models, those including the residual correlations provided the best fit of the data with the 
dominant model exhibiting the lowest AIC value. The residual correlation was used to 
estimate the polygenic component by the formula [2ρ(ΡΟ)]*[σ2 /σ
τ
 *] and was found to be 
13% in the dominant model, 15% in the recessive model and 16% in the codominant 
model. Based on these results the Mendelian models (models 6, 8 and 10) provided the 
most parsimonious fit of the data, but discrimination between these models appeared to be 
impossible. 
DISCUSSION 
Based on data of these FCH families, both the aggregation of elevated apoB levels 
and the distribution of dense LDL subfraction profiles were shown to have a genetic basis 
in this lipid disorder. Because inheritance of the traits was investigated for each trait 
separately, the observed segregation of the individual traits may also have been caused by 
one genotype controlling both phenotypes. However, the segregation of dense LDL 
subfraction profiles corrected for putative apoB genotypes assigned by segregation 
analysis, still provided evidence for the presence of a Mendelian mechanism which 
exclusively controls the distribution of dense LDL subfractions profiles. Thus, it is likely 
that the presence of elevated plasma apoB levels and the predominance of small dense 
LDL are controlled by distinct genetic mechanisms in FCH. 
Recently, we have demonstrated that a single major recessive locus controls the 
predominance of dense LDL subfraction profiles in these FCH families (25). This was 
consistent with the findings of Austin et al. (4). In contrast to an approach using a 
dichotomous classification of LDL subfraction pattern, or detection of the LDL peak 
particle diameter as performed by others (4,40,41), the great inter-individual variation in 
the LDL subfraction profiles would best be described by the continuous variable K. This 
К value is characterized by the relative contribution of all detected LDL subfractions to 
the total LDL subfraction profile (25,31). Compared with the general population, our 
analysis revealed a twice as high gene frequency in FCH families (25,31). Other reports 
support that also the physical and chemical properties of LDL particles in subjects with 
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FCH differ from those of normolipidemic controls (42). Many of these properties 
appeared to be independent of plasma triglyceride concentrations (43), supporting the 
specificity of dense LDL for this common lipid disorder. 
The observed codominant Mendelian model of inheritance explaining the familial 
cluster of elevated plasma apoB levels in these FCH families (26) was reported previously 
in two other studies on FCH families (16,17). Also in families of patients with 
cardiovascular disease, which not completely met the FCH criteria, a codominant major 
locus effect was observed (14,35,44). Therefore, the genetic model for elevated plasma 
apoB level aggregation could explain both the genetic influence on plasma lipids and the 
increased incidence of cardiovascular disease in FCH families. So far, linkage analyses 
were not able to map a gene responsible for elevated apoB levels (45-47), although some 
markers showed some association (48). Interestingly, also linkage between markers of the 
apoB gene and the LDL subclass phenotype В could be excluded (49). 
The presence of more than one locus controlling the plasma apoB levels and the 
LDL subfraction profiles has been previously suggested by observed bimodality of plasma 
apoB levels in FCH subjects with dense LDL (50). Furthermore, the reported lack of 
association between LDL subclass phenotype and apoB level genotype in a contingency 
analysis (17) is consistent with the present findings. Jarvik et al. demonstrated that a 
mixed Mendelian model of apoB inheritance was favored over a non-Mendelian 'major 
environmental' model after adjustment of apoB levels for LDL subclass phenotypes (17). 
Based on this, it was hypothesized that a multifactorial threshold model of inheritance of 
FCH, in which all subjects with the 'high' apoB genotype (i.e., 'BB') are over the 
threshold to develop FCH and in which subjects with the 'intermediate' or 'low' apoB 
genotype (i.e., 'AB' and 'AA', respectively) may be pushed over the threshold by having 
an additional allele for pattern В (i.e., dense LDL) (17). By contrast, the present study 
demonstrated inheritance of LDL subfraction profile after correction for the predicted 
genetic influence by apoB genotypes. This suggests inheritance of dense LDL subfraction 
profiles irrespective of the metabolic influence of elevated plasma apoB levels in FCH. 
In assessing the validity of the results obtained from this study, several factors 
must be considered. First, the inability to rigorously distinguish those who are affected 
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from those who are not because of the absence of a specific marker so far. In addition, 
the fact that several defects may be involved in the phenotypic expression of FCH, 
predisposes for genetic heterogeneity in study samples (5,17,25). Large pedigrees, as used 
in this study, are expected to increase homogeneity. On the other hand, with a disorder 
frequency of 1 to 2% and probably additive genetic influences, the introduction of more 
than one causative trait may occur in a single family (17). Second, we adjusted a 
phenotype for the predicted genetic effects of another locus according to a method which 
was used before (17,38,39). This procedure necessitates a fairly valid assignment of the 
putative apoB genotype. Therefore, we only used those individuals with genotype 
probability above 70% to establish the influence on К values. The existence of different 
mean apoB levels among these apoB genotypes, which were also very similar to apoB 
genotype related concentrations predicted by the segregation analysis (26), supported the 
consistency of the genotype assignment. The significant influence of the different apoB 
genotypes on the К values was interpreted as metabolic relation between plasma apoB and 
LDL subfraction profile expression, although the direction of this influence could not be 
determined. In these FCH families, the metabolic relation between these two variables was 
also indicated by the original correlation between crude plasma apoB and crude К values, 
which, however, completely disappeared after the adjustment procedure of the К value for 
apoB genotype-specific influence. Therefore, the persistency of inherited susceptibility 
observed with the LDL subfractions adjusted for the influence of apoB genotypes is 
unlikely due to inadequate correction of LDL subfraction profiles. 
Final proof of the major genes involved must come from the identification of 
susceptibility loci. Since the apoB locus itself could be excluded, other candidate genes 
involved in apoB overproduction have to be investigated. Possibly, defects preceding apoB 
secretion which may result in increased substrate delivery to hepatic apoB synthesizing 
cells (51), or defects in regulatory components of apoB synthesis such as the microsomal 
triglyceride transfer protein (52) can be considered. As far as plasma dense LDL is 
concerned, a locus near the LDL receptor on chromosome 19 has been linked to a 
predominance of these particles in plasma of normolipidemic subjects (53). This has been 
confirmed by a recent study which indicated a multilocus determination of dense LDL, 
186 
Inheritance ofapoB and LDL subfractions in FCH 
comprising the LDL receptor locus as well, but also the apoAI-CIII-AIV gene cluster, the 
cholesteryl ester transfer protein locus, and the manganese superoxide dismutase locus 
(41). The authors suggested that different genetically determined metabolic mechanisms 
may give rise to dense LDL particles, without finding evidence for genetic interaction 
with apoB production. Further studies have to establish these relations in hyperlipidemic 
families to better understand the atherogenic risk. 
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SUMMARY 
Since the first description in 1973, familial combined hyperlipidemia (FCH) has kept 
lots of its secrets about etiology and the origin of associated premature vascular disease. 
Initially, FCH has been depicted as a monogenic autosomal inherited lipid disorder. 
However, mounting evidence suggests that FCH is more likely a heterogenous disorder 
comprehending key features of hyperapobetalipoproteinemia, the atherogenic lipoprotein 
phenotype, familial dyslipidemic hypertension and the insulin resistance syndrome. This 
heterogeneity in presenting lipid phenotype, still covered by the generally accepted 
diagnostic criteria for FCH, complicates the search for one or more common 
characteristics. In clinical practice, the absence of a specific marker for the disorder 
demands time-consuming family investigation before the diagnosis FCH is allowed in 
individuals. To have a chance to identify one or more specific marker(s) for the disorder, 
a combination of biochemie and genetic studies on apoBlOO containing lipoproteins 
behaviours, including LDL subfractions, were performed in variable subsets from our data 
of 687 subjects from 40 FCH families. These families were gathered through well-known 
probands from the out-patient lipid clinic. 
In chapter 3a and 3b, we evaluated the short term pharmacologic effects of two 
drugs with different mechanism of action (i.e., gemfibrozil and simvastatin) on plasma 
cholesterol and triglyceride concentrations, apoBlOO, apoCIII, apoAI and Lp(a) in 81 
FCH patients. In a subset, also changes in LDL subfraction profile distribution and LDL 
oxidizability after treatment were studied. Considering plasma lipids, simvastatin reduced 
more effectively the plasma cholesterol concentration, whereas gemfibrozil reduced more 
effectively the plasma triglyceride concentration. However, the observed VLDL plus LDL 
cholesterol concentrations, both before and after both treatments, corresponded very well 
with those of total plasma apoBlOO and thus the number of particles. The reduction in 
apoCIII level corresponded with the reduction in plasma triglyceride concentration in these 
FCH subjects. It was concluded that the total plasma apoBlOO level represents the number 
of particles, which contain a constant cholesterol concentration in different FCH lipid 
phenotypes, despite treatment. The plasma apoCIII level may represent a variable amount 
of triglycerides per VLDL particle. Studies on LDL subfraction profiles before and after 
treatment showed that a decrease in triglyceride concentration corresponded with a 
reduction of the small dense LDL concentration, revealing a more buoyant LDL 
subfraction profile. Remarkedly, although triglyceride levels were frequently reduced to 
'normal' values, the overall LDL subfraction profiles remained dense. This explains the 
observed small effect on LDL oxidizability, which is strongly related to LDL density. 
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Insulin resistance is associated with changes in lipid metabolism which are explained 
by overproduction of VLDL and impaired clearance of triglyceride rich lipoproteins due 
to increased hepatic availability of free fatty acids and reduced LpL activity, respectively. 
Because these features meet some of the criteria for FCH, insulin resistance may play a 
serious role in the etiology of FCH. So far, the presence of insulin resistance in FCH 
patients has been suggested only by indirect measurements. In chapter 4 we compared the 
insulin sensitivity directly by means of the euglycemic hyperinsulinemic clamp technique 
of male non-obese, normotensive FCH patients with that of their non-affected relatives. In 
addition, an oral 75 gram glucose tolerance test (OGTT) was performed and forearm 
blood flow (FBF) was measured by venous occlusion plethysmography during the clamp. 
Although all participants had a normal glucose response after the glucose load, FCH 
patients showed higher baseline fasting C-peptide levels and hyperinsulinemia after OGTT. 
Mean whole body glucose uptake during the clamp was lower in FCH patients compared 
with the non-affected relatives. Interestingly, the glucose uptake correlated significantly 
with LDL density expressed by the so called К value, which we defined earlier. 
Furthermore, the FBF increased significantly in non-affected relatives but not in patients. 
Therefore, FCH patients which are characterized by a predominance of small dense LDL 
are insulin resistant as compared with their respective non-affected relatives exhibiting 
more buoyant LDL. This insulin resistance may partly be explained by a decreased 
insulin-induced vasodilation in skeletal muscle in FCH patients. For further research on 
the etiology of FCH, genes involved in the insulin resistance syndrome should be 
considered. 
Hyperlipidemia due to reduced clearance of triglyceride rich lipoproteins is 
associated with both the FCH lipid phenotype and a metabolic mechanism wich provokes 
the formation of small dense LDL particles. In chapter 5 and 6, two factors: (i) 
decreased LpL activity and (ii) apoE polymorphism, involved in the clearance of 
triglyceride-rich lipoproteins were investigated in FCH families, (i) Compared with a 
population control group, the frequency of the recently described LpL Asn291-»Ser 
mutation happened to be five to ten times higher in Dutch FCH patients (reported by 
others), and was found in 3 of 17 investigated FCH probands in our study. Using a 
pedigree-based maximum likelihood estimate on belonging family data, we demonstrated 
that, irrespective of age, gender and body mass index, the LpL(Asn291-»Ser) mutation 
significantly affects the levels of plasma and VLDL triglycerides, and VLDL and HDL 
cholesterol, but not those of plasma and LDL cholesterol. These findings show that this 
LpL mutation is associated with elevated lipid levels, indicating that it may be one of the 
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genetic factors predisposing to FCH in the families studied, (ii) The impact of the apoE 
polymorphism on interindividual variation in plasma lipid, lipoprotein concentrations, and 
LDL subfraction profiles was studied in 201 well-defined FCH patients. In line with 
observations in other populations, carriers of the apo ε2 allele exhibited a substantial 
higher plasma triglyceride concentration and a lower LDL cholesterol level, while subjects 
with the apo ¿4 allele had significant higher total plasma cholesterol and LDL cholesterol 
levels. Furthermore, it is likely that in FCH populations the apo e4 allele is slightly over-
represented. Although the apoE polymorphism by itself contributes significantly to the 
lipid and lipoprotein concentrations, and showes small effect on chemical composition of 
LDL from FCH subjects, it has no distinct effect on the distribution of LDL subfractions. 
This finding provides further evidence that a LDL subfraction profile consisting of small 
dense LDL particles is a characteristic feature in FCH patients, irrespective of apoE 
related metabolic influence. 
The increased risk to develop cardiovascular disease in FCH, hard to explain by 
frequently only mild elevated plasma lipids, may be related to increased levels of small 
dense LDL particles, which are more prone to in vitro oxidative modification. In chapter 
7 we compared the in vitro resistance to copper induced oxidation of total LDL obtained 
from FCH relatives with either buoyant LDL or dense LDL. In addition, the LDL 
concentrations of antioxidant α-tocopherol and the coenzyme Q10 were measured and 
related to LDL oxidizability. It appeared that dense LDL particles from subjects with 
FCH are less resistant to in vitro oxidation if compared with buoyant LDL from 
normolipidemic relatives. Compared with subjects with an overall buoyant LDL 
subfraction profile, the redox status of coenzyme Q10 was reduced in subjects with an 
overall dense LDL subfraction profile, independently of the plasma cholesterol or 
triglyceride concentration. Therefore, a reduced redox status of coenzyme Q10 as 
observed in FCH patients, can be considered as an important indicator of already ongoing 
in vivo oxidative LDL modification. This observation increasingly connects small dense 
LDL to the presence of (premature) athérosclérose. 
The plasma apoB is considered to be an estimate for the amount of particles 
determining one of the different FCH lipid phenotypes. Therefore, the familial plasma 
apoB level distribution was hypothesized to be a reliable reflection of the familial "FCH 
status". In chapter 8 we describe the genetic coherence between different FCH lipid 
phenotypes represented by the plasma apoB level in 40 FCH families comprizing 623 
individuals. By performing a segregation analysis on standardized plasma apoB levels, and 
after exclusion of one family with extreme apoB values, we demonstrated an autosomal 
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codominant mode of inheritance for plasma apoB levels. Although all Mendelian models 
of inheritance were prefered over non-Mendelian models, an autosomal dominant mode of 
inheritance, as initially described by Goldstein (1973), was rejected. 
Since the occurence of small dense LDL in FCH patients is consistent irrespective of 
metabolic interferences, we performed analyses, described in chapter 9, to establish 
genetic influences on LDL subfraction profile distribution in 40 FCH families. Initially, 
LDL subfraction profiles of family members were described by a continuous variable K, 
which subsequently was standardized for variation due to age, sex, and hormonal status. 
By regression analysis it was shown that 60% of the variability of parameter К could be 
explained by lipid and lipoprotein levels. The remaining variability in parameter К was 
best explained by a major autosomal locus, recessively inherited, with a high population 
frequency, and an additional small polygenic component. Therefore, the clustering of 
atherogenic dense LDL subfraction profiles appear to have a genetic basis in these FCH 
families. However, since metabolic influences, i.e., elevated triglyceride levels, may 
jointly be responsible for the expression in LDL density, additional analyses were needed 
to unravel this relation between environmental, metabolic and genetic factors determining 
the LDL subfraction profile in FCH. 
Because of differences in the observed genetic models for apoB and LDL subfraction 
profiles inheritance, it was deduced that the genetic mechanism underling apoB 
metabolism may differ from the mechanism involved in the expression of LDL particle 
density. In a final analysis, presented in chapter 10, This hypothesis was tested by 
evaluation of the inheritance of small dense LDL subfraction profiles (i.e., К values) after 
correction for the predicted genetic influence of a putative apoB locus, assigned by the 
previous segregation analysis. Segregation analysis of residual LDL subfraction profiles 
provided substantial evidence for a major locus inheritance pattern. Therefore, it was 
concluded that the previously observed inheritance of elevated plasma apoB levels indeed 
differed from the genetic influence on LDL subfraction distribution. These findings may 
support the search for molecular defects involved in the expression of the FCH phenotype 
associated with a preponderance of small dense LDL in patients. 
GENERAL CONCLUSIONS 
1. FCH is a metabolically and genetically heterogeneous lipid disorder. 
2. Both factors that induce VLDL overproduction such as insulin resistance, or 
diminish the clearance of triglyceride-rich lipoproteins, such as decreased LpL 




3. Although not specific for this disorder, most FCH patients differ from their 
unaffected relatives by exhibiting a LDL subfraction profile predominated by small 
dense LDL particles, irrespective of their presenting lipid phenotype. 
4. The increased cardiovascular risk in FCH may be explained by the increased 
suseptibility to oxidation of the small dense LDL particles as reflected by a in vivo 
reduced redox status of coenzyme Q10. 
5. The plasma apoB concentration is an estimate for the number of VLDL and LDL 
particles involved in a FCH lipid phenotype. The inherited susceptibility of elevated 
plasma apoB levels in FCH demonstrates the genetic coherence of the disorder. 
6. FCH is probably caused by a combination of genetic factors: those that influence the 
number of lipoprotein particles and those that determine the density of LDL 
particles. 




Samenvatting en Conclusies 
Chapter 12 
SAMENVATTING 
Hoewel de eerste beschrijving van familiaire gecombineerde hyperlipidemie (FCH) 
dateert uit 1973, bestaan er nog steeds veel onduidelijkheden rondom de etiologie en de 
geassocieerde vroegtijdige athérosclérose bij deze aandoening. Oorspronkelijk werd 
aangenomen dat FCH een monogenetische autosomaal overervende vetstofwisselings-
stoomis was. Op grond van aanvullende gegevens nadien wordt tegenwoordig 
verondersteld dat FCH een heterogene aandoening is, waarbij karakteristieken van 
hyperapobetalipoproteïnemie, het "atherogene lipoprotéine fenotype", familiaire 
dyslipidemische hypertensie en het insulineresistentie syndroom kunnen worden 
waargenomen. Hoewel deze heterogene fenotypische presentatie nog steeds past binnen de 
algemeen aanvaarde diagnostische kriteria voor FCH, wordt het vinden van een specifieke 
marker voor de aandoening hierdoor bemoeilijkt. In de dagelijkse praktijk noodzaakt het 
gebrek aan zo'n specifieke marker tot tijdrovend familie-onderzoek voordat een correcte 
individuele diagnose kan worden gesteld. Met behulp van uitgebreid biochemisch en 
genetisch onderzoek naar het gedrag van apoBlOO bevattende lipoproteïnen, inclusief LDL 
subfracties, werd getracht specifieke kenmerken van FCH te identificeren. Dit onderzoek 
werd verricht bij verschillende subgroepen van in totaal 687 patiënten en familieleden uit 
40 FCH families, verzameld via probandi bekend van de lipidenpolikliniek. 
In hoofstuk 3a en 3b werden de korte termijn farmacologische effecten van twee 
geneesmiddelen met een verschillend werkingsmechanisme (n.l. het fibraat gemfibrozil en 
de HMG-CoA reductaseremmer simvastatine) op de plasmaconcentraties van cholesterol, 
triglyceriden, apoBlOO, apoCIII, apoAI an Lp(a) geëvalueerd bij 81 FCH patiënten. In 
een subanalyse werden de veranderingen in LDL subfractieprofielen en de LDL 
oxideerbaarheid na behandeling bestudeerd. Simvastatine bleek de plasma cholesterol-
concentratatie effectiever te verlagen dan gemfibrozil, terwijl de plasma triglyceride-
concentratie sterker werd verlaagd door gemfibrozil. De VLDL plus LDL cholesterol-
concentratie, zowel voor als na beide behandelingen, correspondeerde goed met de plasma 
apoBlOO concentratie, een maat voor het aantal lipidendeeltjes. De verlaging van de 
apoCIII concentratie kwam goed overeen met de afname in plasma triglyceriden. 
Geconcludeerd werd dat het plasma apoBlOO bij FCH het aantal deeltjes vertegen-
woordigt. Deze bevatten een constante hoeveelheid cholesterol die niet wordt beïnvloed 
door de behandeling. Het plasma apoCIII kan gezien worden als een maat voor de 
hoeveelheid triglyceriden per VLDL deeltje. Bestudering van het LDL subfratieprofiel 
voor en na behandeling liet zien dat een afname van de triglyceridenconcentratie 
resulteerde in een afname van de hoeveelheid zware LDL subfracties. Opmerkelijk was de 
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bevinding dat bij normalisering van de plasma tnglyceriden het LDL subfractiepatroon van 
deze FCH patiënten bleef bestaan uit overwegend zware LDL subfracties. Dit verklaart 
waarschijnlijk het geringe effect van de beide behandelingen op de oxideerbaarheid van 
LDL, welke sterk gerelateerd is aan de LDL dichtheid. 
Insuhneresistentie wordt geassocieerd met veranderingen in het lipidenmetabolisme 
welke worden verklaard door overproductie van VLDL en een gestoorde klaring van 
tnglveenderijke lipoproteinen. Deze veranderingen worden toegeschreven aan een 
toename van de vnje vetzuurconcentratie in de levercel en een verminderde lipoproteme-
hpase (LpL) activiteit Omdat een deel van deze veranderingen ook wordt waargenomen 
bij FCH, zou insuhneresistentie wel eens een belangrijke rol kunnen spelen in de enologie 
van FCH Tot nog toe werd de aanwezigheid van insulineresistentie bij FCH patiënten 
alleen via indirecte bepalingen vastgesteld In hoofdstuk 4 werd middels de euglycemische 
hypennsuhnemische clamptechniek de gevoeligheid voor insuline bij mannelijke niet-obese 
normotensieve FCH patiënten vergeleken met die van hun niet aangedane familieleden 
Aanvullend werden de resultaten van een orale glucose tolerantietest (OGTT) geëvalueerd 
en werd tijdens de clamp een meting van de onderarmsdoorbloeding (FBF) door middel 
van veneuze occlusiepletysmografie verricht Hoewel alle deelnemers een normale 
glucoserespons tijdens de OGTT lieten zien, werd bij FCH patiënten een hogere 
uitgangswaarde voor het C-peptide en een hyperinsulinemie na de OGTT waargenomen. 
De gemiddelde totale lichaamsopname van glucose tijdens de clamp was lager in FCH 
patiënten vergeleken met hun niet aangedane familieleden Interessant genoeg correleerde 
deze glucose opname tijdens de clamp met de individuele LDL dichtheid Verder nam de 
FBF bij niet aangedane familieleden, in tegenstelling tot de FCH patiënten, tijdens de 
clamp toe Dus FCH patiënten, gekarakteriseerd door een overmaat aan zware LDL 
deeltjes bleken vergeleken met hun met aangedane familieleden met een lichter LDL 
subfractiepatroon insulineresistent te zijn Deze insuhneresistentie kon voor een deel 
verklaard worden door een afgenomen insuline gemedieerde vasodilatatie in de skeletspier 
bij FCH patiënten Bij verder onderzoek naar de enologie van FCH zullen ook de genen 
die van belang zijn bij het insulineresistentiesyndroom moeten worden betrokken 
Hyperlipidemie veroorzaakt door een vertraagde klaring van tnglycendenjke 
hpoproteinen wordt geassocieerd met zowel het FCH fenotype als met metabole 
mechanismen die resulteren in de formatie van zware LDL subfracties In hoofdstuk 5 en 
6 werden twee factoren die een rol spelen in de klaring van tnglycendenjke lipoproteinen 
(i) afgenomen LpL activiteit en (и) invloeden van het apoE polymorfisme, onderzocht in 
FCH families, (i) Vergeleken met een controlegroep voor de algehele populatie komt een 
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recent beschreven LpL Asn291-»Ser mutatie 5 tot 10 keer vaker voor in Nederlandse FCH 
patiënten (elders gerapporteerd) en werd deze in 3 van de 17 onderzochte FCH probandi 
uit onze studie teruggevonden. Middels een maximale 'likelihood' berekening op basis van 
de familiestructuur van deze 3 probandi bleek dat onafhankelijk van de leeftijd, het 
geslacht en de body mass index, deze LpL mutatie een significant invloed heeft op de 
concentratie van VLDL triglyceriden, VLDL cholesterol en HDL cholesterol. Deze 
bevinding laat zien dat de LpL Asn291-»Ser mutatie leidt tot verhoogde lipidenwaarden, 
waardoor het een genetische factor kan zijn die predisponeerd voor FCH in de 
onderzochte families, (ii) De invloed van het apoE polymorfisme op initerindividuele 
variatie in lipiden, lipoproteïnen concentraties en LDL subfractiepatronen werd onderzocht 
bij 201 aangedane FCH patiënten. In overeenstemming met door anderen in verschillende 
populaties waargenomen effecten op lipidenconcentraties, hadden carriers van het apo e2 
allei een hogere plasma triglycerideconcentratie en een lagere LDL cholesterol-
concentratie. Carriers van het apo e4 allei hadden een significant hogere plasma en LDL 
cholesterolconcentratie. Verder werd een hogere frequentie van het apo «4 allei in de FCH 
populatie aangetroffen. Ondanks de invloeden op plasma lipiden en -lipoproteïnen werd er 
slechts een marginale invloed op de LDL samenstelling en het LDL subfractiepatroon 
gevonden. Deze bevinding onderstreept dat onafhankelijk van door apoE genotypen 
gerelateerde metabole invloeden, een zwaar LDL subfractiepatroon FCH karakteriseert. 
Het verhoogde risico op cardiovasculaire aandoeningen bij FCH, onvoldoende 
verklaard door de vaak slechts geringe lipidenverhoging, wordt mogelijk versterkt door de 
overmaat aan zware LDL subfracties, welke gevoeliger zijn voor oxidatieve modificatie in 
vitro. In hoofdstuk 7 vergeleken we de in vitro resistentie tegen door koperionen 
geïnduceerde LDL cholesterol oxidatie bij FCH familieleden met een licht versus een 
zwaar LDL subfractiepatroon. Tevens werden de concentraties van de antioxidantia a-
tocopherol en coenzyme Q10 in LDL deeltjes bepaald en gerelateerd aan de gemeten LDL 
oxidatiegevoeligheid. Het bleek dat, vergeleken met licht LDL van de normolipidemische 
familieleden, zware LDL deeltjes van FCH patiënten minder resistent waren tegen in vitro 
koperoxidatie. Vergeleken met familieleden met een licht LDL subfractiepatroon was de 
redoxstatus van het coenzym Q10 bij FCH patiënten met een zwaar LDL subfractiepatroon 
onafhankelijk van de lipidenconcentraties afgenomen. Deze afgenomen redoxstatus van 
coenzym Q10 kan gezien worden als een indicator voor reeds in vivo optredende LDL 
oxidatie. Deze gegevens onderbouwen de hypothese dat zwaar LDL eerder leidt tot 
oxidatieve modificatie van deze deeltjes, een proces dat geassocieerd wordt met 
(premature) athérosclérose. 
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De plasma apoB concentratie kan worden beschouwd als een schatting voor de 
hoeveelheid deeltjes verantwoordelijk voor één van de verschillende FCH lipiden-
fenotypen. Daarom werd verondersteld dat de verdeling van apoB concentraties over de 
verschillende familieleden een goede afspiegeling zou zijn van de "FCH status" in een 
familie. In hoofstuk 8 beschrijven we de genetische samenhang tussen de verschillende 
FCH lipidenfenotypen, vertegenwoordigd door een plasma apoB concentratie, in 40 FCH 
families. Met behulp van een segregatie analyse van gestandaardiseerde apoB waarden, 
waarbij één familie met extreme apoB waarden was uitgesloten, werd een autosomaal 
codominant model voor overerving aangetoond. Hoewel alle Mendeliaanse modellen voor 
overerving prevaleerde boven de niet-Mendeliaanse modellen, werd een dominant model 
zoals in 1973 door Goldstein e.a. werd verondersteld, verworpen. 
Omdat de aanwezigheid van een zwaar LDL subfractiepatroon bij FCH patiënten, 
onafhankelijk van metabole invloeden, een constant gegeven blijkt te zijn werd in 
hoofdstuk 9 een analyse uitgevoerd om na te gaan of genetische invloeden het LDL 
subfractiepatroon bij FCH bepalen. Allereerst werden de LDL subfractiepatronen vertaald 
in een continue variabele K, welke vervolgens werd gestandaardiseerd voor variatie door 
leeftijd, geslacht en hormonale status. Door middel van regressie-analyse werd aangetoond 
dat 60 % van de variatie in K-waarde kon worden verklaard door variatie in lipiden- en 
lipoproteïnenwaarden. De resterende variatie kon na een segregatie analyse het beste 
worden verklaard door de aanwezigheid van een major autosomaal locus, dat recessief 
overerft en een hoge populatiefrequentie heeft in combinatie met een geringe additionele 
polygenetische component. Op grond van deze uitkomst wordt verondersteld dat de 
clustering van zware LDL subfractiepatronen in deze FCH families ook een genetische 
basis heeft. Echter omdat, blijkens de regressie-analyse, lipidenconcentraties het LDL 
subfractiepatroon mede bepalen waren aanvullende analyses noodzakelijk om de relatie 
tussen metabole factoren en genetische factoren, verantwoordelijk voor de uiteindelijke 
expressie, verder te ontrafelen. 
Omdat in de onderzochte families het model voor de apoB overerving verschilde van 
het overervingsmodel voor de LDL subfractiepatronen, zou het genetische mechanisme 
verantwoordelijk voor het apoB metabolisme anders kunnen zijn dan het mechanisme 
betrokken bij de expressie in LDL dichtheid. In een finale analyse, gepresenteerd in 
hoofdstuk 10, werd deze hypothese getest door hernieuwde evaluatie van de LDL 
subfractiepatroon (K-waarde) overerving na correctie voor de voorspelde genetische 
invloed door het veronderstelde apoB locus. Segregatie analyse met de residuale K-waarde 
leverde overtuigend bewijs voor een resterend major locus effect. Op grond hiervan werd 
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geconcludeerd dat het eerder gevonden apoB overervingsmodel inderdaad verschilde van 
de genetische invloed op de LDL subfractiepatronen. Deze bevinding kan een bijdrage 
leveren bij de verdere zoektocht naar moleculaire defecten betrokken bij de expressie van 
het FCH lipidenfenotype dat wordt gekenmerkt door een overmaat aan zwaar LDL bij 
FCH patiënten. 
ALGEMENE CONCLUSIES 
1. FCH is een metabool en genetisch heterogene vetstofwisselingsstoornis. 
2. Zowel factoren die VLDL overproductie induceren, zoals insulineresistentie, als 
factoren die leiden tot een vertraagde klaring van triglyceriderijke lipoproteïnen, 
zoals verminderde LpL activiteit en het apoE polymorfisme, dragen bij tot de 
presentatie van het FCH lipidenfenotype. 
3. Hoewel niet specifiek voor deze aandoening, onderscheiden FCH patiënten zich van 
hun niet-aangedane familieleden door een zwaar LDL subfractiepatroon, on-
afhankelijk van het presenterende lipidenfenotype. 
4. Het verhoogde risico op cardiovasculaire aandoeningen bij FCH kan worden 
verklaard door de toegenomen gevoeligheid voor oxidatie van zware LDL deeltjes, 
in vivo weerspiegeld door de afgenomen redoxstatus van het coenzym Q10. 
5. De plasma apoB concentratie is een maat voor het aantal VLDL en LDL deeltjes dat 
betrokken is bij een FCH lipidenfenotype. De overerving van verhoogde apoB 
concentraties in FCH families geeft de genetische samenhang van de aandoening 
weer. 
6. FCH wordt waarschijnlijk veroorzaakt door een combinatie van genetische factoren: 
namelijk die factoren die het aantal lipoproteïnendeeltjes bepalen en die factoren 
verantwoordelijk voor de dichtheid van LDL deeltjes. 
7. Tot nog toe kunnen individuele FCH patiënten niet worden geïdentificeerd aan de 
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In tegenstelling tol wat de pioniers in de beschrijving van familiaire gecombineerde 
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deze vetstofwisselingssloornis een /w/ygenetische aandoening is 
J L Goldstein el al. J Clin Invest 1973,52 1544-1568 
Dir proefschrift 
II 
Bij de diagnostiek van familiaire gecombineerde hyperlipidemie wordt de waarde van het 




Bij het inschatten van het risico op prematuur vaathjden is niet alleen de hoogte van het 
LDL cholesterolgehalte, maar ook de samenstelling van de LDL deeltjes van belang 
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Hoewel er voldoende aanwijzingen zijn dal het LDL subfractiepatroon genetisch wordt 
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Gedegen familie-onderzoek is aangewezen bi| de opsporing van die personen die baat 
zullen hebben bij een preventieve cholesterolverlagende behandeling 
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VI 
Afwijkingen in cardiovasculaire reflexlestcn waarbij middels een tinapress apparaat 
automatisch variaties in bloeddruk en hartslag worden gemeten, duiden op een gestoorde 
werking van het autonome zenuwstelsel 
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Omdat de afgifte van endotheline-1 wordt gestimuleerd door geoxideerd LDL kunnen 
endothelinereceptorantagonisten in de toekomst een rol gaan spelen in de behandeling van 
athérosclérose door remming van chemoattractie van monocyten en proliferatie van gladde 
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Bij een typisch klachtenpatroon voor coronaire insufficientie en kenmerkende afwijkingen 
op het electrocardiogram dient de diagnose cholelithiasis mede overwogen te worden 
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IX 
Zowel hel ontbreken van adequate kinderopvang in grote overheidsinstellingen als een 
onvoldoende capaciteit in de zorg voor ouderen is anno 1997 onacceptabel 
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Hoewel het bij een verouderende samenleving maatschappelijk onverantwoord lijkt, dient 
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